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ABSTRACT
The poly(ADP-ribose) polymerase (PARP) family of enzymes in humans is comprised of 17
proteins. PARP-1, the first member of the family, synthesizes a large, complex post-translational
modification, poly(ADP-ribose). While PARP-1 and some other PARPs have been extensively
functionally characterized, the enzymatic and cellular functions of many PARPs are unknown.
This thesis presents work that seeks to characterize the enzymatic functions of the PARP family.
First, experimental demonstration of the automodification capacity of each PARP is presented.
We find that PARP enzymatic activity largely conforms to bioinformatic predictions of PARP
activity. Then, we seek to provide a structural rationale for these enzymatic capabilities based on
the analysis of extant and modeled crystal structures of each PARP. We present a structural
hypothesis for catalytic differences among PARPs. Finally, we examine methods for the
identification of cellular targets of PARP activity and functional interaction partners of PARPs.
Together, these elements of PARP characterization will aid in the discovery of physiologically
relevant targets and a mechanistic understanding of PARP enzymatic activity in the cellular
context.
Thesis Supervisor: Paul Chang
Title: Linda and Howard Stern Career Development Assistant Professor of Biology
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Post-translational modification
After translation by the ribosome, proteins often undergo a series of modifications. These
modifications may be necessary for the full functionality of the enzyme, or they may occur at
various points during the lifespan of the protein to regulate its activity in response to cellular or
extracellular conditions. Types of post-translational modification include targeted protein
cleavage, the alteration of amino acid residues, and the non-covalent or covalent attachment of
other chemical entities. Of this last class, the best-studied post-translational modifications
include phosphorylation, methylation, and acetylation. There are, however, a wide variety of
other modifications that can change the properties of amino acids and the proteins of which they
form a part. A recent survey of post-translational modifications shows that while many different
types and even more individual modifications have been identified thus far, there are many more
sites and their likely functional implications that have yet to be identified (Khoury, Baliban, and
Floudas, 2011; Figure 1).
This thesis is concerned with one particular class of post-translational modification in
human cells, ADP-ribosylation. In particular, I seek to understand how one class of enzymes,
the poly(ADP-ribose) polymerases, or PARPs, synthesizes ADP-ribose modifications of varying
chemical characteristics onto proteins by examining their enzymatic activity, structural elements,
and interaction partners. Together, these analyses begin to suggest mechanisms of modification
that will aid in the elucidation of the role of these enzymes and the post-translational
modifications they synthesize in regulating cell behavior.
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Indeed, several prokaryotic toxins use the mechanism of mono(ADP-ribosylation) to disable
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their hosts by impairing host protein function. Diphtheria toxin and Pseudomonas aeruginosa
exotoxin A modify a diphthamide residue on EF-2, inhibiting protein synthesis; Pseudomonas
aeruginosa exotoxin S, Clostridium botulinum toxins C2 and C3, and Salmonella enterica SpvB
disrupt the actin cytoskeleton by modifying actin or regulatory proteins such as Ras, Rho, and
Rac; while cholera, E. coli LT1 and LT2 and pertussis toxins modify G proteins, resulting in
inhibited GTPase activity or decoupling of the G protein from its receptor (Corda and Di
Girolamo, 2003). Mono(ADP-ribosylation) is also used by viruses such as bacteriophage T4 to
modify host RNA polymerase (Corda and Di Girolamo, 2003). This stimulates viral
transcription via preferential recognition of T4 promoters by modified polymerase (Sommer et
al., 2000).
More recently, mono(ADP-ribosylation) has been shown to be synthesized by various
eukaryotic enzymes as well. Eukaryotic mono(ADP-ribosylating) enzymes fall into three
general classes: the ADP-ribosyltransferase (ART) ectoenzymes, NAD*-dependent tRNA
2'phosphotransferases, and the NAD*-dependent deacetylases. There are five ART enzymes in
humans, which are glycosylphosphotidylinositol-anchored to the cell membrane and act mainly
extracellularly to modify integrins, thereby regulating cell-matrix interactions, and also regulate
T-cell receptor signaling (Lin, 2007). Most ARTs display a cholera-like catalytic RSE motif
(Laing et al., 2011). The second class is typified by an S. cerevisiae enzyme, Tptlp, and its
homologs in higher eukaryotes and E. coli, which transfers the 2' phosphate from the tRNA
splice junction to NAD*, producing cyclic ADP-ribose (Spinelli et al., 1998). The third class is
the NAD*-dependent deacetylases, best represented by the well-known sirtuins. The yeast
protein Sir2 and its homologs use NAD* to deacetylate proteins, particularly histones, which
results in transcriptional silencing and lifespan increase (Lin 2007). The acetyl group serves as
16
the substrate for ADP-ribosylation, and a series of chemical reactions leads to the release of the
acetyl group from the protein in the form of O-acetyl-ADP-ribose. Because of the chemical
similarity between the deacetylation mechanism of the sirtuins and ADP-ribosylation, it is
thought that some sirtuins, even those that appear incapable of deacetylation, may ADP-
ribosylate themselves or other targets. For example, there is evidence that yeast Sir2 and mouse
SirT6 can ADP-ribosylate themselves, and that mouse SirT4 ADP-ribosylates glutamate
dehydrogenase (Lin 2007).
More complicated than the addition of a single ADP-ribose moiety to an amino acid
residue is the modification of proteins with a long polymer of ADP-ribose, known as poly(ADP-
ribose) (PAR). PAR is primarily synthesized by a family of enzymes known as the poly(ADP-
ribose) polymerases, or PARPs. Although PARPs were long thought to be unique to eukaryotes,
functional homologues in bacteria and archaea have recently been discovered (Slade et al.,
2011). The structure of PAR and the enzymatic activity of PARPs have been studied for 50
years, but are still not well understood. Understanding the chemistry of PAR is critical to
elucidating the mechanism of its synthesis by PARPs and of its myriad functions as a post-
translational modification.
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NAD+
Mono(ADP)-ribosylation Poly(ADP)-ribosylation
Prokaryotic enzymes Eukaryotic enzymes
Cholera toxin ADP-ribosyltransferases
(ARTs) Eukaryotic enzymes
Diphtheria toxin Sirtuins Poly(ADP-ribose) polymerases (PARPs)
Pertussis toxin PARPs (postulated)
Salmonella toxin
Figure 2. ADP-ribosylation reactions in the human cell. ADP-ribosylation reactions use
NAD' as a common precursor. The nicotinamide moiety of NAD* (orange pentagon) serves as
the leaving group while the ADP-ribose moiety (blue circle) becomes attached to the protein
target. Mono(ADP-ribosylation) is the addition of a single ADP-ribose moiety to an amino acid
residue, and is carried out by both prokaryotic and eukaryotic enzymes. Poly(ADP-ribosylation)
is the generation of a long chain of ADP-ribose units attached to a single amino acid residue and
is synthesized by the (primarily eukaryotic) PARP enzymes.
Poly(ADP-ribose) (PAR)
PAR was originally identified as the reaction product of an enzyme purified from hen
liver nuclei (Chambon, Weill, and Mandel, 1963). The enzyme, also found in calf thymus, hog
and rat liver nuclei, but not E. coli, incorporated ATP into a product thought to be polyA.
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However, the unidentified enzyme displayed characteristics distinct from those hitherto known in
RNA polymerases - it was DNA-dependent, not inhibited by the absence of other nucleotide
triphosphates, and, perhaps most strikingly, activated 1000-fold by the addition of nicotinamide
mononucleotide (NMN, Figure 3). Early characteristics of the reaction product indicated that it
was acid-insoluble, insensitive to both DNase and RNase treatment, and a polymer of
approximately 100 nucleotides in length. Further study of the enzyme and its product in rat liver
nuclei demonstrated that nicotinamide adenine dinucleotide (NAD*), not NMN and ATP, was
the substrate for the enzyme, and that the ADP-ribose moiety of NAD* was incorporated into the
polymer while the nicotinamide was released (Figure 3; Nishizuka et al., 1967; Reeder et al.,
1967). Hence, the enzyme product became known as poly(ADP-ribose), or PAR. PAR is
synthesized by PARPs, a family of enzymes discussed in detail below, and hydrolyzed by
poly(ADP-ribose) glycohydrolase (PARG) (Schreiber et al., 2006). Original studies only
identified a single enzyme responsible for the synthesis of PAR; upon discovery of other related
enzymes, the enzyme first characterized by Chambon, Weill, and Mandel was renamed PARP- 1.
Treatment with snake venom phosphodiesterase resulted in an acid-soluble product,
which upon treatment with acid resolved into a single compound composed of a ratio of 1 mole
adenine: 2 moles ribose: 2 moles phosphate (Nishizuka et al., 1967; Reeder et al., 1967). The
subunits of polymer were proposed to be connected via ribose-ribose linkages, since chemical
treatments excluded the possibility of linkages through the amino group or adenine and revealed
that only one ribose per adenine had free hydroxyl groups (Reeder et al., 1967). Chambon and
colleagues were able to establish the linkage more specifically between the 2' position of the
adenosine ribose and the 1' position of the incoming nicotinamide ribose (Figure 3; Chambon et
al., 1966).
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Figure 3. Chemical structures of poly(ADP-ribose) and precursor molecules. A)
Nicotinamide mononucleotide (NMN) and adenosine triphosphate (ATP), the enzyme precursors
as defined by Chambon, Weill, and Mandel (1963). B) The substrate for ADP-ribose synthesis,
NAD*. C) Poly(ADP-ribose) as attached to a protein via an ester linkage (most likely with
either a glutamic acid or aspartic acid, or a terminal lysine residue). Shown are two linear
linkages and one branched linkage between ADP-ribose units. Ribose position labels are
shown for the first linear linkage. Green arrows indicate positions of cleavage by venom
20
phosphodiesterase, yielding products whose relative composition of adenine, ribose, and
phosphate led to the elucidation of ADP-ribose structure.
The development of early purification techniques for PAR, primarily based on other
nucleotide purification techniques such as phenol extraction and hydroxylapatite columns,
enabled further characterization of the polymer (Reeder et al., 1967; Sugimura, et al., 1971).
These studies found that a minor reaction production of treatment of purified PAR with
phosphodiesterase indicated a branched structure for PAR, with one ribose moiety attached to
two others (Figure 3; Miwa et al., 1979). Roughly 2% of the digestion products were of this
branched variety, leading to an estimated branching frequency of one branch per 20 or 30 ADP-
ribose subunits. These branches provide a further differentiating structural feature besides length
that indicates a unique functional role for PAR as opposed to mono(ADP-ribose) in the cell.
The earliest studies of PAR posited that it was not chemically attached to other
nucleotides or to proteins (Reeder et al., 1967). Soon thereafter, however, researchers discovered
that PAR was attached to histones, most likely through glutamic acid and aspartic acid residues
via an ester linkage (Nishizuka et al., 1968; Hayaishi and Ueda, 1977). Non-histone targets were
soon discovered (Smith and Stocken, 1975). Although consensus modification sequences have
not yet been identified, PAR modifications have been detected on glutamic acid, aspartic acid,
and lysine residues of proteins (Ogata et al., 1980; Altmeyer et al., 2009). Various methods and
techniques are currently being employed to identify sites of modification (Hengel and Goodlett,
2012; Jiang et al., 2010; Jiang et al., 2012; Rosenthal et al., 2011; Tao et al., 2009).
PAR modification has three distinct mechanisms of function (Figure 4). First, the
modification itself can change the charge properties of the modified protein and disrupt protein
interactions. Examples of this are PAR modification which inhibits chromatin remodeling,
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regulates nuclear-cytoplasmic shuttling of NF-icB and p53, and disrupts the binding of the mouse
transcription factor CLOCK to its DNA element, thereby maintaining circadian rhythms (Gibson
and Kraus, 2012). Second, and more interestingly, the large size of PAR creates a scaffold to
which other proteins can bind to recruit complexes. The activation of PARP-1 synthesis activity
at sites of DNA damage, for example, recruits DNA repair proteins such as APLF and XRCC1
via protein-PAR interactions (Li et al., 2010; El-Khamisy et al., 2003). At the same time, the
PAR at the site of DNA damage recruits factors necessary for IKKy activation to modulate
apoptotic responses (Stilmann et al., 2009). Third, binding to PAR can itself modulate the
activity of proteins. DNMT1 non-covalent binding to PAR, for example, inhibits its DNA
methylase activity (Reale et al., 2005). These mechanisms of function can also work in
combination.
Covalent modification
1. Change in function of
A - modified protein
3. Change in function
of binding protein
2. Scaffold
Figure 4. Mechanisms of PAR function. 1) PAR may serve as a covalent modification which
changes the function of the modified protein. 2) PAR may serve as a scaffold for protein
recruitment to which proteins necessary for functional complex formation may bind. 3) PAR
binding may change the function of a protein, or some combination of these three mechanisms
may explain the function of PAR.
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PAR
acceptor
In order to understand recruitment to the PAR scaffold and modulation of activity by
PAR binding, it is helpful to characterize the interaction between proteins and PAR. To date,
there are four known motifs that recognize and bind to PAR. These are the PAR binding motif
(PBM), the PAR-binding zinc finger (PBZ domain), the macro domain, and the recently
identified WWE domain. The PBM was the first PAR-binding module to be discovered and is
characterized by an 8 amino acid motif: [HKR] 1-X2-X 3 -[AIQVY]-[KR] 5-[KR]-[AILV]7-
[FILPV]8. It is common in the genome, but is most highly represented in DNA repair proteins
like XRCC1 and proteins involved in chromatin remodeling and RNA processing (Kalisch et al.,
2012; Gibson and Kraus, 2012). The structural basis for PAR recognition is unknown because
the PBM does not appear to interact with anything smaller than PAR, making crystallization
difficult. However, it is thought that the basic character of the residues in the PBM provide a
good interaction surface for the negative residues of PAR (Kalisch et al., 2012).
Better characterized but rarer in the human genome is the PBZ domain, which has so far
been found to be present in only three proteins: the mitotic checkpoint protein CHFR and the
DNA repair proteins APLF and SNM1. APLF contains tandem PBZ domains, each unit of
which can recognize the glycosidic linkage between ADP-ribose units in PAR (Gibson and
Kraus, 2012). Structural studies of CHFR demonstrated two adenine binding sites, meaning the
PBZ domain could recognize two ADP-ribose moieties simultaneously (Kalisch et al., 2012).
Interestingly, many proteins involved in the regulation of genome stability in Dictyostelium
discoidium, Caenorhabditis elegans, and Drosophila melanogaster contain PBZ domains,
whereas their mammalian homologs contain PBM domains (Kalisch et al., 2012).
The macro domain, originally identified as the non-histone component of histone variant
macroH2A, is highly conserved from archaea to humans. There are many varieties of macro
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domains with different recognition capabilities for PAR and other ADP-ribose derivatives.
Some macro domains, notably the human MacroD1 protein and the macro-like DUF2263 fold
from Thermonospora curvata, are capable of hydrolysis of ADP-ribose derivatives, similar to
poly(ADP-ribose) glycohydrolase (PARG) activity (Slade et al., 2011; Kalisch et al., 2012).
Macro domains are often present in tandem, aiding in the speedy recruitment of macro-
containing proteins to sites of active PAR synthesis via cooperativity of binding (Gibson and
Kraus, 2012). Interestingly, macro domains are present in some PARPs, as discussed below.
The last recognized PAR binding domain, the WWE domain, is also present in many
PARPs and is otherwise primarily found in ubiquitin ligases. The WWE domains of ubiquitin
ligase RNF146, PARP- 11, and other proteins have been shown to be able to bind iso-ADP-
ribose, a molecule that is only present in PAR and not in mono(ADP-ribose) (Wang et al., 2011).
----- B------------------- -Z
r - -- -- - - -- - - - - - - - I -WWE demain NH2
N -------- 1-
0--PPBZ-N-O
</ I
0 0 N
argeit N1 1
Macrodomin
Figure 5. Recognition sites of PAR binding modules. Reprinted by permission from
Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology, New insights into the
molecular and cellular functions of poly(ADP-ribose) and PARPs, Bryan A. Gibson and W. Lee
Kraus, copyright 2012.
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The diversity of PAR binding domains and mechanisms of PAR function indicate that the
polymer plays many important roles in the cell. While many functions for ADP-ribose
modifications in general and PAR in particular have yet to be discovered, there are three key
roles for PAR that have been elucidated so far. First of all, PAR is required for all multicellular
eukaryotic life. In particular, it is necessary for the maintenance of genomic integrity under
genotoxic stress (Koh et al., 2005). This is because of its key role in the recruitment of DNA
repair machinery to sites of DNA damage. PAR modification on PARP-1 helps to recruit
XRCC1, which also becomes modified by PAR. PAR modifications on PARP-1, XRCC1, and
histone Hi recruit other PAR-binding factors critical to the repair of damaged DNA, such as
chromatin remodelers and silencing complexes (Gibson and Kraus, 2012). In a second (and
related) role, PAR also can regulate transcription through its interaction with chromatin
remodeling factors (Kraus, 2008). Finally, PAR synthesized at the mitotic spindle is critical for
proper cell division. PAR synthesis and its interaction with NuMA is required for spindle
assembly, and the interaction between PAR and NuMA aids in spindle pole assembly (Chang,
Jacobson, and Mitchison, 2004; Chang, Coughlin, and Mitchison, 2005; Chang, Coughlin, and
Mitchison, 2009).
In order to understand how PAR can play these diverse and important roles, more must
first be known about the enzymes responsible for synthesizing PAR in these cellular locations,
the poly(ADP-ribose) polymerases or PARPs.
Poly (ADP-ribose) polymerases (PARPs)
The enzyme primarily responsible for the synthesis of nuclear PAR was identified and
partially purified from rat liver nuclei in 1971 and named poly(ADP-ribose) polymerase, or
PARP (Yamada et al., 1971). Later, PARP was first fully purified from pig thymus (Tsopanakis
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et al., 1976). The discovery of further enzymes with PAR synthesizing ability followed: PARP-
2 emerged as the source of residual DNA-dependent PARP activity in PARP-1 -/- mouse
embryonic fibroblasts (Am6 et al., 1999); PARP-4 was identified as a key component of vault
particles, which are large ribonucleoprotein complexes of unknown function (Kickhoefer et al.,
1999); and PARP-3, PARP-5a, PARP-5b, and PARP-7 were also identified by cloning and
various functional screens (Johannson, 1999; Smith et al., 1998; Kaminker et al., 2001; Ma et al.,
2001).
Then, the advent of public genome sequence databases allowed researchers to search for
homologous proteins in the human genome. Their results revealed many diverse contexts for the
human PARP domain: there are 17 genes in humans which encode a region of sequence
homology to the PARP-1 catalytic domain. The PARP-domain regions of the proteins encoded
by these genes display 23%-79% sequence identity to the PARP domain of PARP-1. Together,
the enzymes encoded by these genes comprise the PARP superfamily (Am6 et al., 2004; Otto et
al., 2005).
Although all PARPs by definition contain a region of homology to the functional PAR-
synthesizing domain of PARP-1, different PARPs contain very different sets of functional
domains coupled to the PARP domain (Figure 6A). Interestingly, the similarity of sequence in
the PARP domain corresponds well to which other domains are present in a given PARP protein.
Otto and colleagues generated a phylogram of the PARP family based on the sequence of the
PARP domain, but using the full sequence of each PARP results in a strikingly similar diagram
(Otto et al., 2005; Figure 6B). These observations have led to the grouping of the PARP family
into subfamilies based on these two elements: the similarity of their PARP domains, and more
tellingly, their sharing of key functional domains.
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Figure 6. The diverse PARP family. A) The domain structure of the PARP family. Domains
are color-coded as follows: turquoise, macro; green, PARP; purple, WWE; brown, RRM; pink,
CCCH zinc finger; light blue, BRCT; dark green, alpha helical domain; bright pink, VWFA;
dark blue, WGR; salmon, CCHC zinc finger; light orange, ankyrin repeat; yellow, SAM. The
green hatches in the PARP domain represent the positions of the three key catalytic residues; red
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hatches indicate deviation from the canonical residue of PARP- 1. All PARPs and domains are
shown to scale. B) Dendrogram based on multiple sequence alignment of the full protein
sequence of all PARPs in UniProt indicates evolutionary relationships; distances are not to scale.
There are four generally recognized PARP subfamilies, and the remaining PARPs fall
into the "unclassified" category. The DNA-dependent PARPs are so named for their similarity
to PARP- 1 and its requirement of DNA binding for maximal activity and include PARP- 1,
PARP-2, and PARP-3. The tankyrases are PARP-5a and PARP-5b and are named for the
notable presence of ankyrin repeats in their structure. PARP-7, PARP-12, and PARP-13 are the
CCCH zinc finger PARPs because they contain a special zinc finger that binds RNA. The macro
PARPs, PARP-9, PARP-14, and PARP-15, each contain 2-3 macro domains, a domain originally
identified in histone variant macro H2A which has been demonstrated to bind to ADP-ribose and
related molecules, as introduced previously. PARP-4, PARP-6, PARP-8, PARP-10, PARP-11,
and PARP- 16 are all unclassified PARPs, since they lack the subfamily-specific domains,
although PARP-4 and PARP- 10 in particular have other domains of functional interest which
will be examined in more detail in Chapter 3.
Interestingly, bioinformatic work also identified high conservation of many of these
PARPs throughout eukaryotes (Otto et al., 2005). PARP-1 and PARP-5a orthologues are found
in, among other species, Mus musculus, Gallus gallus, Tetraodon nigroviridis (pufferfish),
Drosophila melanogaster, Caenorhabditis elegans, and Dictyostelium discoideum, while PARP-
1 orthologues are additionally present in Arabidopsis thaliana, Gibberella zeae (ear root
microfungus), and Entamaoeba histolytica. In total, pufferfish and mouse have 16 human PARP
orthologues, chicken has 12, Arabidopsis has 10, Dictyostelium has 9, Entamaoeba has 6,
Gibberella and Caenorahabditis each have 3, and Drosophila has 2 (Otto et al., 2005). Thus,
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understanding the diversity of PARP family structure function is of relevance beyond the human
cell.
Functions of PARPs
Many of the best-characterized functions of PARPs and PAR are those mediated by
PARP-1. For example, the recruitment of important DNA repair factors, from XRCC1 and p53
to chromatin remodeling factors, is a result of the binding of PARP-1 to single-stranded DNA
breaks and its subsequent activation via auto-ADP-ribosylation (Gibson and Kraus, 2012). The
branched nature of PAR elucidated by Miwa and colleagues is also a feature of PAR synthesized
by PARP-1 that appears to be unique (Miwa et al., 1979).
By contrast, PARP-5a synthesizes much shorter and generally linear polymer of about 20
units of ADP-ribose (Rippmann et al., 2002). PARP-5a and its polymer have four crucial
demonstrated roles in the cell. First, PARP-5a is critical for mitotic regulation; it localizes to the
spindle pole and modifies spindle proteins such as NuMA. PARP-5a localization and NuMA
modification by PAR are required for proper spindle formation and sister chromatid segregation
(Chang et al., 2005; Chang et al., 2009). The second role of PARP-5a is in Wnt signaling, in
which PARP-5a modifies axin with PAR, leading to axin degradation and the subsequent
activation of Wnt signaling. Third, PARP-5a plays a role in bone formation by modifying 3BP2,
leading to its degradation. The degradation of 3BP2 is required for B cell receptor and integrin
activation, and the lack of PAR leads to the disease cherubism. Finally, PARP-5a is essential for
telomere maintenance; the synthesis of PAR on TRF1 leads to TRF1 degradation and the
elongation of telomeres (Riffell et al., 2012). Thus, like PARP-1, PARP-5a plays many critical
roles in the proper functioning of multicellular organisms.
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Recently, PARP-16, which was previously uncharacterized, was shown to play a critical
role in the unfolded protein response. PARP-16 upregulates its activity during endoplasmic
reticulum (ER) stress by modifying itself, and then it modifies the ER stress sensors PERK and
IRE Ia. This ADP-ribosylation modification in turn stimulates the kinase activity of both stress
sensors and the endonuclease activity of IRElIa (Jwa and Chang, 2012). Thus, PARPs play key
functional roles in many critical types of stress.
PARP catalytic activity
The catalytic activity of most PARPs is as yet experimentally undefined. However,
bioinformatic predictions of activity have been made based on the presence or absence of the key
catalytic HYE motif. The histidine and tyrosine residues are thought to be important for
coordination of NAD* binding, while the glutamate residue has been shown to be critical for
polymer elongation in PARP-1 (Ruf et al., 1996; Ruf et al., 1998; Marsischky et al., 1995).
Sequence analysis of key residues of the PARP catalytic domain has shown that PARPs 6-16
lack the catalytic glutamate, suggesting that these enzymes are in fact only capable of
transferring a single ADP-ribose moiety or a very short polymer to target proteins (Otto et al.,
2005; Kleine et al., 2008). PARP-9 and PARP-13 are believed to be catalytically inactive since
they lack not only the catalytic glutamate but also the histidine residue involved in NAD*
coordination.
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Table 1. Demonstrated and predicted enzymatic activity of the PARP family. Adapted with
permission from Kleine et al., 2008.
PARP domain structure
So far, most structural studies of the PARP family have focused on the NAD* binding
pocket. There are historical and practical reasons for the desire to understand how PARP
domains bind incoming substrate NAD*. Historically, the structural basis of NAD* binding by
many mono(ADP-ribosylating) toxins was understood, and it was therefore hypothesized that
PARPs might bind NAD* in a similar fashion. ADP-ribosylating enzymes are divided into two
groups based on the identity of residues in their NAD* binding pockets: the CT group, which,
like the cholera toxin, coordinates NAD* with an arginine residue, and the DT group, represented
by diphtheria toxin, which uses a histidine for the same function. Interestingly, despite these
differences and low overall sequence similarity, both types of ADP-ribosylating enzymes use a
glutamate residue to catalyze the ADP-ribosylation reaction, and both groups contain an NAD*-
31
binding scaffold with conserved sets of residues (Domenighini and Rappuoli 1996). Even before
the crystallization of any PARPs, their structural and sequence similarities to these other ADP-
ribosylating enzymes were noted.
Crystal structures of PARP- 1 and other PARPs were able to confirm the putative
structural similarity between the NAD*-binding pockets of PARPs and other ADP-ribosylating
enzymes. Specifically, PARP- 1 displayed similarity to the DT group, including diphtheria and
pertussis toxins (Am6 et al., 2004). Further structural studies have confirmed and expanded
these identified sequence and structural similarities. Both prokaryotic and eukaryotic ADP-
ribosylating enzymes have a conserved NAD* binding core consisting of a central 6-stranded
beta sheet with 3 highly conserved motifs. The first, R/H-G-T/S, encompasses the critical
NAD*-interacting arginine (CT group) or histidine (DT group). The second NAD* binding motif,
S-T-S in the CT group or Y/Xio/Y in the DT group, also aids in NAD* binding (Hottiger et al.,
2010). Structural studies have demonstrated that the STS and YXY motifs bind NAD* in the
same conformation and have the same general shape, a "scorpion" fold, where the "head" of the
scorpion is either tyrosine or serine, and the "tail" is aromatic or aliphatic. All PARPs except for
PARP-9 have or are predicted to have this conserved structure (Lee et al., 2010). The third
NAD* binding motif, Q/E-X-E with a turn-turn in the CT group, both helps to coordinate NAD'
and appears to play a role in substrate recognition (Hottiger et al., 2010). Together, these three
motifs make up both the RSE triad present in the CT group, including arginine, cysteine, and
asparagine ARTs, and the HYE triad of the DT group, including diphtheria, exotoxin A, and
PARPs. Notably, the PARPs can be further broken down into two groups based on the identity
of the glutamate position: those that have glutamate, and those that substitute a different amino
acid at this position. This has been posited to correlate roughly with PARP enzymatic capability
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- those with glutamate are thought to be capable of synthesizing polymer, while those that lack
glutamate are thought to be active but not able to synthesize poly(ADP-ribose) (Hottiger et al,
2010; Kleine et al, 2008; Table 1).
The practical reason for studying the NAD* binding pocket of the PARPs is that it lends
itself to the development of new therapeutics. PARP inhibitors have been successful in clinical
trials for melanoma, breast cancer, and ovarian cancer (Lee et al., 2010). Therefore,
understanding the structural basis and similarities of NAD* binding in PARPs and toxins could
lead to improved and better-targeted therapeutics to inhibit undesirable ADP-ribosylation
activity.
Proposed reaction mechanisms for the synthesis of PAR by PARPs
In order to explore the potential impact of inhibitors on PARP cellular function, it is first
necessary to understand the chemistry of PARP enzymatic activity. The synthesis of PAR by
PARPs involves two chemically different steps. In the first step, initiation, an ADP-ribose
moiety is attached to the protein via a side chain residue. The second step, elongation, is the
formation of the linkage between the two ribose moieties of adjacent ADP-ribose units. Because
the nucleophiles in initiation and elongation are not the same, the enzyme is thought to play a
slightly different role in catalyzing each of these steps.
The initiation reaction is believed to be catalyzed primarily by the conformation of NAD*
binding. NAD* is bound by the enzyme in a constrained orientation that resembles the
oxocarbenium transition state. This internal strain helps to drive the reaction, because it is
relieved after breaking the bond with the nicotinamide (Ruf et al., 1998). The equivalent
reaction of a similar enzyme, diphtheria toxin, was characterized as a "dissociative SN2
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reaction," since the bond character of the NAD* molecule during the reaction suggested that the
bond to the nicotinamide is almost broken by the time of nucleophilic attack (Berti et al., 1997).
The nucleophile of the initiation reaction depends on which amino acid residue is being
modified. Thus far, the residues which are known to be modified by PAR are glutamic acid,
aspartic acid, and lysine (Ogata et al., 1980; Suzuki et al., 1986; Messner et al., 2010). Glutamic
acid and aspartic acid both have carboxyl groups which can act as good nucleophiles. This
suggests that the catalytic glutamate is likely not required for the initiation reaction in this case,
which has been verified by mutational studies in which a PARP-1 mutant lacking the catalytic
glutamate is still capable of mono(ADP-ribosylation) (Ruf et al., 1998). The catalytic glutamate
is thus not important for binding the substrate NAD*, but may play a role in the stabilization of
the oxocarbenium transition state (Figure 7A; Marsischky et al., 1995; Kleine et al., 2008).
The modification of lysine residues is suggested to proceed slightly differently (Altmeyer
et al., 2009). In this case, due to the weaker nucleophilic character of the lysine side chain as
compared to glutamic or aspartic acid, it is proposed that the nicotinamide group leaves before
attack of lysine on the oxocarbenium ion. There is some suggestion elsewhere in the literature
that PARP-1 is capable of such an SN1-type NADase reaction, but it has not been extensively
studied (Altmeyer et al., 2009; Kleine et al., 2008). The lysine-ribose linkage is then proposed to
rearrange via a Schiff base intermediate to a more stable ketamine linkage (Figure 7B). The role
suggested for the catalytic glutamate in this mechanism does not differ markedly from that
proposed for the initiation of ADP-ribosylation onto acidic residues. Whether lysine or
glutamic/aspartic acid modification of target proteins is more common is currently unknown.
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Figure 7. Proposed PAR initiation reaction mechanisms. A) Role of the catalytic glutamate
in stabilizing the oxocarbenium transition state. Reprinted from Molecular Cell, Volume 32, H.
Kleine et al., Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-
Ribosylation, p. 57-69, Copyright 2008, with permission from Elsevier. B) Formation of lysine-
ADP-ribose linkage. Reprinted from M. Altmeyer et al., Molecular mechanism of poly(ADP-
ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites,
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The catalytic glutamate appears to play a more extensive role in elongation, as
demonstrated by the mutational studies cited previously. In elongation, the nucleophile, namely
the hydroxyl group of the last previously added ADP-ribose residue, is much weaker. Thus, in
order to catalyze the reaction, the enzyme likely enhances its nucleophilicity via polarization. In
addition to stabilizing the oxocarbenium transition state of the NAD* via hydrogen bonds to the
2' hydroxyl of the nicotinamide ribose, it is thought that the glutamate also forms hydrogen
bonds to the nucleophile hydroxyl. This polarizes both nucleophile and electrophile (Ruf et al.,
1998). Replacement of the catalytic glutamate by a non-polar residue, as is the case in many of
the PARPs, would therefore be expected to result in reduced stabilization of the transition state
conformation of NAD* but more crucially also decreased nucleophilicity of the attacking ADP-
ribose hydroxyl, suggesting a lack of polymer-synthesizing activity in these PARPs.
This thesis seeks to examine the enzymatic and functional implications of the sequence
diversity in the PARP catalytic domain. First, the enzymatic capabilities of the PARPs are
experimentally determined. Next, I provide a possible structural rationale for these enzymatic
capabilities, and finally, explore methods for the identification of cellular targets of ADP-
ribosylation and functional interaction partners. Together, these elements of PARP
characterization will aid in the discovery of physiologically relevant targets and the
establishment of a mechanistic understanding of PARP enzymatic activity in the cellular context.
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Chapter 2
PARP enzymatic activity assays
43
Introduction
Since the PARP proteins are enzymes by definition, it is critical to delineate their
enzymatic capabilities in order to understand their potential biological functions. PARPs are
postulated to have one of three types of enzymatic activity: poly(ADP-ribose) synthesis,
mono(ADP-ribose) synthesis, or inactivity. Bioinformatic comparisons of the sequence and
structure of PARP domains have been used to predict which of these activities each PARP is
likely to have. The key determinant in these bioinformatic predictions of PARP activity is the
identity of the residues equivalent to the HYE catalytic motif of PARP- 1 (see Chapter 1, Table 1;
Kleine et al., 2008). Those PARPs that match PARP- 1 at each of these positions, therefore
containing an HYE motif of their own, are predicted (or in some cases demonstrated) to have
PAR synthesizing capability, like PARP- 1. More common in the PARP family is the
maintenance of only the histidine and tyrosine, which have been shown to be critical for the
binding and coordination of the substrate NAD*, which is used to add an ADP-ribose moiety to
protein or an elongating ADP-ribose chain. In these PARPs, glutamate is replaced with a
different residue. These PARPs are posited to be capable of the initiating step (adding a single
ADP-ribose to an amino acid residue) but not competent to generate PAR, since the mutation of
the glutamate residue in PARP-1 leads to mono(ADP-ribosylation) activity (Rolli et al., 1997).
Finally, there are two PARPs, PARP-9 and PARP-13, which lack not only the glutamate but also
the histidine, and for this reason are thought likely to be enzymatically inactive. Thus, the
identity of the HYE triad in each PARP has led to a prediction of its enzymatic capability.
While these bioinformatic predictions provide a useful educated guess as to the activity of
each PARP, thus far only 7 of 17 human PARPs have been fully empirically tested for enzymatic
activity (Hottiger et al., 2010). Therefore, we sought to assess the enzymatic activity of all
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PARPs experimentally. To do so, we performed standard automodification assays, which
examine the capability of each PARP to ADP-ribosylate itself. Of the PARPs that are known to
be enzymatically active, the activity of PAR synthesis has been shown to be primarily directed
towards the PARP itself (Rippmann et al., 2002; Tao et al., 2009). Thus, automodification
assays, first developed to demonstrate the enzymatic activity of bacterially-expressed isolated
PARP domains, have become the standard in the field for experimentally determining PARP
enzymatic activity (Simonin et al., 1993; Smith et al., 1998). Using full-length PARP purified
from an appropriate human cellular complex is a relatively recent experimental development and
has not been used even for many PARPs whose catalytic activity is thought to be well defined
(Kleine et al., 2008). However, full-length human PARPs expressed in human cells could
include other functional domains or post-translational modifications which regulate PARP
activity but would not be present in recombinant catalytic domains. Therefore, we sought to test
the enzymatic activity of all PARP family members in the most physiologically relevant way
possible, as tagged PARP constructs purified from human cells for use in in vitro biochemical
assays.
Results and Discussion
Purification of GFP-PARPs
In order to study the PARP proteins in vitro, we developed GFP clones of each PARP for
transfection and exogenous expression in human cells. GFP-PARP containing plasmids were
transfected into 293F cells, a cell type specialized to be able to grow in suspension to maximize
the cell-to-volume ratio. The larger number of cells available in a given volume of media in
suspension culture facilitates the growth of cell quantities needed for efficient biochemical
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purification. Cells were examined by microscopy both one and two days after transfection.
Most PARPs had the highest transfection efficiency and fewest dead cells one day post-
transfection, so cells were harvested at this time for most experiments. After cell lysis, GFP-
PARPs were immunoprecipitated by 3E6 monoclonal mouse GFP antibody complexed to Protein
A magnetic beads. Immunoprecipitates were then washed with buffer containing three times
physiological salt (450 mM NaCI) to reduce the number of background proteins present in each
sample. Immunoprecipitates of each GFP-PARP are shown as resolved by SDS-PAGE in Figure
1.
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Figure 1. Purification of GFP-PARPs. 293F cells were transfected with expression plasmids
containing GFP-PARP constructs. One day post-transfection, GFP-PARP proteins were
immunoprecipitated from lysates generated from the transfected cells. Immunoprecipitated
samples were resolved by SDS-PAGE. Molecular weight markers (left) and molecular weights
corresponding to each PARP (bottom, identified by PARP number above each gel) are shown.
Asterisk indicates molecular weight of IgG.
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First determination of PARP enzymatic activity
We set out to confirm biochemically the enzymatic activity of each PARP purified under
physiological, non-stressed conditions. To identify the catalytic activity of the PARPs
experimentally, we purified each full-length GFP-tagged PARP from human 293F cells. To
examine enzymatic activity, we tested the capability of our precipitates to incorporate the ADP-
ribose moiety under physiological salt conditions, using the substrate of a physiological
concentration of NAD* supplemented with 32P-NAD*. Because they are full-length proteins
expressed in their native human cell context, PARPs in our assays should contain physiologically
relevant modifications and native interacting partners of high binding affinity that could be
critical regulators of PARP activity. The presence of native modifications has been shown to be
critical for certain PARPs; for example, phosphorylation of PARP-5a by Plkl has been
demonstrated to increase its PARP activity (Ha et al., 2012).
One potential objection to our assay protocol could be the interference of large epitope
tags with physiological enzymatic activity. However, it has previously been shown that the
placement of a large epitope tag, such as the TAP tag on either end of a PARP, does not affect
enzymatic activity (Kleine et al., 2008). To confirm that placement of the GFP-fusion, 8 kD
larger than the TAP tag, at the N-terminus of the PARPs also does not affect enzymatic activity,
we compared the enzymatic activity of N-terminal and C-terminal fusions to PARP-1. GFP-
fusions at either end of both PARPs incorporated similar amounts of NAD*, suggesting that,
indeed, placement of the GFP-fusion does not affect ADP-ribose synthesis activity of the PARPs
(Figure 2).
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Figure 2. Placement of epitope tag does not affect enzymatic activity. GFP-PARP- 1 or
PARP-1-GFP was expressed in and purified from 293F cells and analyzed for enzymatic activity
using 32P-NAD* incorporation assays. Purifications were split into 4 equal samples, resolved via
SDS-PAGE and Coomassie stained (left), or incubated with 0, 50 or 100 pM NAD*
supplemented with 32P-NAD* (right).
PARP subfamilies were tested in parallel with a defined quantity of PARP-1, to normalize
each assay, and under increasing concentrations of NAD* to demonstrate substrate dependence.
In all cases where ADP-ribose synthesis activity was detected, each enzyme exhibited a linear
dose-dependent response to increasing concentrations of 32P-NAD* /NAD*. Assays were
repeated a minimum of 3 times with similar results. For each assay, a portion of purified protein
sample was resolved by SDS-PAGE and stained by Coomassie to ensure that similar amounts of
protein were used. However, while the assays used similar amounts of each PARP, it is
important to note that our results may not directly report on the relative activity of PARPs to one
another. While we could express and quantify the amount of each PARP, there were in some
cases coprecipitating contaminants, including other PARPs, which made unambiguous
quantitation of signal difficult (see below). PARP-3, -7, -11 and -15 were difficult to express or
purify (Figures 1 and 3); however, sufficient amounts of protein were used to assign activities for
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each PARP unambiguously.
Three activities can be distinguished in our assays: long PAR synthesis, mono(ADP-
ribose) or oligomer synthesis, and lack of activity. Due to variability in length and, potentially,
branching of the attached polymer structure, proteins modified by long PAR resolve
heterogeneously on SDS-PAGE. Thus, long PAR synthesis is indicated by smears of 3P-NAD*
incorporation above the predicted molecular weight of each PARP that synthesizes long PAR. In
contrast, because monomer or oligomer are smaller than PAR, oligomer-synthesizing enzymes
incorporate 32P-NAD' at the predicted molecular weight of the PARP and do not display a
mobility shift of signal. The resolution of our gels does not allow mono(ADP-ribose)
modifications to be distinguished from oligomers; thus, it is possible that rather than mono(ADP-
ribosylation), PARPs are generating oligomer (this distinction is discussed in greater detail at the
end of this chapter). For this reason we term active PARPs that do not generate a long molecular
weight smear as enzymes synthesizing "OAR," or oligo(ADP-ribose). PARPs that did not
incorporate NAD*, i.e., catalytically inactive enzymes, lacked signal even at high concentrations
(100 pM) of NAD*.
Overall, our results largely confirm the bioinformatic predictions of activity.
Interestingly, while the majority of PARP activity in our assays is directed at the PARP itself, in
many samples we identified incorporation at additional molecular weights, which may
correspond to co-precipitating target proteins modified by ADP-ribose. Since 3 2P-NAD* was
added post-immunoprecipitation and high salt washes, these co-precipitating proteins must be
tightly associated with and modified by PARPs present in the purification. Thus, our results
might also be useful in the identification of the targets of each PARP, particularly in combination
with mass spectrometry analysis (see Chapter 4).
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Figure 3. Analysis of PARP enzymatic activity. Activity assays were performed as described
in Figure 2. For each assay, the members of one PARP subfamily were analyzed together with
PARP-1I as a normalizing control. Asterisks indicate the molecular weight of the respective
PARP.
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DNA-dependent PARPs
PARP-1 and -2 exhibited a signal pattern consistent with PAR synthesis activity, while
PARP-3 appeared to synthesize OAR (Figure 3). Interestingly, while there is PAR activity at the
molecular weight of PARP-2, the majority of signal incorporated in the PARP-2 precipitations
migrates at a molecular weight consistent with PARP- 1 modification. This result is in keeping
with previous work showing that PARP- 1 and -2 heterodimerize and modify each other
(Schreiber et al., 2002). Since the ratio of PARP-2 to PARP-1 is higher in the PARP-2 assay, this
could suggest that PARP-1 activity is upregulated by PARP-2 binding and/or modification.
PARP-3 incorporated only minor amounts of NAD*, even at 100 ptM (Figure 3). The mobility of
incorporated signal indicated short PAR synthesis, consistent with recent reports (Loseva et al.,
2010).
Tankyrases
PARP-5a and -5b both incorporated the ADP-ribose moiety of NAD* in a manner
consistent with PAR synthesis activity. In agreement with our previous results, PARP-5a activity
is low when purified from asynchronous populations of cells (Chang et al., 2005). In contrast,
under identical purification conditions PARP-5b precipitations incorporated high amounts of 32P-
NAD*, and the majority of incorporated signal in PARP-5b preparations resolved at and above
the molecular weight of PARP-5a, suggesting that at least some of the signal in the PARP-5b
preparation could be synthesized by PARP-5a after activation by PARP-5b (Figure 3). Previous
work demonstrated that, like PARP-1 and PARP-2, PARP-5a and PARP-5b heterodimerize and
transactivate. This indicates a likely strong physiological and functional interaction between the
two tankyrases, consistent with the results of our assay (Sbodio et al., 2002). Together, our
results for PARP-5a and PARP-5b demonstrate that enzymatically active PARP-5a co-
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precipitates with PARP-5b under physiological conditions, and that tankyrases appear to require
heterodimerization for full enzymatic activity. These interactions are confirmed by mass
spectrometry analysis in Chapter 4.
CCCH Zn finger PARPs
PARP-7 and -12 incorporated NAD* signal in a pattern consistent with OAR synthesis,
while both isoforms of PARP-13 are inactive (Figure 3). PARP-7 and -12 show the highest
incorporation of signal at their own molecular weights, indicating that auto-modification is the
dominant activity for these PARPs. However, several other bands were identified in our PARP-7
and -12 activity assays, suggesting that these bands might represent targets of modification by
PARP-7 and -12. Signal at the molecular weight of PARP- 13 is present in our PARP- 12
preparations, suggesting that PARP-13 could serve as a target of ADP-ribosylation by PARP- 12.
This agrees with our previously published results demonstrating binding and functional
interactions between PARP-13.2, -13.1 and -12 (Leung et al., 2011).
Interestingly, we noted an additional high molecular weight smear above the
incorporation signal of PARP-7. Since PARP- 1 and PARP-7 both localize to the nucleus, it is
possible that they could interact functionally in the cell, suggesting that PARP- 1 could have
copurified with PARP-7 and that the observed pattern could be due to PARP-1 modification of
PARP-7. To test this possibility, we repeated the PARP-7 activity assays under conditions of
PARP-1/2 inhibition using AZD2281 and PARP-5a/5b inhibition using XAV-939. Treatment
with high concentrations of XAV-939 had no effect on PARP-7 incorporation assays, while
treatment with AZD2281 dramatically reduced incorporation of signal by PARP-7 even at the
molecular weight of PARP-7 (Figure 4). This result suggests that PARP-7 modification requires
PARP- 1/2 activity and that these PARPs cooperate to synthesize PAR. Alternatively, it is
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possible that AZD2281 is not specific for PARP-1 and could inhibit PARP-7 activity. Without
further structural information, it is not possible to exclude this possibility.
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Figure 4. A possible functional interaction between PARP-1 and PARP-7. Activity assays
were performed for PARP-1 and PARP-7 in the presence of AZD2281 (PARP-1/2 inhibitor) and
for PARP-5b and PARP-7 in the presence of XAV-939 (PARP-5a/5b inhibitor) as described in
experimental procedures.
Macro PARPs
PARP-9 failed to incorporate NAD* at its molecular weight, suggesting a lack of catalytic
activity which is consistent with previous reports (Aguiar et al., 2005). However, PARP-9
instead displayed a higher molecular weight signal. This signal could be due to co-purified
PARP-1 (Figure 3), suggesting that these two PARPs could function together. PARP-14 and -15
incorporated NAD* in a manner consistent with OAR activity (Figure 3). As in PARP-7 and
PARP- 12, our results suggest that both PARPs have multiple targets since multiple bands were
also present in the autoradiogram.
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Unclassified PARPs
Surprisingly, PARP-4 was inactive in our assays at all of the tested NAD* concentrations,
which for PARP-4 included 1 mM NAD' (Figures 3 and 5). The lack of PARP-4 enzymatic
activity contrasts with previous reports using bacterially expressed PARP-4 catalytic domain and
purified vault particles (Kickhoefer et al., 1999). One possible cause of this discrepancy is that,
unlike all the other PARPs, the catalytic domain of PARP-4 is located in its N-terminus. Thus,
one possible interpretation is that the lack of activity in our assay could be due to the N-terminal
position of our GFP tag. We tested this by generating a C-terminal fusion to PARP-4, but this
was also inactive under all conditions (Figure 5). Another possibility is the presence of a number
of mutations identified in the commercially available full PARP-4 clone used in our assays.
While none of these mutations are present in the catalytically critical residues, they may
nevertheless impact binding interactions or modifications that are critical for full PARP-4
activity. Alternatively, it is possible that the difference in our assay methods as compared to
those employed by Kickhoefer and colleagues results in a loss of activity - that is, that the PARP
domain alone may be functional, but that other domains of PARP-4 may be inhibiting its activity
outside the context of the vault particle and its relative interaction partners (Kickhoefer et al.,
1999).
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Figure 5. PARP-4 appears inactive under multiple conditions. Activity assays were
performed as described in materials and methods and with NAD* concentrations of 10 pM, 100
gM, 500 pM, and 1 mM for PARP-1, N-terminally tagged GFP-PARP-4 (PARP-4N), and C-
terminally tagged PARP-4-GFP (PARP-4C).
PARP-6, -8, -10, -11 and -16 all incorporated NAD' in a manner consistent with OAR
activity, with the primary activity in these assays being automodification (Figure 3). Similar to
other OAR-synthesizing PARPs, we also identified a distinct banding pattern for PARP-6, -8 and
-11, indicating that the binding proteins which co-immunoprecipitate are likely targets of
modification. Our assays suggest that the enzymatic activity of PARP-16 under physiological
conditions is low (Figure 3). By contrast, PARP-10 activity was high, displaying a smear
possibly indicative of PAR synthesis, in contrast with previous reports (Kleine et al., 2008).
Resolution of the PARP-10 activity samples on a lower percentage SDS-PAGE gel demonstrated
more clearly that PARP-10 most likely synthesizes OAR, in keeping with published work
(Figure 6; Kleine et al., 2008).
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Figure 6. PARP-10 synthesizes OAR. PARP-10 activity assay performed as in Figure 2 but
resolved on a 6% polyacrylanmide gel. (For reference, PAR synthesis on a 6% gel can be seen in
the PARP-1 assay in Figure 8.)
High-stringency activity assays
In our initial assays, immunoprecipitates were washed in 450 mM NaCl buffer prior to
incubation with NAD*. Under these conditions, additional bands of signal that did not correspond
to the molecular weight of the purified PARP were identified, despite the purity of our samples
as demonstrated by Coomassie stain (Figures 1 and 3). Mass spectrometry analysis of the
immunoprecipitates revealed the presence of other PARP enzymes in some samples,
complicating interpretation (see Chapter 4). Therefore, we increased the stringency and use of
the salt washes. Wash buffer salinity was increased to 1M NaCl and was used both in sample
preparation prior to each incorporation assay and following each assay to remove excess
unincorporated NAD*, free polymer, and any other contaminants. This treatment reduced the
extraneous radioactive signal. Additionally, the absence of PARP- 1 in samples where it was
previously present (as shown by incorporation assay results and mass spectrometry
corroboration) was demonstrated by immunoblot (Figure 7). Therefore, assays were performed
56
under these conditions. Despite high wash stringency, a signal of ADP-ribose incorporation was
detected at the dye front of all enzymatically active PARPs in a protein concentration-dependent
manner. This signal could not be removed by extensive 1M NaCl washing. While our
conclusions as to the enzymatic capabilities of each PARP due to its automodification pattern did
not change from those drawn from the data in Figure 3, the data in Figure 8 demonstrate the roles
of individual PARPs with more confidence.
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Figure 7. New purification strategy removes PARP-1 assay contamination. GFP-PARP-7
lysates and immunoprecipitates generated according to the protocol used in Figure 1 were
immunoblotted for PARP-7 and PARP-1.
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Figure 8. High stringency wash analysis of PARP enzymatic activity. GFP-PARPs were
purified from 293F cells and analyzed for enzymatic activity using 3P-NAD* as a substrate for
ADP-ribose incorporation. Purifications were split into 4 equal samples, resolved via SDS-
PAGE and Coomassie stained (left), or incubated with 0, 50 or 100 piM NAD* supplemented
with 3P-NAD* (right). The positions of molecular weight markers are indicated to the left, and
the calculated molecular weight of the GFP-PARP to the right. Asterisks indicate GFP-PARP
stained by Coomassie.
DNA-dependent PARPs
PARP-1 and -2 incorporated the ADP-ribose moiety of NAD* in a manner consistent
with PAR synthesis activity, similar to previously published reports (Figure 8; Simonin et al.,
1993; Amd et al., 1999). When washed with buffer containing 450 mM NaCl, PARP-2 exhibited
strong incorporation of signal at the molecular weight of PARP-1, and we confirmed the known
functional interaction of these PARPs by mass spectrometry (Figure 3; see also Chapter 4). 1M
NaCl washes removed the incorporated signal at the molecular weight of PARP- 1, and the
remaining signal was consistent with PARP-2 activity alone. As PARP-2 levels were difficult to
visualize by Coomassie stain, we used PARP-2 antibody for immunoblot to demonstrate efficient
protein capture (Figure 9). PARP-3 incorporated ADP-ribose at its molecular weight in a pattern
suggestive of OAR synthesis activity, consistent with recent reports (Figure 8; Loseva et al.,
2010).
Tankyrases
We confirmed previously reported results that PARP-5a and -5b incorporated NAD* in a
manner consistent with PAR synthesis (Figure 8; Smith et al., 1998; Cook et al., 2002). We had
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difficulty visualizing PARP-5a and -5b by Coomassie and thus used affinity-purified antibodies
against each PARP for immunoblot. Interestingly, one potential reason for the lack of
modification of PARP-5a seen in our assays is that it is already highly modified, visible by the
electrophoretic mobility shift detected by PARP-5a antibody (Figure 9).
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Figure 9. Expression of PARP-2, PARP-5a, and PARP-5b in high stringency activity
assays. GFP-PARP-2, PARP-5a and PARP-5b lysates generated as described in Figure 8 were
immunoblotted with their respective anti-PARP antibody.
CCCH Zn finger PARPs
The majority of signal incorporated by PARP-7 resolved at its molecular weight (Figure
8). Additional signal was incorporated as a smear under both 450 mM NaCl and 1M NaCl wash
conditions. This smear exhibited characteristics of PARP- 1 activity, and PARP- 1 was identified
in PARP-7 purifications under 450 mM NaCl wash conditions by mass spectrometry (Chapter 4).
However, immunoblot against PARP- 1 in our PARP-7 preparations under 1 M NaCl wash
conditions indicates that PARP-1 is not present in these immunoprecipitates, suggesting that
PARP-7 generates OAR which is perhaps slightly longer in length than that made by other OAR-
synthesizing PARPs. Additionally, these immunoblots show that although we were not able to
visualize GFP-PARP-7 by Coomassie, we have captured sufficient amounts of enzyme (Figure
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7). PARP-12 incorporated NAD* in a pattern consistent with OAR synthesis, while both
isoforms of PARP-13 were inactive (Figure 8).
Macro PARPs
PARP-9 failed to incorporate detectable amounts of NAD', suggesting that it is
catalytically inactive, in agreement with previous reports (Figure 8; Aguiar et al., 2005). PARP-
14 and -15 incorporated NAD* in a manner consistent with OAR synthesis (Figure 8). While
this contrasts with the earliest published reports that identified PAR synthesis for PARP-14 and
PARP-15, more recent reports have demonstrated mono(ADP-ribosylation) activity for PARP-14
(Aguiar et al., 2005; Kleine et al., 2008). Since this assay does not distinguish mono(ADP-
ribose) from oligo(ADP-ribose), this work is still consistent with our results. Even under
stringent wash conditions, multiple bands were present in the PARP-15 autoradiogram,
indicating the co-precipitation of potential targets of PARP-15 activity.
Unclassified PARPs
PARP-4 incorporation was consistent with synthesis of PAR, albeit shorter than that of
other PAR-synthesizing enzymes (Figure 8). PARP-6, -8, -10, -11 and -16 each incorporated
NAD* in a manner consistent with OAR synthesis (Figure 8). Identification of OAR activity for
PARP-10 is consistent with previously published reports showing that the enzyme does not
synthesize PAR (Figure 8; Kleine et al 2008).
PARG treatment of PARP enzymatic products suggests the presence of OAR modifications
Because of the inability to resolve between short oligomers (OAR) and mono(ADP-
ribosylation) in our gels, we wished to distinguish more accurately between these synthesis
capabilities using enzymatic treatment with poly(ADP-ribose) glycohydrolase (PARG). Since
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PARG is an exoglycosidase that cannot hydrolyze the proximal ADP-ribose unit directly
attached to protein, release of any ADP-ribose product from treatment with PARG should be
indicative of OAR rather than mono(ADP-ribose) synthesis (Slade et al., 2011). By contrast, a
PARP which is modified at many sites by mono(ADP-ribose) should display no decrease in
automodification signal after treatment with PARG. The automodified PARP samples (as shown
in Figure 8) were treated with PARG for 30 minutes or 60 minutes. The remaining ADP-ribose
modification attached to the synthesizing PARP was analyzed via SDS-PAGE, as before, while
the released reaction product was analyzed via thin layer chromatography (TLC).
We first tested the enzymatic activity of PARG in our assays using PARPs known to
generate PAR. As expected, the majority of PAR attached to PARP-1 and PARP-5b was
hydrolyzed within 30 minutes, as demonstrated via PAGE analysis by the loss of higher
molecular weight smears of signal with a residual signal resolving at the molecular weight of the
PARP (Figure 10). Since additional incubation with PARG for up to 1 hour did not significantly
reduce the intensity of this residual signal, it likely represents the proximal ADP-ribose unit
directly attached to each modification site on the PARP. In each case, TLC analysis of the
products released by PARG hydrolysis identified ADP-ribose, confirming the activity of the
enzyme (Figure 10).
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Figure 10. PARG hydrolysis of PARP-1, PARP-5b, and PARP-10 reaction products
demonstrate ADP-ribose release for each PARP. PARP modifications (generated as in Figure
8) were treated with PARG for 0, 30, or 60 minutes. The remaining modified protein at each
time point was analyzed by SDS-PAGE and autoradiogram and the cleaved product in the PARG
reaction supernatant was resolved via TLC (right). Treatment of both PAR-synthesizing PARP
reactions and OAR-synthesizing PARP reactions with PARG resulted in a decrease in the ADP-
ribose signal resolving at or above the molecular weight of each PARP. PARG treatment shows
release of ADP-ribose as identified by comparison to 32P -NAD* and 32P-ADP-ribose sizing
standards (marked at right).
Similar to the hydrolysis treatment of PAR-synthesizing PARPs 1 and 5b, PARG
treatment of PARP- 10 incorporation reactions, predicted to consist of mono(ADP-ribos)ylated
PARP-10, also resulted in a reduction of the PARP-attached ADP-ribose signal when analyzed
by SDS-PAGE (Figure 10; Kleine et al., 2008). Signal was reduced between 0 minutes and 30
minutes (89% of original signal), and further reduced at 60 minutes (82% of original signal),
indicating the continued release of ADP-ribose from the modifications attached to the PARP.
Multiple assays yielded similar results. TLC analysis of the PARG reaction products confirmed
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ADP-ribose release at all time points (Figure 10). Together, these results suggest that the ADP-
ribose modifications generated by PARP-10 are longer than single units of ADP-ribose. In fact,
despite the bioinformatic predictions that PARP-10 would only be capable of mono(ADP-
ribosylation), this is consistent with the findings of Kleine and colleagues that PARP-10
generates dimers and trimers of ADP-ribose (Kleine et al., 2008). Since the ADP-ribose attached
to PARP-10 did not result in the major shift in molecular weight typically associated with PAR
modification, but the modifications were longer than mono(ADP-ribose), these results suggest
that ADP-ribose modifications synthesized by PARP-10 are neither mono(ADP-ribose) or PAR,
but rather short oligomers of ADP-ribose. This also appears to be true for other PARPs in our
assays (Figure 11).
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Conclusions
In agreement with predictions from previous studies, our analysis suggests that most
PARPs do not generate long polymers of PAR commonly associated with PARP activity, but
instead catalyze shorter ADP-ribose oligomer (OAR) structures, which contain more than one
unit of ADP-ribose but do not result in dramatic shifts in electrophoretic mobility, unlike PAR
(Table 1). Although these assays do not definitively determine the length of polymer generated
by any given PARP, they do demonstrate that there is a significant difference in the
automodifying PAR synthesis capability among members of the PARP family.
PARP Catalytic Auto-ADP- Polymerase Oligo-ADP-Ribosyl Postulated (Oligo [0]
core Ribosylation Activity Transferase Activity versus Poly [P])
motif
Table 1. Summary of demonstrated enzymatic activity of the human PARP family. Newly
confirmed activities are highlighted in lighter colors. Green indicates postulated polymer
activity, red indicates postulated oligoner activity, and gray indicates postulated inactivity.
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If the presence of the catalytic glutamate is as critical to the reaction mechanism as
posited by Ruf and colleagues, it is somewhat puzzling that so many PARPs which lack a
catalytic glutamate could be capable of oligomer synthesis (Ruf et al., 1998). The catalytic
glutamate is thought to be important both for stabilizing the oxycarbenium ion transition state of
the substrate NAD' as well as enhancing the nucleophilicity of the attacking hydroxyl of the
ADP-ribose via hydrogen bonding, which most oligomer-synthesizing PARPs would presumably
not be capable of due to their replacement of the glutamate with nonpolar residues such as
isoleucine and leucine. While the glutamate may be the most efficient means of catalyzing the
linkage between ADP-ribose moieties, it is possible that other factors which enhance this
mechanism might exist in other PARPs, allowing them to catalyze the formation of a small
number of ribose-ribose linkages, albeit not nearly as efficiently. For example, Ruf and
colleagues suggest that the glutamate is not involved in NAD* binding, but the substrate NAD' is
bound by the PARP (through the involvement of the conserved histidine and tyrosine residues) in
a conformation similar to that of the oxycarbenium transition state (Ruf et al., 1998). Moreover,
Altmeyer and others suggest that PARPs may be able to use this geometry to drive the release of
nicotinamide, resulting in the formation of the oxycarbenium ion prior to nucleophilic attack
(Altmeyer et al., 2009). Thus, it might be possible that the constrained geometry of NAD'
binding enables attack by a relatively weak nucleophile such as a hydroxyl, even without
polarizing the hydroxyl to enhance its nucleophilic properties. This mechanism appears less
likely or favorable than catalysis by glutamate, however, and thus our surprising finding that
many PARPs appear to synthesize oligomer rather than monomer should be verified by other
experimental means. For example, comparison of the results of our PARG treatment assays to
PARG treatment assays conducted on incorporation assays using 2' deoxy NAD*, which should
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prevent the formation of any modification longer than monomer, would help to ascertain the
presence of oligomers in our original assays.
The implications of OAR synthesis being the predominant activity of the PARP family
include limited mechanisms of function. Generally, ADP-ribose modifications are thought to
function via at least two mechanisms: as direct modifications of protein that result in a change in
protein function or as scaffolds for protein binding (Chang et al., 2004, 2009; Kotova et al.,
2009; Ahel et al., 2009; Leung et al., 2011). While longer polymers of ADP-ribose do not rule
out direct modification as a mechanism of function, mono(ADP-ribose) or very short OAR are
unlikely to act as scaffolds due to their small surface area. Thus, depending on its structure,
OAR could function via either mechanism. Among the PAR synthesizing enzymes, PARP-1 and
-2 have been shown to synthesize longer branched structures, while PARP-5a is thought to
generate shorter linear polymers (Kleine et al., 2008). While the functional relevance of these
structurally distinct polymers is currently unclear, one possibility is that they confer protein
binding specificity.
Additionally, it has been proposed that mono(ADP-ribose) modifications can serve as
substrates for elongation to PAR (Kleine et al., 2008). Since OAR could also serve as a substrate
for elongation, a close examination of this possibility is critical to identify potential functional
interactions between OAR and PAR.
Materials and Methods
PARP activity assays
293F suspension cells were transfected with GFP-PARP DNA 25 h prior to purification. Cells
were washed 3 times in ice-cold PBS, diluted 1:4 with cell lysis buffer (CLB) (150 mM NaCl, 50
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mM HEPES pH 7.4, 1 mM MgCl2, 1% Triton X-100, 1 pM DTT, 10 mM EGTA, and protease
inhibitor cocktail) then incubated 10 min on ice. Lysates were cleared via centrifugation (16100
g/ 10 min). GFP-PARP was immunoprecipitated using 3E6 antibody (Invitrogen) conjugated to
Protein A Dynabeads (Invitrogen), washed twice in CLB containing 450 mM NaCl, then
resuspended in CLB with 1 pM ADP-HPD (PARG inhibitor to prevent degradation). Samples
were incubated with 0, 50 or 100 pM NAD* containing a constant ratio of 2.5 ICi 32p_
NAD*:100 ptM per reaction for 30 min at 16'C, washed and eluted in Laemmli sample buffer
(Bio-Rad, #161-0737) for 10 min at 650C. Samples were resolved on TGX 7.5% Tris-glycine
gels (Bio-Rad), dried (Invitrogen gel dry kit), and exposed to a phosphor screen for 24 h.
Assays were repeated a minimum of 3 times with similar results. We attempted to normalize for
protein input into each assay. A portion of each was examined via Coomassie staining.
High stringency PARP activity assays
Lysates were prepared as above and then cleared via centrifugation (16K g/ 10 min or 100K g/
30 min). GFP-PARP was immunoprecipitated using 3E6 antibody (Invitrogen) conjugated to
Protein A Dynabeads (Invitrogen), washed thrice in CLB containing 1 M NaCl, then
resuspended in CLB with 1 ptM ADP-HPD. Samples were incubated with 0, 50 or 100 pM
NAD* containing a constant ratio of 2 piCi 3 2P-NAD*:100 pM per reaction for 30 min at 25*C,
washed and eluted in Laemmli sample buffer for 10 min at 65'C. Samples were resolved on
polyacrylamide gels of the appropriate percentage (6%, 8%, or 10%), dried (Invitrogen gel dry
kit), and exposed to a phosphor screen for 24-48 h. Assays were repeated a minimum of 3 times
with similar results. A portion of each sample was examined via Coomassie staining (Colloidal
Blue, Invitrogen) or immunoblot.
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PARG treatment
PARG was purchased from Trevigen Inc. PARP activity assays were incubated with PARG
(200 ng/ml in 50 mM KPO4, 10 mM p-mercaptoethanol, 20'C) for 30 or 60 min. Reactions were
washed in 1M NaCl CLB and eluted in Laemmli sample buffer at 65'C for 10 min. Samples
were resolved on PAGE gels, then dried. For thin layer chromatography (TLC), PARG reactions
and 3 2 P -NAD* and 32P-ADP-ribose (Oka et al., 2006) were spotted onto PEI-cellulose matrix
(Sigma), developed in 1.0 N acetic acid, dried, and developed again in 0.9 N acetic acid/0.3 M
LiCl. For each PARG reaction, TLC plates and PAGE gels were exposed together in the same
autoradiogram.
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Chapter 3
PARP crystal structure analysis
73
Introduction
Structural and functional studies of the PARP catalytic domain of PARP-1 have revealed
residues critical for the coordination and binding of the substrate NAD*, which provides the
ADP-ribose moiety that PARP enzymes attach to an incoming protein (the initiation reaction) or
existing ADP-ribose chain (the elongation reaction). With the advent of PARP inhibitors as a
useful clinical tool for the treatment of certain cancers, more recent structural studies of PARP- 1
have focused on the interaction of the PARP domain with inhibitors in order to design more
potent pharmaceuticals. As PARP inhibitors progress through clinical trials, many researchers
have realized that the positive effects of PARP inhibition appear to extend beyond a possible role
in regulation of the DNA damage response, suggesting PARP-1-independent effects of PARP
inhibitors. This has prompted an interest in understanding the potential effects of inhibiting the
remaining PARP family members. To this end, Wahlberg and colleagues measured the
interaction strength and crystallized the catalytic domains of several members of the PARP
family in complex with different PARP inhibitors (Wahlberg et al., 2012). These studies
suggested, as expected, that the majority of PARP inhibitors, which are largely NAD* analogues,
are not PARP-specific.
Bioinformatic predictions of PARP activity for the entire PARP family have now been
experimentally tested (see Chapter 2). In combination with increasing numbers of solved crystal
structures of PARP catalytic domains, this allows for the first time a systematic analysis of the
relationship between unique and conserved PARP domain structural elements and PARP
enzymatic activity (Wahlberg et al., 2012; Karlberg et al., 2010; Ruf et al., 1998; Kirby et al.,
2012; Lehtiu et al., 2009; Karlberg et al., 2012). While previous studies have focused on the
comparative analysis of a small number of structural elements among a few PARPs or detailed
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structural features of a single PARP, this study aims to analyze each relevant feature of the entire
PARP domain across the PARP protein family (Kleine et al., 2008; Wahlberg et al., 2012). Not
all PARP domains currently have solved structures, but the high degree of sequence homology
within PARP subfamilies and the large number of available structures allows for informative
modeling of the remaining PARP structures to expand our analysis. First, we examine the
overall structure of the PARP domain across the PARP family in solved crystal structures, and
then we focus on two particular regions of the PARP domain previously identified as critical for
the enzymatic activity of PARPs: the donor site, where substrate NAD' (or inhibitor) binds to
the catalytic domain for hydrolysis to ADP-ribose, and the acceptor site, where the modification
target (amino acid residue or ADP-ribose chain) binds to the PARP. The relative positions of
these sites and other key residues in the PARP domain are shown in Figure 1. Highlighted in
cyan and shown in stick format are the three key catalytic residues - histidine, tyrosine, and
glutamate - experimentally identified in PARP- 1 and identified by sequence alignment in other
PARPs. Shown in yellow is the D-loop which Wahlberg et al. (2012) define as the "lid" of the
NAD*-binding donor pocket, and shown in red is the [4 - [5 loop identified by Kleine et al.
(2008) as a key contributor to the difference in catalytic activity between PARP-1 and PARP- 10.
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D-loop % Acceptor site
Donor site
04-05 loop
Key catalytic residues
Figure 1. The PARP fold of PARP-1 showing key residues and regions. The overall
structure is shown in green in ribbon form, key catalytic residues are shown in cyan in stick
form, the D loop identified by Wahlberg et al. (2012) is shown in yellow and the p4/5 loop
identified by Kleine et al. (2008) is shown in red.
After individual analysis of each PARP, we perform a comparative analysis of the less
well-studied PARPs aligned to the two best-characterized PARP subfamilies, the DNA-
dependent PARPs (PARP-1 and PARP-2) and the tankyrases (PARP-5a and PARP-5b). Next,
we model the remaining PARP domains and compare their potential structural features to other
PARPs to gain insights into structural reasons for their observed enzymatic activity.
Finally, we present an analysis of the crystal structures of 11 other functional domains in
PARPs. This section updates the analysis presented by Am6 and colleagues nine years ago and
provides further insight into the physiological roles of PARPs (Am6 et al., 2004).
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Together, the analyses outlined above and presented in this chapter identify structural
elements which differ among the human PARPs, helping to explain the observed differences in
catalytic activity demonstrated in Chapter 2 and through the work of others. These structural
elements are of two kinds. First, there is the presence or absence of a catalytic glutamate, which
is thought to catalyze the formation of polymer by stabilizing the transition state of the substrate
NAD* while polarizing the attacking hydroxyl group of ADP-ribose to enhance its
nucleophilicity. Non-polar substitutions of the catalytic glutamate, as present in PARPs 6-16, are
likely unable to perform this role. Second, while the shape of the NAD' binding site is fairly
similar in each PARP, the structure and composition of the acceptor site, where the terminal
ADP-ribose binds, varies significantly among the PARPs, and allows us to distinguish four
different types of catalytic activity, each of which has a distinctive pattern of residue identity and
modeled distance from the ADP-ribose: inactivity, branched polymer synthesis, linear polymer
synthesis, and oligomer synthesis. The only crystallized inactive PARP, PARP-13, replaces the
histidine of the NAD' binding site with a tyrosine which extends up into the NAD* binding site,
likely resulting in steric hindrance of the binding of NAD*, hence explaining PARP-13's
inactivity.
Among active PARPs, there is no clear reason why NAD* binding capacity should differ.
In PARPs which can synthesize branched polymer (PARP-1 and PARP-2), the PARP interacts
with the pyrophosphate moiety of ADP-ribose via a histidine at a distance of 2-5 A, a lysine at a
distance of 5 A, and the peptide backbone at distances of 3.3-3.8 A; the catalytic glutamate is
between 3.1 and 5 A from the hydroxyl groups of the adenine ribose; and a methionine residue at
a distance of 3.6-4.5 A interacts electrostatically with the adenine ring. PARPs which
synthesize linear polymer, by contrast (PARP-5a, PARP-5b, and modeled PARP-4) maintain
77
similar residue identities and distances in the interactions with the ribose and adenine, but the
pyrophosphate-interacting residues are replaced (glycine for histidine in PARP-5a and PARP-5b)
and/or at much greater distances to the pyrophosphate (-6-8 A) than those of PARP-1 and
PARP-2, indicating weaker stabilization of this portion of the ADP-ribose which is critical for
the orientation of ADP-ribose conducive to branch formation. Finally, the oligomer-synthesizing
PARPs, in addition to their lack of a catalytic glutamate (and correspondingly greater distances
to the ribose, often around 7A), also display greater distances to the pyrophosphate (often above
1OA) and often potential steric clash with the adenine ring via replacement and shortened
distance of the methionine (2.4-3.3 A). This indicates that in addition to a diminished role in
enhancing nucleophilicity of the ADP-ribose hydroxyl, oligomer-synthesizing PARPs probably
bind less well to ADP-ribose as a substrate for modification.
We also considered other structural elements in our attempt to explain catalytic
differences among the PARPs. Overall, the shape of the PARP domain does not vary among
different PARPs and is thus thought not to determine catalytic activity. Other regions of the
PARP domain which may be important for PARP functionality but do not appear to have a
bearing on the catalytic activity of PARPs per se include the D-loop, which may regulate NAD*
and inhibitor binding, and the P4-$5 loop, whose shape may be important for intermolecular
PARP interactions, neither of which were explicitly considered in our analysis. In conclusion,
our analysis provides several possible structural reasons for the observed differences in catalytic
activity among the PARPs.
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Results and discussion
Catalytic domain
The solved crystal structures of PARP-1, -2, -3, -5a, -5b, -10, -12, -13, -14, -15, and -16 were
aligned in PyMol and are shown in Figure 2 in ribbon form in the same orientation (Table 1 lists
the exact crystal structures used in our analysis; Wahlberg et al., 2012; Karlberg et al., 2010; Ruf
et al., 1998; Kirby et al., 2012; Lehti5i et al., 2009; Karlberg et al., 2012). Strikingly, the overall
composition and shape of the PARP catalytic domain in isolation is largely conserved, even
though the overall sequence homology among all PARPs is relatively low. We have highlighted
in each PARP domain the three previously identified key structural elements, as defmed by
sequence homology, that are shown for PARP-1 in Figure 1, and we will return to them later in
the analysis. Note that the crystal structures of PARP-14, -15, and -16 are missing portions of
the yellow D-loop and PARP-16 is missing the red p4 - p5 loop, preventing firm conclusions
about the role of these regions in the enzymatic activity of these PARPs.
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PARP PDB Resolution Wilson Inhibitor Inhibitor structure
ID Rfree (A) plot B-
factor
(A2)
1 3L3M .275 2.50 45.6 A927929 / F
C~ ~ gl .-
Ci-- C.7 Ci-C2 N20 C
C14
24 123
2 3KCZ .237 2.00 20.2 3AB 0  c N'
3 3FHB .254 2.30 19.6
10 3HKV .242 2.10 34.3
12 2PQF .244 2.20 44.4 c c2
14 3GOY .292 2.80 62.2 1y0 1
16 4FOD .287 2.70 65.3 c c c N
Sa 3UH4 .234 2.00 27.0 XAV939
5b 3KR8 .255 2.10 20.0
C CAKN Z~iC 1,H
HAH CAF AP ,, C CAI
\ )' 4 CAQ AE
CAU CAC
15 3GEY .270 n/a n/a PJ34 CAF
CAI CAE
CAA NAMI T CIH
1.1 C CAP CAU CAS HAH
CAB C CAC . CARK.JCAQ,
CAJ r AN OA
13 2x5y .149 1.05 7.7 n/a n/a
Table 1. PARP crystal structures and inhibitors. The indicated crystal structures of PARPs
(identified by their Protein Database (PDB) ID) co-crystallized with inhibitors were used for
analysis. Where possible, crystal structures with the same inhibitor (usually 3AB, a general
PARP inhibitor) were chosen. Rfree, resolution, and the B-factor as measured by Wilson plot are
provided (information from PDB and from the Electron Density Server). The structures of
inhibitors are shown at right.
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Branched polymer
DARP.1 DADD.9
Unbranched polymer
Oligomer Inactive
DADn-4t
Figure 2. The PARP domain has a conserved fold. One representative crystal structure of
each previously determined PARP catalytic domain (PDB database) is shown in the same
orientation. PARPs are organized by experimentally determined synthesis activity: polymer with
many branches (branched polymer), polymer with few branches (unbranched polymer),
oligomer, and inactive. Colors are as in Figure 1.
The donor pocket
Previous analysis of the crystal structures of PARPs has largely focused on the NAD*-
binding donor pocket, since this region is also where PARP inhibitors bind and many structural
studies have been primarily interested in characterizing the PARP - inhibitor interaction.
Therefore, we decided to examine the key features and residues in this portion of the PARP
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domain (Figure 3). We have shown in magenta the inhibitor bound to each PARP (for the
identity and structure of the inhibitors, please see Table 1). The three key catalytic residues
highlighted in cyan are His, Tyr, and Glu for PARP-1. The histidine and tyrosine residues have
been shown to be critical for coordination of NAD*, while the glutamate has been shown to be
critical for elongation of polymer. The tyrosine residue is conserved and is in roughly the same
position in all PARPs whose structures have been determined. The histidine is also conserved in
all enzymatically active PARPs.
Branched polymer
PARP-1 PARP-2
Unbranched polymer
PARP-5a
P-3 PARP-10 PARP-12
Inactive
PARDP-4%
PARP-15
Figure 3. PARP domains have a similar NAD* binding pocket. The same crystal structures
shown in Figure 2 focused on the NAD* donor pocket, where free NAD* binds to be
incorporated by the enzyme as an ADP-ribose modification onto a protein or poly(ADP-ribose)
substrate. Colors are as above. Shown in magenta is the inhibitor used for crystallization
purposes in each case.
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gomer
PAR
PARP-5b
Of the PARPs crystallized thus far, PARP-13 is the only PARP that is demonstrated to be
enzymatically inactive. Notably, in the PARP-13 catalytic domain crystal structure, no NAD*-
analogue inhibitor is bound. Two potential explanations for this are evident from the crystal
structure in comparison with the other PARPs. One is that the conserved histidine is a tyrosine
in PARP-13. The hydroxyl group of the tyrosine extends up into the NAD* binding pocket,
potentially sterically hindering NAD* from binding. The second key difference in PARP- 13 is
the position of the D-loop, which folds in much more tightly to the tyrosine, thereby limiting the
size of the NAD* binding pocket. Together, these observations suggest that the enzymatic
inactivity of PARP-13 is most likely due to the inability of the catalytic domain to bind substrate
NAD*.
The original bioinformatic predictions of PARP enzymatic activity were largely based on
the identity of the residue equivalent to Glu988 of PARP-1. PARPs 1-5b all conserve the
glutamate at this position, while the remaining PARPs replace it with shorter, generally non-
polar residues. Because of the altered chemical characteristics of this residue, it was proposed
that it would not be able to catalyze the modification of the incoming protein or ADP-ribose
moiety/moieties. However, many mono(ADP-ribosylating) enzymes also have a catalytic
glutamate at this position and yet are not capable of polymer synthesis (Domenighini and
Rappuoli, 1996). Analysis of the structure and position of these residues shows similar
placement regardless of identity, although the majority of the non-glutamate residues are further
away from the NAD* binding site and therefore might be less efficient at interacting with NAD*.
However, such an argument fails to explain why many of these PARPs are highly enzymatically
active (Chapter 2), indicating that they bind NAD* (or inhibitor analogues) quite efficiently and
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suggesting that the identity of the key donor-site residues alone does not determine the type of
ADP-ribose modification synthesized by each enzyme.
The acceptor pocket
In order to investigate structural differences that might explain the variety of ADP-ribose
modifications that PARPs are capable of synthesizing, we wished to explore aspects of the
catalytic domain outside of the traditional "catalytic pocket" (the donor pocket) that might affect
the length of polymer generated by each PARP. One potential contribution to this difference was
postulated by Kleine and colleagues to be the loop in between beta strands 4 and 5 (as they
numbered them; Kleine et al., 2008). Shown in red in Figure 2, it is evident that PARP-1,
PARP-2, and PARP-3 have notably longer 04 - $5 loops than the other PARPs. Kleine and
coworkers suggested that the much shorter $4 - $5 loop of PARP-10 allowed for the interaction
of two molecules of PARP-10 at this surface in such an orientation that the second molecule of
PARP- 10 could provide catalytic residues lacking in a single molecule to facilitate the transfer of
the ADP-ribose moiety to the second PARP-10 molecule (Kleine et al., 2008). In fact, when the
researchers mutated the isoleucine of PARP- 10 which replaces the catalytic glutamate of PARP-
1 to a glutamate, they found that it reduced oligomer-synthesis activity without creating polymer-
synthesis activity. They hypothesized that this was due to steric hindrance of the binding of the
modification target, the glutamate residue of the other PARP molecule. (If the shape of the
enzyme does not change significantly upon this mutation, this explanation appears unlikely,
since the isoleucine is at a much greater distance from the potential binding site of the residue to
be modified as discussed below.) However, the generality of such a mechanism is unknown,
and fails to explain why the tankyrases, which have a p4 - p5 loop of similar length, are capable
of longer polymer synthesis while PARP- 10 is not. Moreover, the mutational experiment
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described above suggests that the PARP's ability to bind to and stabilize its modification target
(in the case of elongation, an ADP-ribose moiety) is critical to the enzyme's ability to synthesize
PAR.
Therefore, to understand the structural basis of enhanced elongation capability, we
examined the ADP-ribose binding pocket of the PARP domain originally studied by Ruf and
colleagues in PARP-1 (Ruf et al., 1998). Since much of the work towards a structural
understanding of PARP function has had a practical emphasis on inhibitor design, most attention
in the literature has been paid to the donor NAD* binding pocket which, as we have suggested,
may be responsible for the distinction between inactive and active enzymes but cannot fully
explain the variety of polymer lengths that PARPs can generate. Instead, differences in the
interaction surface of the PARP catalytic domain responsible for binding of the modification
target, if notable, could provide a rationale for PAR versus shorter ADP-ribose (OAR) synthesis.
The acceptor pocket of PARP- 1 was crystallized using the ADP-ribose analogue carba-
NAD* (Ruf et al., 1998). This allowed for the identification of residues in PARP-1 involved in
stabilizing hydrogen bond interactions with the ADP-ribose moiety. Most key interactions are
with the phosphate groups of ADP-ribose through the enzyme residues His826, Lys903, and the
backbone of two residues in the p4 - p5 loop. Interestingly, the catalytic glutamate (Glu988) sits
between the two pockets and is able to interact not only with the NAD* in the donor site but also
with the hydroxyl groups on the ribose. Finally, the authors point out stabilizing interactions
with the methionine of the D-loop. When the methionine is mutated to a bulkier residue, the
binding of ADP-ribose or its analogues to the site is prevented.
We highlighted the key interacting residues in PARP- 1 mentioned above in light orange
in Figure 4A, which focuses on the acceptor pocket. To analyze the structure of the remaining
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PARPs in this region of their domain, we highlighted the equivalent key residues (by sequence
homology) in the remaining PARPs. The identity, position, and B-factors of these residues are
shown in Table 2. We also measured the distances of the key potential interactions identified by
Ruf and colleagues for each PARP based on modeling carba-NAD' into the binding site of each
PARP (Figure 4B; Ruf et al., 1998). PARPs were aligned and the carba-NAD' co-crystallized
with PARP-1 was then retained in each subsequent aligned PARP. In the majority of cases, the
measured distances were greater than the resolution of the structure (see Table 1). Although the
distances may not be as accurate as experimental co-crystallization with carba-NAD*, they
provide a sense of the shape of the acceptor pocket of other PARPs. In particular, the B-factor
values for PARP-1, PARP-2, PARP-3, PARP-5a, PARP-5b, and PARP-10 are relatively low,
indicating less flexibility at these positions to accommodate the binding of ADP-ribose; on the
other hand, PARP-12, PARP- 14, PARP-15, and PARP-16 have B-factors that are higher,
indicating that they might have the flexibility to adapt their shape to the binding of a substrate in
the acceptor pocket.
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PARP H826 K903 985/986 E988 M890
1 H826 K903 985/986 E988 M890
Ca B-factor 69.90 22.40 28.0 22.4 27.0
Average side chain B-factor 76.5 32.41 34.92 35.62
2 H394 K469 555/556 E558 M456
Ca B-factor 17.98 7.87 18.45 12.45 13.14
Average side chain B-factor 16.2 10.0 13.98 18.72
3 S348 K421 511/512 E514 R408
Ca B-factor 28.49 14.97 12.73 12.63 14.83
Average side chain B-factor 27.61 17.62 13.59 14.76
4 H404 T484 544/545 E547 N471
5a G1140 K1220 1288/1289 E1291 M1207
Ca B-factor 24.26 17.97 29.18 23.34 29.22
Average side chain B-factor n/a 22.53 28.25 42.42
5b G987 K1067 1135/1136 E1138 M1054
Ca B-factor 11.26 5.65 10.99 7.97 14.81
Average side chain B-factor n/a 8.38 11.03 22.8
6 n/a 1515 n/a 1581 A502
7 V485 Y571 628-629 1631 M558
8 n/a 1739 n/a 1805 M726
10 A843 L926 984/985 1987 V913
Ca B-factor 38.11 27.69 48.34 30.78 43.16
Average side chain B-factor n/a 28.94 33.26 44.87
11 M154 Y236 310/311 1313 V223
12 L521 Y603 657/658 1660 S590
Cc B-factor 52.79 50.52 59.99 54.57 65.47
Average side chain B-factor 50.82 50.37 54.41 65.39
14 Q1557 Y1640 1698/1699 L1701 A1627
Ca B-factor 81.96 61.61 62.93 61.51 108.74
Average side chain B-factor 89.79 100.27 69.73 59.96
15 R493 Y576 634/635 L637 S563
Ca B-factor 44.28 28.15 32.06 27.84 29.37
Average side chain B-factor 52.7 36.89 26.58 33.39
16 T117 L189 253 Y254 L176
Ca B-factor 61.8 39.41 56.75 51.83 94.49
Average side chain B-factor 57.58 46.34 63.52 98.46
Table 2. Key acceptor site residues of active PARPs. The equivalent residues to those
identified in the acceptor site of PARP- 1 by Ruf et al. (1998) are identified in each PARP by
sequence alignment and shown in the table above. For PARPs with crystal structures, the B-
factor of the backbone alpha carbon and the average B-factor of the side chain atoms as
presented in the PDB file are provided for the crystal structures used in the analysis (shown in
Table 1).
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Branched polymer
PARP.1 DARD...7
Unbranched polymer
Oligomer
PARP- PARP1fl PARD.17
PARP-14 PARP-15
Inactive
PARP-16
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A
BH826 - K903 - 985 backbone - 986 backbone - E988 - M890
PARP pyrophosphate pyrophosphate pyrophosphate pyrophosphate ribose - ADP
1 4.8 4.8 3.5 3.3 3.1/5.0 3.6
2 1.9 5 3.8 3.6 4.6/3.1 4.5
3 10.1 2.1 3.9 3.4 2.1/3.9 2.8
5a 9.2 1.3 6 6.9 3.6/5.6 3.7
5b 8.9 1.3 7.1 7.3 5.5/4.2 3
10 8.7 4.8 12.5 10.3 7.0/4.0 3.7
12 10.6 2.3 11.6 9.3 5.9/3.3 5
13 10.6 4 11.7 9.8 6.4/4.9 2.4
14 16.2 4.8 13.3 10.1 7.8/4.8 3.3
15 17.8 5 13.3 10.7 7.4/4 4.2
16 8 2.5 n/a 3.5 4.7/4.2 12.3
Figure 4. The acceptor pocket varies drastically across the PARP family. A) The same
crystal structures shown in Figure 2 focused on the acceptor pocket, where an elongating chain
of poly(ADP-ribose), or, alternatively, a protein substrate, binds for modification by a unit of
ADP-ribose. The backbone of the catalytic histidine and tyrosine (or equivalent) residues is
shown in cyan, while the key catalytic glutamate (or equivalent) is shown in stick form as it
interacts with both pockets. Key residues or backbone for acceptor pocket interactions as
identified by Ruf et al. (1998) are shown in light orange. B) Table showing distances as
measured by PyMol between the residues equivalent (by sequence alignment) to those of PARP-
1 shown at the top of the table and elements of the ADP-ribose analogue.
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Not surprisingly, PARP-2 is very similar in structure and distances to PARP- 1, in
agreement with the similar enzymatic activity and overall high degree of sequence and structure
homology between the two PARPs. In contrast, the tankyrase proteins, which have much shorter
$4 - [5 loops than PARP-1 and -2, had notable differences to the DNA-dependent PARPs in the
placement of residues that could interact with ADP-ribose, even though the identities of the
residues were largely conserved. In particular, the interactions of the PARP domain with the
pyrophosphate are likely diminished due to increased distances and altered residue identities
which would prevent the formation of stabilizing hydrogen bonds with the pyrophosphate. For
example, His826 is replaced by a glycine which is approximately 9 A away from the
pyrophosphate and therefore likely contributes little to the binding energy of pyrophosphate.
Due to the curtailed and flattened p4 - p5 loop, the backbone residues of this loop are also
further removed from interactions with pyrophosphate and again likely do not stabilize the ADP-
ribose in this position. The lysine, on the other hand, is much closer to the pyrophosphate group
than its equivalent in PARP-1 and -2, suggesting a possible steric clash which might destabilize
ADP-ribose binding in this position. Interestingly, however, the glutamate and methionine are
similarly positioned to PARP-1 and -2, indicating that interactions with the ribose and ADP
moieties are similar.
The differences in pyrophosphate binding capacity of PARP-1/2 and PARP-5a/5b could
have implications for the branch structure of PAR. It has previously been noted that PARP-1/2
can synthesize highly branched PAR structures, whereas the tankyrases generate largely linear
polymer. Ruf and colleagues propose that branches generated by PARP- 1 could be due to
flipping of the orientation of the ADP-ribose in the acceptor site, because the key interactions
with the pyrophosphates would not depend on the orientation of the ADP-ribose moiety (Figure
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5; Ruf et al., 1998). Our analysis suggests that such flipping to create branches is more unlikely
in the tankyrases because the interactions with the orientation-neutral pyrophosphate are less
energetically favorable. Thus, analysis of the acceptor site provides a possible structural
explanation for the observed difference in branching capability.
Linear Branched
H2 N N HO- 
O(ADP-ribose
N"I,,/N H Lys93.. HO
Lys9OCla 0P-0-P0....
O Backbone 96
..0 0*'0 0.O0 H 
I IaBackbon916
Q 0.HO
OH \ - Backbone 98 N N
(ADP-rboe)j--O OH NH2
Figure 5. ADP-ribose orientations in the acceptor site for linear vs. branched linkage
formation. Hydroxyl groups involved in the formation of each linkage are shown in red. Left,
the orientation of ADP-ribose bound to PARP- 1 in the acceptor site to form a linear ADP-ribose
linkage with the incoming NAD* substrate. Right, a model of the orientation suggested by Ruf
et al. (1998) which would allow for the formation of branched linkages.
To determine if the acceptor site can also distinguish between the synthesis capabilities of
various lengths of polymer, we analyzed the acceptor sites of the remaining PARPs with solved
crystal structures. Aside from PARP-3, most had D4 - D5 loops of similar length and placement
to the tankyrases (PARP-16 could not be determined as these residues are missing in the crystal
structure). Because of the placement of this loop, the distances between the backbone residues
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of the loop and the pyrophosphate were generally much greater, although this may be a property
of one particular crystal structure, since the B-factor of this region was quite high for these
PARPs (between 32.06 for PARP-15 and 62.93 for PARP-14). The same was true of the residue
equivalent to His826 (again, the B-factors varied substantially, from 38.11 for PARP-10 to 89.79
for PARP- 14). However, these characteristics are also true of the tankyrases, with much less
flexibility as determined by low B-factors, and therefore do not explain the inability to make
long polymers.
The key differences instead lie in the position and identity of residues that are largely
conserved between PARP-1/2 and PARP-5a/5b but differ in the other PARPs. There are three
main sequence differences, namely the residues equivalent to Glu988, Lys903, and Met890 of
PARP- 1. The lack of a catalytic glutamate could have severe consequences for PAR-
synthesizing ability, since the polar character of the glutamate side chain allows it to form
hydrogen bonds with the hydroxyl groups of the nicotinamide ribose of NAD* and the adenine
ribose of ADP-ribose, thereby catalyzing the reaction by stabilizing the transition state and
enhancing the nucleophilicity of the attacking moiety. However, experimental evidence suggests
that the stabilization of the transition state is not the only important consideration for the
synthesis of PAR by PARPs. PARP-3 has a catalytic glutamate, but is unable to synthesize
polymer (Chapter 2). Meanwhile, replacement of the isoleucine at this position in PARP-10 by a
glutamate does not result in polymer-synthesizing activity by this PARP (Kleine et al., 2008).
Thus, it is useful to consider residues that are instead likely involved in binding the modification
target (particularly ADP-ribose for the synthesis of PAR) , and these include Lys903 and
Met890. Mutation of these two residues can abolish PAR synthesis activity while maintaining
mono(ADP-ribosylation) activity (Ruf et al., 1998; Rolli et al., 1997). The lysine at position 903
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in PARP-1 is only conserved in PARP-2, PARP-3, PARP-5a, and PARP-5b. Mutating this
residue to glutamine or glutamate rendered the enzyme incapable of polymer synthesis,
indicating its importance in the acceptor site (Ruf et al., 1998). The other PARPs have neutrally
charged side residues which would not be capable of the same degree of interaction with the
pyrophosphate, even though the distances between these two elements do not vary significantly
among PARPs. Thus, the missing lysine at this position could play a significant role in the
inability of these PARPs to generate longer polymer.
While the lysine residue provides an explanation for most of the OAR-synthesizing
PARPs' inability to generate longer polymer, PARP-3 is similar to PARP-1 and -2 at that
position and thus would be expected to display a similar synthesis activity, which it does not.
Examination of the second least-conserved residue, Met890, provides a partial explanation.
Mutation of Met890 in PARP- 1 to a valine caused a steric clash that reduced PARP activity 200-
fold (Rolli et al., 2007; Ruf et al., 1998). Interestingly, PARP-1, PARP-2, PARP-5a, PARP-5b,
PARP-7, and PARP-8 are the only PARPs maintaining a methionine at this position, while
PARP-10 and PARP-11 have a valine in this position. The other PARPs have residues at this
position which are too far away (PARP- 12, PARP-16), in the wrong orientation to interact
effectively (PARP- 14, PARP- 15), or might actually sterically hinder ADP binding like the
PARP-1 M890V mutant, which has no enzymatic activity (PARP-3, PARP-13; Rolli et al.,
1997). This could result in an enzyme which generates shorter polymer. An additional
explanation for PARP-3 lack of processivity could be the replacement of the stabilizing His826
with a serine that is located too far away from the pyrophosphate to stabilize it.
Together, the elements of the acceptor site discussed here provide a structural rationale
for the difference in enzymatic activity observed across the PARP family. His826, Lys903, and
93
the backbone of residues 985 and 986 appear to be critical for the support of branching
capability, while both Glu988 and Met890 appear to define the ability to synthesize polymer.
Notable deviations from the positioning and identity of these residues from those in PARP-1
disrupt one or both of these enzymatic capabilities.
Comparative analysis of the PARP fold
While side-by-side analysis provides an indication of key differences among PARPs, alignment
of structures together provides the capability to observe more subtle changes in structure. To this
end, we have aligned the experimentally determined crystal structures of the PARPs both to
PARP-1/PARP-2 (Figure 6) and PARP-5a/PARP-5b (Figure 7). We provide a view of the whole
PARP domain (top panel) and a side view that encompasses both the donor and acceptor pockets
(bottom panel). This analysis makes the similarity between the tankyrases and the OAR-
synthesizing PARPs that was previously noted in our region-specific analysis above more
evident.
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PARP-1 PARP-3
PARP-14 PARP-15 PARP-16
PARP-3 PARP-5a
PARP-10
PARP-5b
PARP-12 PARP-13
PARP-14 PARP-15 PARP-16
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PARP-1
PARP-5bPARP-5a
Figure 6. Comparison of PARP domains and donor/acceptor pockets to PARP-1/PARP-2
reveals key loop structures. The PARP folds of PARP- 1 and PARP-2 were aligned using
cealign in PyMol. Top left, PARP- 1 is shown in blue (ribbons) with lighter blue key catalytic
and acceptor binding residues (sticks) while PARP-2 is shown in yellow (ribbons) with green
key catalytic and acceptor binding residues (sticks). In subsequent panels PARP-1 is shown in
light grey, PARP-2 is shown in darker grey, and each PARP is shown in magenta. Top,
complete PARP domain; bottom, donor/acceptor pocket.
Other PARPs diverge from the PARP-1/PARP-2 structural model
PARP- 1 and PARP-2 have highly similar structures and positioning, as evident in Figure
6. However, many aspects of these structures appear to be unique among the PARP family.
Although key catalytic residues appeared to be in similar locations in the other PARPs in Figure
2, aligning them together demonstrates slightly different placement of the residues (Figure 6,
top). The differences in the position of the D-loop lid noted by Wahlberg and colleagues are also
more evident (Wahlberg et al., 2012). A closer inspection of the donor and acceptor sites reveals
fairly striking differences in loop structure behind the donor pocket and confirms the $4 - [5
loop difference previously observed. Together, these smaller differences in placement might
help to explain why PARP-1/PARP-2 enzymatic activity is the exception rather than the norm in
the PARP family.
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PARP-3 PARP-10
PARP-13 PARP-14
PARP-3 PARP-10
PARP-14 PARP-15
Figure 7. Comparison of PARP domains and donor/acceptor pockets to PARP-5a/PARP-
5b reveal similarity of OAR-synthesizing fold to the tankyrase fold. The PARP folds of
PARP-5a and PARP-5b were aligned using cealign in PyMol. Top left, PARP-5a is shown in
blue (ribbons) with lighter blue key catalytic and acceptor binding residues (sticks) while PARP-
5b is shown in yellow (ribbons) with green key catalytic and acceptor binding residues (sticks).
In subsequent panels PARP-5a is shown in light grey, PARP-5b is shown in darker grey, and
each aligned PARP is shown in magenta. Top, complete PARP domain; bottom, donor/acceptor
pocket.
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PARP-15 PARP-16
PARP-5a
PARP-13
PARP-12
PARP-15
PARP-12PARP-5a
Tankyrases and OAR-synthesizing PARPs share structural similarities
As previously noted from the analysis of the PARP fold and donor and acceptor pockets, the
tankyrases share many gross structural similarities with the OAR-synthesizing PARPs. The
position of key catalytic residues and the overall fold structure is quite similar, suggesting the
importance of the differing residues in the acceptor pocket.
Models of uncrystallized PARP catalytic domains
To date, six PARPs lack experimentally determined crystal structures deposited in the PDB.
Since we now have experimentally determined information about their enzymatic activities, their
subfamilies and their function, it is useful to approximate a possible structure for these PARPs to
continue the analysis we have performed on previously determined crystal structures. In order to
generate sequence-homology based models, we used two freeware software platforms, Modeller
and SWISS-Model. The generation of models in Modeller was analyzed by two statistical
methods: Verify3D, which calculates the statistical likelihood of each amino acid at each
position and assigns an alignment score (higher is better), and ANOLEA, which assesses non-
local atomic interaction energy (lower is better). For SWISS-Model, the statistical calculation is
an absolute measure of model quality based on the characteristics of solved crystal structures
called QMEAN. The QMEAN analysis results in a Z-score (more positive is better). We have
provided the statistical analysis of both models for each PARP in Figure 8.
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Figure 8. Statistical analysis and validation of PARP models. Each row corresponds to the
two calculated models for each PARP shown in Figure 9. Left, the QMEAN plot and score of
each SwissModel PARP model, a measure of absolute model quality. Middle, the Verify3D plot
of each residue compared to the likelihood of the 3D conformation of the given amino acid at
that position in the Modeller PARP model. Right, the non-local atomic energy of each amino
acid in the conformation predicted by the Modeller PARP model.
The models largely agree with each other in both the general PARP domain shape and in
the details of the acceptor and donor pockets but differ significantly in unstructured loop regions
(Figure 9). This is particularly challenging for PARP-6 and PARP-8, which are both mostly
modeled on PARP-16 due to homology but contain large loop regions which are difficult to
model accurately. Nevertheless, the overall similarity of the two models in our loop and pocket
regions of interest provides confidence in further analysis of the modeled PARP structures.
The degree of homology also corresponds well to the statistical assessments of model
reliability (Table 3). The PARP-7 and PARP-11 models are all based on homology to PARP- 12.
Each of these proteins shares 44-45% identity and up to 67% similarity with PARP-12,
suggesting that these models likely provide much information about the relative structures of
PARP-7 and PARP- 11 despite the lack of crystal structures for these PARPs. The remaining
models have approximately 30% identity and 45% similarity with their respective templates,
although the Modeller PARP-8 model, which uses PARP-1 as a template, has no detectable
homology with PARP-1 aside from a very short stretch. This indicates that these models might
be slightly less reliable, but can nevertheless provide some sense of the structural elements that
might regulate the synthesis of PAR.
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Planck Bioinformatics Toolkit and the best structural match was selected automatically. The
sequence alignment and selected template structure were then used by Modeller to generate a
structural model. The Modeller-generated models are shown in magenta throughout the figure.
In the second modeling program, the PARP domain sequence from each PARP without a crystal
structure was entered into SWISS-MODEL, which then aligned the sequence, selected a
template, and generated a model. SwissModel models are shown in yellow throughout the
figure. In each row, from left to right: alignment of Modeller and SwissModel PARP domains;
alignment of Modeller PARP domain (magenta) to its template (gray); alignment of SwissModel
PARP domain (yellow) to its template (gray); alignment of Modeller and SwissModel
donor/acceptor sites; alignment of Modeller donor/acceptor site to its template; alignment of
SwissModel donor/acceptor site to its template.
PARP model PARP template % identity % similarity
4 1 30 47
6 16 31 46
7 12 45 64
8 1 very low
8 16 29 42
9 14 35 47
9 15 30 45
11 12 44 67
Table 3. Homology of PARP models and their respecive PARP templates. Percent identity
and similarity calculated by alignment in NCBI BLAST with default settings
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&BLAST PROGRAMS=blastp&PA
GE TYPE=BlastSearch&SHOW DEFAULTS=on&LINK LOC=blasthome).
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PARP subfamily structural analysis
A complete set of PARP structures or structural models allows for analysis of similarities and
differences within and between subfamilies. We have provided this analysis for both models of
each PARP and its subfamily in Figure 10. While the aligned subfamilies look different before
alignment, when superimposed the subfamilies display largely remarkable similarity. PARP-10,
in particular, appears very closely related to the zinc finger PARPs, while PARP-6, -8, and -16
differ significantly from the other subfamilies. The zinc finger PARPs and macro PARPs also
share a similar structure.
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PARP-12 1-7
SwissModel PARP-8Modeller PARP-8
P4 Modeller PARP-8 '4 SwissModel PARP-8
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Figure 10. Subfamily breakdown of PARP crystal structures reveal cross-subfamily
similarities. Top, alignments of subfamilies (models and determined structures). Colors as in
Figure 9 unless otherwise noted. Bottom alignment of subfamilies to each other; zinc finger in
red, PARP-10 in gray, macro in green, 6/8/16 in blue. Left, full domain, right, donor/acceptor
sites.
The acceptor pocket of modeled PARPs
While one must be careful when drawing conclusions from the modeled PARP structures,
we performed a similar analysis of residue distances in the models' acceptor sites to ask whether
we could detect any obvious explanations for OAR activity. Universally, the PARPs followed
the pattern of all but the DNA-dependent polymerizing PARPs of lacking pyrophosphate support
from the H826 or equivalent residue - either this residue was too far away (often on the order of
10 A) or in the wrong orientation or wrong chemical character to interact with ADP-ribose
through hydrogen bonds (Table 4). The increased distance of H826 in PARP-4, for example,
could explain its generation of shorter polymers than those synthesized by PARP- 1 (see Chapter
2, Figure 8); PARP-5a is known to generate shorter polymers than PARP-1, and also has an
increased distance between H826 and the ADP-ribose (Kleine et al., 2008). The residue
equivalent to the Lys903 residue of PARP- 1 was often at an appropriate distance, but in an
improper orientation to interact effectively with the pyrophosphate. The backbone residues were
often much further away than in PARP-1 - and in particular, PARP-6 and PARP-8 lack these
residues and therefore cannot interact with the pyrophosphate moiety of the ADP-ribose. This
lack of stabilization of the ADP-ribose could help to explain the inability of these enzymes to
synthesize poly(ADP-ribose) (see Chapter 2, Figure 8). In general, the same types of arguments
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and assessments made for the crystallized OAR-synthesizing PARPs appear to hold for the
remaining PARPs without determined crystal structures.
985 986
H826 - K903 - backbone - backbone -
pyro- pyro- pyro- pyro- E988 - M890 -
PARP model phosphate phosphate phosphate phosphate ribose ADP
4 Swiss 6.9 6.9 4 3.7 5.2/2.5 4.8
4 Modeller 10.4 3.7 2.2 2.9 4.4/3.3 6.2
4 average 8.65 5.3 3.1 3.3 4.8/2.9 5.5
6 Swiss n/a 4.1 n/a n/a 6.4/6.6 10.7
6 Modeller n/a 2.1 n/a n/a 4.5/7.1 11.5
6 average n/a 3.1 n/a n/a 5.45/6.85 11.1
7 Swiss 13.4 3.5 11.7 9.3 3.2/5.9 7
7 Modeller 10.2 4.5 11.4 10.2 3.3/6.1 7.6
7 average 11.8 4 11.55 9.75 3.25/6.0 7.3
8 Swiss n/a 1.8 n/a n/a 6.4/6.8 9.5
8 Modeller n/a 5.7 n/a n/a 4.7/7.4 1.6
8 average n/a 3.75 n/a n/a 5.55/7.1 5.55
9 Swiss 14.3 3.8 12 9.4 4.5/6.9 4.1
9 Modeller 14.6 4.3 11.7 9.3 5.7/6.8 2.4
9 average 14.45 4.05 11.85 9.35 5.1/6.85 3.25
11 Swiss 9.6 3.2 12.3 9.8 3.5/6.2 2.7
11 Modeller 9.4 2.4 11.1 8.9 3.7/5.7 3.5
11 average 9.5 2.8 11.7 9.35 3.6/5.95 3.1
Table 4. PARP Model distances to carba-NAD* are consistent with demonstrated
enzymatic activity. Table showing distances as measured by PyMol between the residues
equivalent (by sequence alignment) to those of PARP-1 shown at the top of the table and
elements of the ADP-ribose analogue.
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Beyond the PARP domain: the role of other functional domains in PARP activity
regulation, localization, and function
In order to investigate the cellular functions of PARPs, an examination of the
contributions to function and localization of the non-PARP domains helps to contextualize PARP
activity in the cell and suggest possible roles and mechanisms for PARPs in a variety of cellular
processes. Previously, a similar analysis was presented in Am6 et al. (2004). However, since the
publication of that review, much more has been discovered about the functions of both the
PARPs and their non-PARP domains. Therefore, we return to an investigation of the known
roles of other domains present in PARPs. We have chosen to focus on 11 of these domains, as
the remaining identified domains (see Schreiber et al. 2006, Am6 et al. 2004) are not as well
characterized and provide less insight into PARP localization and function. The remaining
domains are the major vault protein binding domain (PARP-4), the HPS domain (PARP-5a),
vault inter-a-trypsin (PARP-4), helical transmembrane domain (PARP-16), SAP (SAF-A/B,
Acinus, and PIAS) (PARP-2), poly-serine (PARP-8), poly-leucine (PARP-10, -16), glutamine
rich (PARP-10), and poly-alanine (PARP-12).
Some of these domains are known to play a critical role in the regulation of PARP
activity. The WGR domain transfers the conformational change induced upon zinc finger-
mediated PARP-1 binding to damaged DNA to the PARP domain (Langelier et al., 2012). The
SAM domain of tankyrases mediates their mutual interaction, allowing for transmodification and
mutual stimulation of enzymatic activity (De Rycker and Price, 2004). Further roles of these and
other domains are examined below. Table 5 summarizes the findings of our analysis.
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Domain
CCHC (PARP-
like) zinc
finger
BRCT
Other proteins Domain function Domain Distance to Structure
with domain localization PARP
domain (aa)
1 DNA ligase III,
Arabidopsis
AtZDP 3' repair
enzyme
1,4 BRCA-1, XRCC1,
53BP1
VWA 4
WGR 1, 2, 3, C.
elegans
tankyrase
Ankyrin
repeat
SAM
WWE
CCCH zinc
finger
Macro
RRM
UIM
Ku7O, von
Willebrand
factor,
complement
factors, integrins
Just PARPs
5a, Sb Ankyrin, BCL3,
IKB, RNase L,
Shank, 53BP2,
Swi4/Swi6
5a,Sb Shank
7, 11, 12, E3 ubiquitin
13, 14 ligases (RNF146),
Deltex1
7, 12, 13 TTP/Tisll,
ZC3H14
9, 14, 15 macroH2a and
variants,
MacroDi and
D2, viral proteins
10 Musashi, RNPs,
nucleolin
10 S5a, Vps27/Hrs,
epsins
DNA binding
(specifically nick or
ss break
recognition)
Protein-protein
interactions,
phospho-peptide
binding
Multiprotein
complexes,
adhesion, signal
transduction,
pathogen response,
DNA damage
DNA binding, PARP
activation, ssRNA
binding
Protein-protein
interactions
Self-association and
heteromeric
protein binding
PAR binding,
protein interaction
w/ ankyrin
RNA binding
(mRNA, poly A),
stress granule
recruitment
NAD+ metabolite
binding, processing
RNA and protein
binding
Bind ubiquitin,
promote their own
ubiquitinatlon
Nucleus
Nucleus
Mostly
extracellular
Nuclear
Cytoplasm,
plasma
membrane,
extracellular,
nucleus,
mitochondria
585
PARP-1 312
PARP-4 275
303
PARP-1 155
PARP-2 174
PARP-3 162
PARP-5a 178
PARP-Sb 183
All subcellular PARP-5a 23
locations PARP-5b 23
Cytoplasm
Nuclear/
cytoplasmic
shuttling, stress
granules
Chromatin,
cytoplasm,
nucleus,
mitochondria
Varied
Endosomes,
proteasome
PARP-7
PARP-11
PARP-12
PARP-13
PARP-14
PARP-7
PARP-12
PARP-13
39
17
26
35
4
185
187
523
PARP-9 141
PARP-14 218
PARP-1S 18
726
116
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........ .... ................ ... 
Table 5. PARP functional domains display high similarity to better-studied equivalent
functional domains. For each functional domain discussed, the known or modeled crystal
structures of the equivalent PARP functional domain are shown in alignment with other
crystallized examples of the domain.
CCHC (PARP-like) zinc finger (PARP-1)
Zinc fingers are a class of structural motif that chelate zinc to maintain a particular fold.
Different types of zinc fingers have been shown to be specialized for the binding of protein or
nucleic acids. There are two varieties of zinc finger that are present in the PARP family, the
CCHC and the CCCH zinc fingers, so named for the key residues involved in chelating the zinc.
First, we will examine the CCHC zinc finger, and we will return to the CCCH zinc fingers later.
The CCHC nomenclature is a shortening of the spacing in between four key residues, three
cysteines and a histidine, and is therefore also written in the more complete form CX2CX28-
3 0HX 2C, where X is any amino acid. The particular arrangement of these residues is conducive
to a fold that is specialized for DNA binding. PARP-1 is the sole member of the PARP family
with such a fold and contains three of them. Interestingly, however, this type of zinc finger was
originally identified in PARP-1 and is therefore also referred to as a PARP-like zinc finger in
some literature.
Not only is the CCHC zinc finger capable of DNA binding, but it is specifically designed
for binding nicked DNA or single-stranded breaks in DNA. Therefore, the presence of this
domain implies and is consistent with PARP- 1 localization in the nucleus and its key role in
DNA repair. The same is true of the few other proteins thus far identified as containing this
domain. Research of this domain outside of PARP-1 has been largely confined to the study of
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human DNA ligase III, another DNA repair enzyme, and the Arabidopsis AtZDP 3' repair
enzyme, which also contains a PARP-like zinc finger important for its functionality (Mackey et
al., 1999; Petrucco et al., 2002).
BRCT (PARP-1, PARP-4)
The BRCT domain appears in the PARP family in PARP-1 and PARP-4. Like the CCHC zinc
finger, it is another domain associated with proteins involved in the DNA damage response. The
BRCT domain is so named as it was originally identified in the terminal (T) region of the
BRCA-1 DNA damage protein. These domains have since been found to be present in other key
components of the DNA damage response, notably 53BP1 (p53 binding protein 1) and especially
XRCC1, which is known to interact with many proteins, including PARP-1 (Masson et al.,
1998). Although this domain does not mediate protein interaction with damaged DNA, in
contrast to the zinc fingers, it does allow for the interaction of proteins involved in the response
both through protein-protein and phosphoprotein interactions (Leung and Glover, 2011). The
BRCT domain appears to be specialized to recognize particular phosphorylated residues. Since
much of the DNA damage response requires signal transmission through protein interactions and
modifications, the presence of a BRCT domain in PARP-1 might aid in recognition of other
DNA damage proteins at the site of DNA damage, or might serve as an additional recruiting tool
for proteins involved in the DNA damage response. In particular, it is known that PARP-1
poly(ADP-ribosylates) itself in the BRCT region, allowing for an interaction with the BRCT
domain of XRCC1, which in turn is modified by PARP-1 and interacts with several other DNA
damage proteins (Loeffler et al, 2011; Beernink et al, 2005). The potential function of the BRCT
domain in PARP-4 is as yet unknown.
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VWA (PARP-4)
The VWA domain was originally identified as a unique motif in the von Willebrand factor
protein, a blood protein important for hemostasis, and is represented in the PARP family in
PARP-4, which contains a number of unusual domains not seen elsewhere in the PARP family.
The VWA domain is found in a large variety of proteins, such as collagen, integrins, complement
factors, and Ku70, and is believed to have a primary role in mediating the formation of
multiprotein complexes, although it has also been implicated in adhesion, signal transduction,
pathogen response, and DNA damage pathways (Whittaker and Hynes, 2002). As a result,
proteins containing the VWA domain display equally varied localization patterns, from
extracellular to nuclear. Although PARP-4's interaction with the major vault protein in the vault
particle appears to be mediated through a separate domain in PARP-4, it is possible that the
VWA could mediate protein interactions. However, no one has specifically determined the role
of this domain in PARP-4, and since it has so many varied functions, it does not provide much
information on its bearing on the function and localization of PARP-4.
WGR (PARP-1, PARP-2, PARP-3)
The WGR domain is, like the CCHC zinc finger and the PARP domain itself, a domain
originally identified in PARPs. Unlike the CCHC zinc finger domain, however, it appears to
play a unique role in regulating the activity of the PARP domain. Originally identified in PARP-
1, WGR domains from PARP-1 and PARP-3 have now been crystallized (Figure 11). Usefully,
the crystal structure of the PARP- 1 WGR domain was done on a longer stretch of sequence
which also includes a zinc finger on the N-terminal end of the WGR domain and the catalytic
domain attached to the C-terminus, so the observation of regulation of the PARP catalytic
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domain by the WGR domain now has a structural explanation (Langelier et aL, 2012). Since the
WGR domain contacts both the PARP domain and the zinc fingers, it provides a physical link
between the binding of damaged DNA and PARP activity. The WGR domain also helps to
position the PARP- 1 automodification domain near both the PARP domain and one of the zinc
fingers, further providing an important structural basis for PARP- 1 automodification.
The WGR domain is present in PARP-1, PARP-2, and PARP-3 in humans, and
interestingly also in C. elegans tankyrase. This allows C. elegans tankyrase to play a role in
DNA damage that its human homolog does not (White et al., 2009). The function of the WGR
domain on its own is unknown, although it has been speculated that it could be important for
DNA binding (Altmeyer et al., 2009). This has not been shown, although in vitro studies suggest
that the WGR domain can bind single-stranded RNA. It is unknown whether this has any
functional relevance. However, domain studies of PARP- 1 have shown that the WGR domain is
in fact quite important for the activation of PARP activity (Langelier et al., 2012). If this is the
primary role of the WGR domain, then it is not surprising that it appears to be unique to the
PARPs thus far. As a result, our analysis of domains in other proteins to shed light on the
potential function of the PARPs is not as informative in this case.
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RCT VWA
DNA ligase ill XRCCI Von Wiliebrand Factor A
PARP-1 zinc finger 1 PARP-1 PARP-4 model
PARP-1 zinc finger 2
WGR ANK SAM
PARP-3 AnkyrinR mouse bifunctional apoptosis regulator
PARP-1 mouse tankyrase PARP-Sa (model)
PARP-5a (model) Shank
WWE CCCH zinc finger Macro
Deltex TisI AFI521
RNF146 PARP-13 PARP-14 macro 1
RRM UIM PARP-15 macro 2
ACF mouse RAPS0
hnRNP L PARP-10 (model)
PARP-10 (model)
Figure 11. PARP functional domains display high similarity to better-studied homologous
functional domains. For each functional domain discussed, the known or modeled crystal
structures of the equivalent PARP functional domain are shown in alignment with other
crystallized examples of the domain.
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CCHC (PARP-4ike) zinc finger
Ankyrin repeats (PARP-5a, PARP-5b)
Ankyrin repeats were first identified in the human ankyrin protein, which mediates interactions
between the membrane and the actin cytoskeleton. They are a helical motif that usually have at
least 4 consecutive repeats but can have many more (Bork, 1993). For example, ankyrin itself
has 24 repeats generally broken down into four subdomains of six repeats, although only a few
repeats are thought to be functionally important. Ankyrin repeats mediate a variety of protein-
protein interactions. Due to their helical structure, there is generally a great variety in sequence
of the ankyrin repeats, allowing for binding specificity (Bork, 1993; Michaely et al., 2002). As a
result, a large number of diverse proteins contain ankyrin repeats, including not only ankyrin and
PARP-5a and PARP-5b (hence their subfamily name, tANKyrases), but also BCL3, IiB, RNase
L, Shank, 53BP2, and Swi4/Swi6 (Mosavi et al., 2004). These proteins localize to every cellular
compartment and even extracellularly. Despite the wide variety of functions, the overall fold
does not vary much (Figure 11). Thus, although a comparative analysis of the ankyrin domain
across many proteins does not indicate where the tankyrases should be localized or their specific
function, it does indicate that protein interaction is critical for their function.
Recently, it has been shown that the ankyrin domain of PARP-5a is important for the
binding of axin, a poly(ADP-ribosylation) target of PARP-5a in the Wnt signaling pathway
(Morrone et al., 2012). Protein screens have also identified many proteins that interact
specifically with the ankyrin domain of PARP-5a and PARP-5b, many of which then serve as
physiologically relevant modification targets. These include Epstein-Barr nuclear antigen 1
(EBNA1), which can no longer maintain the Epstein-Barr virus genome when modified by
PARP-5a, and 3BP2, which can cause cherubism when it is no longer recognized by and
modified by the tankyrases (Deng et al., 2005; Guettler et al., 2011). Therefore, the ankyrin
114
repeats have been shown to be critical for proper targeting and function of the tankyrases in the
cell.
SAM (PARP-5a, PARP-5b)
The SAM domain, also uniquely present in the PARP family in both tankyrases, is another
protein-binding motif. Originally identified in yeast as the sterile-alpha motif, SAM domains are
not as ubiquitous as ankyrin repeats but nevertheless represented in the human genome in
proteins such as Shank (named for its composition of SAM homology and ankyrin repeats).
SAM domain-containing proteins are also present in all subcellular locations and have been
shown to have functional roles in mediating both homotypic and heterotypic protein interactions.
Although SAM domains do not specify the localization or the precise function of the tankyrases,
they are nevertheless critical for the proper cellular function of PARP-5a and PARP-5b. De
Rycker and Price (2004) showed that PARP-5a and PARP-5b interact functionally, and that this
interaction is mediated through their SAM domains. PARP-5a/PARP-5b interaction is required
for the tankyrases to stimulate each other's PARP activity and transmodify each other. In their
positioning and their function, tankyrase SAM domains are thought to be the equivalent of the
alpha helical domain component of the PARP-1 catalytic domain (Am6 et al., 2004). Therefore,
SAM domains are known to play a vital functional role in the activity of the tankyrases even
though they do not determine their localization or the exact cellular role of these PARPs.
WWE (PARP-7, PARP-11, PARP-12, PARP-13, PARP-14)
WWE domains have attracted much attention in recent years as their functional role in proteins
has slowly been unraveled. Aside from PARP domains themselves, which define the PARP
family, they are the most common domain in the PARP family and are present in PARP-7,
PARP- 11, PARP-12, PARP-13, and PARP-14, therefore also crossing subfamily boundaries.
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Aravind (2001) noted early on that the WWE domain was fairly unique and only appeared in two
types of proteins: PARPs and E3 ubiquitin ligases. This suggested functional interplay between
these two post-translational modification pathways. One of the E3 WWE-containing ubiquitin
ligases, Drosophila Deltex, has a tandem WWE domain that is important for Notch receptor
binding. Interestingly, the WWE domain of Deltex binds to the ankyrin repeats of Notch
receptor, indicating a specific domain-mediated interaction (Zweifel et al., 2005).
Recent work, however, indicates that the WWE domain is capable of much more than
protein-protein interaction and in fact can bind poly(ADP-ribose). This has very interesting
implications for crosstalk between ubiquitin and PARP pathways. The WWE domain of the E3
ubiquitin ligase RNF146 has been shown to recognize the ribose-ribose bond in poly(ADP-
ribose) specifically (Wang et al., 2012). This binding capability allows poly(ADP-ribosylated)
proteins to be targeted for ubiquitination, which has actually been shown to be the case for
RNF146 in the Wnt signaling pathway (Zhang et al., 2011).
Wang and colleagues tested a variety of WWE domains, including that of PARP- 11, and
demonstrated that they bind to poly(ADP-ribose) with a few exceptions, notably PARP-14,
which is not expected to bind poly(ADP-ribose) through this domain due to lack of sequence
conservation of key residues (Wang et al., 2012). This may be because PARP-14 contains other
poly(ADP-ribose) binding modules, namely the macro domains to be discussed later, and also
because it is the only PARP of those containing WWE domains which is not a zinc finger PARP
or closely related to this subfamily. While the WWE domain may not have a particular bearing
on subcellular localization, most proteins with functional WWE domains are cytoplasmic and
seem to have a function in poly(ADP-ribose) signaling. Thus, the zinc finger PARPs, like the
macro PARPs, can potentially both generate short ADP-ribose modifications and bind to them.
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CCCH zinc finger (PARP-7, PARP-12, PARP-13)
The second type of zinc finger in the PARP family is not unique to the PARPs, nor was it first
identified in the PARP family, unlike the CCHC zinc finger of PARP- 1. Instead, these zinc
fingers contain a slightly different arrangement of cysteine and histidine residues which change
the binding preference of the zinc finger from nicked DNA to RNA. The zinc fingers in PARP-
7, PARP-12, and PARP-13 are of the type CX7. 11CX 3-9CX 3H. One other family of proteins has a
similar zinc finger, making them quite rare thus far in the proteome. These zinc fingers were
originally identified in tristetraprolin, also known as TTP or TIS 11. TIS 11 homologs are more
restrictive in their placement of the key C and H residues, all following the pattern
CX 8CX5 CX 3H, which may explain some of the difference in the solved structures of PARP-13
zinc fingers and that of TIS 11 (Figure 11). Nevertheless, the zinc fingers of TIS 11 are well-
studied and provide a useful model for the zinc fingers of the PARPs, which to date have been
less well characterized.
CCCH zinc fingers usually occur in tandem, an arrangement which appears to be critical
for the functionality of the zinc finger (Murata et al., 2004; Kelly et al., 2007; Blackshear et al.,
2005). Notably, PARP-7 contains a single zinc finger whereas PARP-12 and PARP-13 have
tandem sets, suggesting that PARP-7 may not be able to bind RNA with its zinc finger, although
this is unknown. Tandem CCCH zinc fingers in TIS1 1, ZC3H14, and the yeast protein Nab2
have been shown to bind mRNA, with ZC3H14 and Nab2 specifically recognizing
polyadenosine tracts (Kelly et al., 2007; Blackshear et al., 2005). The zinc fingers of PARP- 13
have been shown to be critical for binding to viral RNA (Guo et al., 2004). As a result, the role
of PARP- 13 in the antiviral response has been studied, but other physiological roles are
unknown.
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Aside from the ability to bind RNA, however, the influence of the zinc finger domains on
protein localization is more difficult to determine. Many proteins which contain CCCH zinc
fingers shuttle between the nucleus and the cytoplasm. Murata et al. (2004) determined a more
specific cellular localization dependent on functional zinc fingers. They showed that the
presence of an intact tandem CCCH zinc finger domain was required for the recruitment of
TIS11 to stress granules. The tandem CCCH zinc fingers of PARP-12 and PARP-13, despite
differing from TIS 11, could well play a similar role, as these proteins also localize to stress
granules (Leung et al., 2011).
Macro (PARP-9, PARP-14, PARP-15)
The macro domain is an ADP-ribose binding module first identified in the non-histone region of
histone variant macro H2A. Like the CCCH zinc finger, the macro domain occurs in three
PARPs (9, 14, 15) and its presence also defines a PARP subfamily. The macro domain is present
in a wide variety of proteins across all domains of life and is also quite common in viruses (Han
et al., 2011). Although the determined structures of PARP- 14, PARP- 15, and archaeal macro
domains are quite similar (Figure 11), there is a fair amount of structural and functional variety
in macro domains. Certain macro domains appear to have different binding preferences for
different derivatives of ADP-ribose. Some, such as the human proteins MacroD 1 and MacroD2,
are not only capable of binding ADP-ribose or similar molecules, but also have the enzymatic
capacity to cleave O-acetyl-ADP-ribose, a byproduct of sirtuin activity (Chen et al., 2011). Due
to sequence variations between the macro PARPs and MacroD1 and D2, however, it seems
unlikely that the macro domains in PARPs are capable of such a reaction (unpublished
observations).
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Like the WWE domain in other PARPs, a binding module connected to a synthesis
module for a particular post-translational modification has interesting implications, many of
which have been explored in two recent reviews which treat the macro domain in greater detail
(Kalisch et al., 2012; Gibson and Kraus, 2012).
RRM (PARP-10)
The RNA-recognition motif (RRM) is one of many RNA-binding domains and motifs identified
thus far (including, for example, the previously discussed CCCH zinc finger). Although quite
ubiquitous in the human proteome, the RRM only appears in one member of the PARP family,
PARP-10. It is unknown whether this RRM can bind to RNA and, if it does, if PARP-10 is
involved in RNA metabolism. While the catalytic activity of PARP-10 in vitro has been
extensively characterized, its physiological function has been more difficult to determine, aside
from its interaction with c-Myc (Yu et al., 2005). Unfortunately, because the RRM is present in
so many proteins, ranging from RNPs to nucleolin, the localization and function of RRM-
containing proteins is equally varied and provides little clue to potential RNA-based functions of
PARP-10. However, it has been noted that in addition to the RRM, PARP-10 contains a gly-rich
region, both of which are elements present in nucleolin, a c-myc binding partner, that are critical
for its ability to bind RNA (Schreiber et al., 2006). This suggests that these elements could play
a similar function in PARP-10.
UIM (PARP-10)
The link between ubiquitination and poly(ADP-ribosylation) through the WWE domain is
complemented by the presence of a ubiquitin-interacting motif, or UIM, in PARP-10. As with
many of the other binding modules we have previously discussed, the UIM is but one of many
functional domains in the proteome capable of binding ubiquitin. Most of the proteins thus far
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identified to contain a UIM either localize to endosomes or are proteasomal components. These
include S5a, Vps27/Hrs, and epsins. Interestingly, the UIM not only binds ubiquitin, but is also
capable of promoting the ubiquitination of the UIM-containing protein. Thus, UIM-containing
proteins can regulate their own turnover through this motif. While the WWE domains in PARPs
may not interface with ubiquitin pathways, both the BRCT domain of PARP-1 and the UIM of
PARP-10 could potentially provide a means of interaction across post-translational modification
pathways.
Conclusions
For the first time, to our knowledge, we have examined all existing crystal structures of
PARP catalytic domains in concert and determined structural reasons for the limited polymer
synthesis capability of the majority of PARPs. In order for polymer synthesis to occur, the
enzyme must provide two functions: it must render the hydroxyl group of the adenine ribose a
sufficiently good nucleophile, and it must provide a binding surface for the terminal ADP-ribose
to interact with the incoming substrate NAD*. To date, the main reason cited for the lack of
polymer synthesis capabilities in PARP-6 through PARP-16 is the lack of a catalytic glutamate,
which is postulated to perform the first of these functions through hydrogen bonding with NAD*
and ADP-ribose. Since the residues which replace glutamate in these PARPs are non-polar, they
would not be capable of using this reaction mechanism. While the missing available enzyme
chemistry most likely contributes to the lack of PAR synthesis by these enzymes, there is
evidence that there might be other contributing factors. PARP-3 has a catalytic glutamate, but is
not capable of PAR synthesis; replacement of PARP-10 isoleucine by glutamate also fails to
create polymerase activity. This suggests that the stabilization of the ADP-ribose substrate
through binding to the PARP acceptor site could also be important for determining PAR
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synthesis. The relative contributions of binding energies and catalytic glutamate chemistry for
each PARP should be amenable to experimental elucidation. The binding affinity of different
PARPs could be measured by techniques such as isothermal calorimetry or a filter binding assay,
using pure PARP catalytic domain and either ADP-ribose or an acceptable analogue (for
example, Ruf and colleagues used the analogue carba-NAD*, which they observed bound in the
acceptor site but not in the donor site of PARP- 1; Ruf et al., 1998). If the structural predictions
of this chapter are correct, they suggest that PARPs, such as PARP-3 and possibly PARP-10,
should have a lower binding affinity for ADP-ribose, which could largely explain the lack of
polymer-synthesizing activity. For some PARPs, however, the missing glutamate may be of
more critical importance than the binding affinity of the PARP for ADP-ribose.
Our expectation of binding affinity differences among the PARP family for ADP-ribose
arises from the analysis of the acceptor pocket of the PARP domain presented in this chapter. In
addition to the lack of a catalytic glutamate in PARPs which do not synthesize polymer, the
acceptor pocket of the PARP domain displays key structural differences among PARPs with
different catalytic activity. While inactive PARPs can be distinguished by their replacement of
the histidine which coordinates NAD* binding in the donor site with another residue, thus likely
sterically hindering NAD* from binding, there are no major structural differences in the NAD*
binding pocket of active PARPs of different enzymatic capabilities. Instead, we find that PARPs
which synthesize branched polymer (PARP-1 and PARP-2) have acceptor pocket residues which
interact with the pyrophosphate moiety of ADP-ribose at distances of 2-5 A, whereas the
remainder of the PARPs do so at a greater distance (depending on the PARP and the interaction,
-6-18A). Polymerizing PARPs (those that synthesize highly branched polymer, PARP-1 and
PARP-2, and those that synthesize linear polymer, PARP-4, PARP-5a, and PARP-5b) interact
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with the hydroxyl groups via their catalytic glutamate and with the adenine ring via a methionine
residue, whereas in the OAR-synthesizing PARPs, these interactions are either at too great a
distance to provide stabilization ( glutamate replacement residues at a distance of -7A instead of
3-5A) or too close to allow ADP-ribose binding on this surface of the enzyme (methionine
replacement residues at distances of 2.4-3 A from the adenine ring instead of 3.6-4.5 A).
Together, the results of our crystal structure analysis and modeling of the binding of an ADP-
ribose analogue suggest that there could be differences in binding affmiity for ADP-ribose among
the PARPs that should be tested experimentally in the future.
One suggestion of the analysis of the acceptor domain structure of the PARPs is that
polymerizing PARPs might be more effective at binding ADP-ribose than are the other PARPs.
The shape of residues in the acceptor pocket therefore could play a critical role in the binding
preference for ADP-ribose over amino acid residues. Most PARPs, which synthesize OAR,
might have a higher affinity for the amino acid residues they modify than they do for ADP-
ribose, a possibility suggested in the work of Kleine and colleagues (2008). If this is true, these
PARPs could be more chemically competent at initiation than at elongation. Conversely, the
polymerizing PARPs might have an increased affinity for ADP-ribose and thus favor processive
polymerization.
The implications of this structural and enzymatic difference for PARP function in a
cellular context are potentially profound. Other work has shown that different members of the
PARP family can interact with each other functionally. For example, interactions with PARP-2
and PARP-3 have both been shown to activate PARP-1 activity, while PARP-5a and PARP-5b
can interact with each other through their SAM domains and transmodify (De Rycker and Price,
2004). The presence of PARP-5a, PARP-12, PARP-13, and PARP-15 in the context of stress
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granules has also suggested that PARPs with different catalytic capabilities can interact
functionally (Leung et al, 2011). Since initiation and elongation are different chemical
processes, and PARPs which synthesize longer polymer are likely more efficient at elongation
for the structural reasons addressed above (such as more energetically favorable interactions with
the pyrophosphate moiety), this presents the possibility of functional interaction between PARPs.
Thus, it is possible that the initiation steps are carried out by a PARP responsible for
synthesizing shorter ADP-ribose modifications, which is relatively better at initiation, and that
polymer can be elongated off of this platform by another PARP which can synthesize longer
polymer. Understanding functional interactions among the PARP family itself will also be
critical for the elucidation of the mechanism of ADP-ribose modification synthesis. This is one
of the goals of the methods presented in Chapter 4.
By not only examining the catalytic capabilities of the PARPs but also understanding
their localizations and functions through comparison of their domain structures to other better
characterized proteins in the literature, we begin to generate a picture both of the sorts of
pathways in which endogenous ADP-ribose modifications could be involved and of the ways in
which functional domains might regulate PARP activity. For example, the WGR domain in the
DNA-dependent PARPs activates PARP synthesis activity by transmitting the conformational
change induced by zinc finger binding to damaged DNA. Using what is known about the
distance of the WGR domain to the catalytic PARP domain in PARP-1, we can develop
hypotheses about the potential roles of functional domains of other PARPs in regulating PARP
activity. For example, the SAM domains in the tankyrases directly abut the PARP domain in
primary sequence and are known to mediate binding of the two tankyrases to each other and
promote their functional interaction (Table 5). Other domains which are close in primary
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sequence to PARP domains and thus might have some impact on conformational changes in the
PARP domain to stimulate activity are the WWE domain in PARP-7, PARP- 11, and PARP- 12,
and the macro domain in PARP-15. Since these domains interact with ADP-ribose modules, this
presents the exciting possibility that binding to a preexisting ADP-ribose modification could
stimulate synthesis activity, which has important ramifications for the functional interaction of
PARPs. Full crystal structures of PARP proteins, or at least structures containing neighboring
relevant domains, such as the work of Langelier et al. (2012), must be determined for the
remaining PARPs in order to draw conclusions about the impact of other domains on catalytic
activity or polymer length.
Methods
Generation of crystal structure diagrams, alignments, and measurements
All PDB files were visualized and analyzed in PyMOL Molecular Graphics System integrating
and extending Open-Source PyMOL 1.3. Alignments of crystal structures were performed with
the cealign command. Measurements were performed using the "measurement" wizard in
PyMOL.
Models of uncrystallized PARPs and statistics
To generate models of PARPs without crystal structures, two freeware programs were used,
Modeller and SWISS-MODEL. For Modeller, HHPred from the Max Planck Bioinformatics
Toolkit was first used to generate an alignment of each PARP domain of interest to proteins with
existing structures. HHPred usings Hidden Markov Model (HMM)-HMM comparison by
building a profile HMM from multiple sequence alignment and comparing it to a database of
HMMs. We allowed automatic selection of the best template(s) and then created an alignment
used by Modeller to generate a model. Modeller generates molecular topology for the target
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sequence, assigns disulfides in the target from equivalent disulfides in the templates, calculates
coordinates for atoms with equivalent atoms in the templates, builds unknown coordinates using
internal coordinates from the CHARMM topology library, and generates stereochemical,
homology-derived, and special restraints. Optimization of the model uses the variable target
function method with conjugate gradients and is refined using molecular dynamics with
simulated annealing (Sali and Blundell, 1993). See also
http://salilab.org/modeller/manual/nodel9.htm. The generation of each of these models was
accompanied by three statistical analyses. Verify3D calculates the statistical likelihood of each
amino acid at each position and assigns an alignment score. A higher alignment score means
better match with predicted structure. ANOLEA assesses non-local atomic interaction energy;
lower interaction energies in the model are more optimal. SOLVX evaluates model quality by
solvation energies; as another energy-based calculation, lower scores also indicate better model
quality. We found SOLVX analysis to be less informative and have therefore excluded it from
our model evaluation.
SWISS-Model generates a sequence alignment to a protein with a determined crystal structure
and creates a model based on the alignment. The alignment is generated using gapped BLAST
searching (Bordoli et al., 2009). Modelling is carried out by ProModII, which generates model
coordinates by constructing an averaged framework from superimposed template structures,
generating atomic coordinates derived from averaged framework, rebuilding nonconserved loops
from stems by structural homology searches through Brookhaven Data Bank, completing the
main chain using a backbone element library, and reconstituting lacking side chains and
correcting existing side chains using a library of allowed rotamers (Guex and Peitsch, 1997).
Energy is minimized using the GROMOS96 force field (Kiefer et al., 2009).The statistical
125
calculation to assess model quality performed by SWISS-Model is an absolute measure of model
quality based on the characteristics of solved crystal structures called QMEAN. The QMEAN
analysis results in a Z-score (a more positive Z score indicates a better match to likely real
structures.)
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Chapter 4
Strategies to Identify PAR and PARP Interaction Partners
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Introduction
Now that we have developed an understanding of the enzymatic capability of the PARP
family members and provided a structural rationale for differences in PAR synthesis capability, it
is possible to begin looking for what role these enzymatic capabilities play in a cellular context.
In order to do so, it is necessary to identify targets and regulators of PARP activity. There are
multiple experimental strategies which may be employed to begin to elucidate the protein
interactions with PAR, OAR, and PARPs that are critical in the cell. Here, we report on three
methods we have developed to do so. First, soluble PARP overexpressed in and purified from
human cells allows PARP activity to be assayed in new contexts. Second, we discuss techniques
to identify non-covalent PAR-binding proteins. Third, and finally, we identify PARP interaction
partners by two mass spectrometry analyses. Together, these three approaches begin to suggest
an expansion of possible PARP and PAR functions in the human cell and exciting new avenues
for future research.
Results and Discussion
Soluble PARP purification with the ZTS epitope tag
To further develop protein purification techniques for PARPs to allow us to generate
soluble PARP protein for activity assays and other applications, we wished to design a tandem
affinity purification tag that enabled us to make use of purification techniques with which our
laboratory was already familiar. In order to accomplish this, I developed the ZZ-TEV-SBP tag,
henceforth referred to as ZTS. This protein purification tag combines the ZZ domain, which
binds to IgG, with TEV cleavage sites followed by the S binding protein, which can bind to
streptavidin. To purify soluble protein, the tagged protein can be immunoprecipitated with IgG
and then released by TEV protease. If necessary, it can be repurified with a streptavidin column
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for a higher affinity purification. I designed this tag, cloned it into several PARPs, and
performed preliminary expression tests to confirm the proper expression of the constructs. The
structure of the ZTS tag and sample expression tests for two PARPs are shown in Figure 1.
A B
ZT 9 ZT 10
116kD * 116kD
97 kD 97 kD
66 kD 66kD
45 kD 45 kD
IB: PARP-9 PARP-10
MW: 126 kD MW: 139 kD
Figure 1. ZTS-PARP characterization. A) The structure of the ZTS N-terminal epitope tag
complexed to PARP. B) Lysates from cells transfected with ZTS-PARP-9 and ZTS-PARP-10
express the ZTS-PARP construct. Lysates were resolved by SDS-PAGE and immunoblotted
with the respective PARP antibody. Expected molecular weights of each ZTS-PARP are shown
below.
Purifying proteins associated with PAR
The use of soluble ZTS-PARP protein in in vitro assays is potentially useful for the
identification of proteins covalently modified by ADP-ribose, but less useful for the discovery of
proteins which may bind to PAR or OAR non-covalently. Here, we outline two methods for the
purification of PAR binding proteins via PAR purification under native conditions: purification
of cellular PAR and purification of PAR covalently linked to specific PARPs. Together, these
methods provide complementary approaches to the identification of non-covalent PAR-protein
interactions in the cell.
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Each of these techniques uses HeLa S3 suspension cells to generate cytoplasmic lysate.
Suspension cells are used due to their superior cell volume-to-media volume ratio relative to
adherent cells, thus providing greater amounts of cytoplasmic lysate per volume of media. Of the
human suspension cell lines, we specifically chose HeLa S3 cells since these cells are well
characterized, easily transfected with exogenous DNA, have retained critical cell cycle
checkpoints and react predictably to small molecule treatments such as cell cycle arrests,
stressors, and inhibitors (Kung et al., 1990). Thus, by treating HeLa S3 cells with inhibitors
prior to generating cytoplasmic lysates, we can identify PAR binding proteins under distinct
cellular conditions. Finally, HeLa S3 cells can rapidly convert between suspension and adherent
growth, providing convenient methods for the removal of dead cells during adherent growth as
well as the generation of monoclonal cell lines via manual isolation of monoclonal colonies on
plates (Lockart and Eagle, 1959).
The first PAR purification method, cellular PAR purification, modifies an existing PAR
purification technique that uses boronate affinity to isolate in vitro synthesized PAR under
denaturing conditions (Alvarez-Gonzalez, 1988). Our approach also relies on boronate affinity,
but facilitates PAR purification directly from cytoplasmic lysate. PAR contains two cis-diols per
ADP-ribose moiety, each of which binds covalently to the cis-diol residues found on boronate
affinity matrices. Since cis-diols are also found in some small molecules, RNA, and
polysaccharides, these contaminants must be depleted from cytoplasmic lysates prior to
incubation with the boronate affmity matrix. We remove small molecules from the cytoplasmic
lysates using Sephadex G-25 gel filtration, RNA by treating with RNases, and polysaccharides
via preadsorption on lectin columns. Once these contaminants are removed, boronate affinity
chromatography is used to purify PAR and its associated binding proteins from the cytoplasmic
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lysate. PAR binding proteins are then eluted from the boronate affinity matrix via incubation
with ARH3, a soluble PAR glycohydrolase that hydrolyzes PAR and thereby releases PAR
binding proteins (Fig. 2, left). These proteins are then resolved by gel electrophoresis, visualized
by Coomassie or silver stain, and identified by mass spectrometry analyses (Fig. 3, left).
Cellular PAR purification H
Day I ~ Generatelysate (a)
Treat with RNAse, remove
small molecules (b)
Preadsorb on lectin column (c)
Collect flowthrough
containing PAR, bind to
boronate affinity matrix (d)
Elute PAR binding proteins
with ARH3 (e)
SDS-PAGE,
mass
spectrometry
eLa S3 cells
PARP
immunoprecipitation
Transfect DNA Day 0
Add small molecule
inhibitor*
Generate lysate
I
SDS-PAGE,
mass
spectrometry
Lysate modification assay
Day I
% Immunoprecipitate
Add PNAD*
Add fresh cell
ysate 7
SDS-PAGE,
mass
spectrometry
Pure PARP modification assay
Figure 2. Overview of purification strategies. The cellular PAR purification method is
illustrated on the left (white arrows) and is used to purify cellular PAR and its associated
proteins. The PARP immunoprecipitation method is shown on the right and summarizes two
methods, the lysate modification assay (gray arrows) and the pure PARP modification assay
(black arrows). Asterisk indicates optional step. Reprinted by license from Rood, J.E., Leung,
A.K.L., and Chang, P., 2011, Methods for purification of proteins associated with cellular
poly(ADP-ribose) and PARP-specific poly(ADP-ribose), Methods Mol Biol 780, 153-64.
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Cellular PAR PARP
purification immunoprecipitation
ab c de f
Figure 3. Examples of purification strategies. Both images show steps of each purification
resolved on SDS PAGE-gels. Left. Results of cellular PAR purification experiment. Letters
above each lane refer to steps in the purification as marked in Figure 2. Right. Purified epitope-
tagged PARPs prior to automodification and incubation with fresh cell lysate. Reprinted by
license from Rood, J.E., Leung, A.K.L., and Chang, P, 2011, Methods for purification of proteins
associated with cellular poly(ADP-ribose) and PARP-specific poly(ADP-ribose), Methods Mol
Biol 780, 153-64.
The cellular PAR purification method isolates the cellular pool of PAR generated by all
active PAR polymerases (PARPs). Data suggests that PAR polymerized by specific PARPs can
be structurally distinct. For example, PAR polymerized by PARP-1 is highly branched, while
PAR synthesized by PARP-5a is largely linear (Am6 et al., 2004; Rippmann et al., 2002). PARP-
1 and PARP-5a are involved in unrelated cellular pathways, and although both proteins share the
cytoplasm during mitosis, each binds distinct sets of proteins (Chang et al., 2009). This evidence
suggests that the regulation of PAR structure by the PARPs that polymerize it may in turn
regulate the recruitment of specific PAR binding proteins. Thus, the structure of PAR attached to
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each PARP might determine the identity of the PAR binding proteins. A comprehensive
mechanistic understanding of PAR-protein interactions can be attained by identifying proteins
non-covalently bound to the PAR generated by specific PARPs.
To identify PARP-specific PAR binding proteins, we have developed two related
protocols based on the immunoprecipitation of epitope-tagged PARPs expressed in HeLa S3
cells: a lysate modification assay (Fig.2, middle) and a pure PARP modification assay (Fig. 2,
right). These were previously described (Chang et al., 2009). In the lysate modification assay,
exogenous p-NAD*, the substrate for PARP catalysis, is added to the cytoplasmic lysate prior to
immunoprecipitation to increase the concentration of PAR linked to the immunoprecipitated
PARP. Since this reaction occurs prior to purification of the PARP, the PAR attached to the
PARP is due to the activity of the purified PARP along with other PARPs that modify it in trans.
In this assay, the PARPs containing covalently linked PAR and any PAR binding proteins are
purified from cytoplasmic lysate and then analyzed without further incubations. In the pure
PARP modification assay, epitope-tagged PARP is purified without addition of exogenous p-
NAD* and washed in high concentrations of salt to remove binding proteins. The purified PARP
is then incubated with exogenous p-NAD* in vitro to stimulate automodification. Thus, the PAR
structures linked to PARPs in this assay are mainly due to the intrinsic activity of the purified
PARP. The modified PARP is then incubated with fresh cytoplasmic lysate to recruit PARP-
specific PAR binding proteins.
These assays are useful for isolating PAR-interacting proteins, but in order to identify the
proteins, the use of mass spectrometry is often required. Below, we illustrate some of the
insights which can be gained by the use of mass spectrometry on purified PARPs.
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Mass spectrometry confirmation of functional PARP-PARP interactions in the stress
granule
One question in particular which we wished to address with mass spectrometry is the
possibility of functional interaction among PARPs, particularly between different subfamilies of
PARPs. In Chapter 2, we found that, by and large, the enzymatic activity of PARPs is consistent
among members of a subfamily. Given the similarity of enzymatic activities and domain
composition within each subfamily, we sought to understand the functions of individual PARPs
and their subfamilies by identifying their protein binding partners using liquid chromatography
tandem mass spectrometry (LC-MS/MS). We initially pursued this investigation in the context
of assembly of stress granules, ribonucleic protein complexes that form in response to all known
cytoplasmic stressors (Anderson and Kedersha, 2008). We found that five PARPs, PAR, and the
PAR glycohydrolase PARG were all present at stress granules and active in their dynamic
assembly (Leung et al., 2011). Intriguingly, the five PARPs involved in stress granule assembly
have three different catalytic activities: PARP-5a synthesizes PAR, PARP-12 and PARP-15
synthesize OAR, and PARP-13.1 and PARP-13.2, different splice isoforms of PARP-13, are
inactive enzymes that are heavily modified by PAR in the stress granule. This suggested to us
the novel possibility of cross-subfamily functional PARP interaction, where OAR-synthesizing
PARPs could modify a protein, such as an inactive PARP, followed by elongation to PAR by a
PARP that can synthesize this modification. In order to test functional interaction, we looked for
PARP-PARP interactions via overexpression and affinity purification of each stress granule
PARP followed by LC-MS/MS under stress and non-stress conditions. In addition to the
identification of other stress granule components, we were indeed able to find a binding
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interaction between many stress granule PARPs, laying the groundwork for further studies of
their functional interaction (Table 1; Leung et al., 2011).
Immunoprecipitation
25 0 0 0 0
1 17 0 0 0
0 1 6 20 3
0 0 0 0 7
Table 1. PARPs interact in the stress granule. LC-MS/MS data for individual SG-PARP
immunoprecipitates from stressed conditions (20 nM pateamine A, 30 min). The top row
indicates which PARPs were immunoprecipitated and the columns indicate how many peptides
for a particular PARP were detected. Adapted from Leung et al., 2011, Figure S4B.
Mass spectrometry identification of potential PARP targets and regulators: the PARP
interactome
Our identification of a functional interaction between PARPs of different subfamilies in
the stress granule, which we were able to verify by mass spectrometry, led us to ask if other
functional interactions among PARPs or between PARPs and other proteins could also be
discovered by this method. Thus, to identify PARP binding interactions and the specific
pathways in which PARPs function, we expressed and purified each PARP as a GFP fusion in
human HEK 293F cells, then analyzed binding proteins via liquid chromatography mass
spectrometry (LC-MS). These data specifically identify interphase binding interactions, as -95%
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of cells utilized were interphase cells. PARPs were purified under high salt (450 mM NaCl) and
physiological salt (150 mM NaCl) wash conditions, allowing us to identify salt-sensitive and
salt-insensitive binding interactions. For the purpose of this analysis, the data from both
purification conditions have been combined; a list of proteins identified under each condition can
be found in the appendix. For each purification, members of individual PARP subfamilies were
assayed in parallel with PARP-1, which serves as a normalizing control since its binding partners
are well characterized (Isabelle et al, 2010).
We identified numerous binding interactions among PARP family members, including
new interactions within PARP subfamilies, previously identified interactions within subfamilies,
and the first known examples of PARP interactions across PARP subfamilies (Figure 4; Loseva
et al., 2010; Rulten et al., 2011; Sbodio et al., 2002). Additionally, binding interactions among
the PARPs spanned the three enzymatic activities (Figure 5). We also identified specific proteins
that bind multiple PARPs with different enzymatic activities, suggesting that individual proteins
can be modified by both OAR and PAR. Total PARP binding interactions are summarized in
Figures 6, 7, and 8. Individual PARPs are color-coded by subfamily in Figure 6, subfamily
binding interactions are summarized in Figure 7, and binding interactions classified by PARP
enzymatic activities are shown in Figure 8.
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Figure 4. PARP-PARP interactions by subfamily. PARP binding interactions identified via
LC-MS analysis of purified GFP-PARP proteins. Color representations correspond to PARP
subfamilies: red (DNA-dependent PARPs), orange (tankyrases), magenta (CCCH Zn finger
PARPs), cyan (macro PARPs), and grey (unclassified PARPs). The base of an arrow indicates
the immunoprecipitated PARP, the tip of the arrow points to the identified PARP, and two-
headed arrows indicate interactions identified in both directions.
3
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8
4 2 a 5
Figure 5. PARP-PARP interactions by enzymatic activity. Interaction map of PARP
interactions grouped by enzymatic activity. Crimson is OAR synthesis activity, blue, PAR
synthesis, and black, no catalytic activity. Arrows have the same significance as in Figure 4.
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Figure 6. The PARP interactome by subfamily. The complete PARP interactome indicating
each of the protein interactions identified. Color scheme as in Figure 4.
4JW#
Figure 7. Subfamily interactomes demonstrate both shared and unique interaction
partners. Interaction maps of individual PARP subfamily binding interactions. Color scheme
as in Figure 4.
142
Inactive
PAR
Figure 8. Activity interactomes indicate functional overlap among PARPs of different
catalytic capabilities. Interaction map of PARP protein interactions based on catalytic activity.
Color scheme as in Figure 5.
The functional significance of the PARP binding interactions is best explained by
clustering them based on gene ontology (GO) analysis (Li et al., 2005). We selected categories of
biological interest and summed the number of identified peptides for each category as a measure
of enrichment. To normalize across PARPs, each peptide number was divided by the total
number of peptides identified for the relevant PARP. The results were then correlated and
clustered hierarchically according to GO enrichment patterns of each PARP (Figure 9). The
patterns of GO enrichment categories were highly correlated within subfamilies and known
localization patterns, demonstrating the specificity of our approach and suggesting that the
enrichment categories can be used to identify functional pathways associated with each PARP.
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Figure 9. PARP interactions match well to PARP subfamilies. Gene ontology clustering
analysis. Interacting proteins were classified by gene ontology category, then the number of
peptides identified for each category were summed and divided by the total number of PARP
peptides to normalize. The binding interactions for each PARP were then hierarchically
clustered using MATLAB clustergram analysis. PARP names are color-coded by subfamily as
in Figure 4. The dendrogram above the clustergram denotes the clusters and relative distance.
Red indicates enrichment, green indicates depletion, and black indicates neither enrichment nor
depletion of a given gene ontology category for a certain PARP compared to the average among
PARPs.
DNA-dependent PARPs
PARPs 1-3 all bound to one another and PARP-2 and PARP-3 clustered together. The
majority of binding interactions, most notably with DNA damage proteins, were shared among
the DNA-dependent PARPs. Consistent with its cytoplasmic and nuclear localizations, PARP-3
was the most highly enriched of the DNA-dependent PARPs for cytoplasmic proteins (Figure 9).
In addition, we identified a new binding interaction between PARP-3 and XRCC6, a DNA
helicase involved in DNA repair (Gu et al., 1997). Despite the known functional relationships
between the three DNA-dependent PARPs (Am6 et al., 1999; Rouleau et al., 2007), PARP-1 did
not cluster with PARP-2 and PARP-3 (Figure 9). This could be due to additional functions of
PARP- 1 in pathways independent of PARP-2 and PARP-3 as demonstrated by the large number
of unique binding interactions identified for PARP-1 (Figure 7, upper left).
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Tankyrases
Each tankyrase appeared as the major binding partner of the other, consistent with
previous work (Sbodio et al., 2002). PARP-5a and PARP-5b bound proteins of very similar
functions and therefore clustered together (Figure 9). The identity of binding proteins also
largely overlapped (Figure 7, top middle). We identified novel inter-subfamily binding
interactions between PARP-5a, PARP-5b and PARP-10, which we discuss below. In addition,
both tankyrases demonstrated a robust binding interaction with GDP-mannose-4, 6-dehydratase
(GMDS), an interaction unique to the tankyrase subfamily. GMDS is involved in protein
fucosylation and functions in neural development as well as NK-cell mediated tumor
surveillance (Moriwaki et al., 2009). This interaction suggests potential cross-talk between
tankyrases and protein fucosylation pathways. Another shared interaction is with the tumor
suppressor p53 found in the cytoplasm and nucleus (Hollstein et al., 2010). PAR has previously
been shown to regulate p53 localization and activation (Alvarez-Gonzalez, 2007). PARP-5a,
PARP-5b and PARP-6 (see below) were the only identified PARPs that bound to p53, suggesting
that they could regulate p53 function. PARP-5a and PARP-5b also bound proteins involved in
ubiquitin-mediated protein degradation: the Abrol subunit of the BRISC complex (5a and 5b),
BRE (5a), and HERC2 (5b) (Cooper et al., 2010; Dong et al., 2003; Wu et al., 2010). PARP-5a
uniquely bound BRE, a component of the BRCA1-A complex, while PARP-5b bound the E3
ubiquitin ligase HERC2, indicating that both tankyrases had unique interactions that both play a
role in ubiquitin pathways.
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CCCH Zn Finger PARPs
PARP-12 and both isoforms of PARP-13 clustered together in our GO analysis, while
PARP-7 did not, consistent with the overlapping cytoplasmic localization patterns of PARP-12
and PARP-13 and the nuclear localization of PARP-7 (Figure 9; Leung et al., 2011). PARP-12
and PARP-13 binding interactions were highly enriched for RNA binding proteins, consistent
with the presence of the RNA-binding CCCH zinc finger. These included known stress granule
components, in agreement with functions we identified for PARP-12 and PARP-13 in the stress
granule (Leung et al., 2011; Anderson and Kedersha, 2008). In contrast, PARP-7 was not
enriched in RNA binding proteins but rather in diverse categories such as nucleolar, cytoskeletal
and signaling proteins. Importantly, we identified binding interactions between PARP-7, DNA-
dependent PARP- 1 and macro PARP-9, consistent with the nuclear localization of all three
proteins. In addition, we identified inter-subfamily binding interactions between PARP-12 and
PARP- 11.
Macro PARPs
Despite a large number of overlapping binding proteins, there were no direct binding
interactions among macro PARPs. However, PARPs-9 and -14 clustered in our GO analysis,
consistent with their overlapping nuclear localization. Most notable among the PARP-9 and
PARP-14 binding proteins are those involved in DNA repair, such as PARP-1, DNA ligase 3,
XRCC1, XRCC5, XRCC6, FACT complex subunits, and DNA-PK (Wood et al., 2005).
Interestingly, PARP-14 bound the non-macro PARP-13.1 and PARP-16. PARP-9 has the largest
number of unique interactors among the entire PARP family (Figure 6). Notable among these are
actin and its binding proteins and nuclear membrane and matrix proteins (Gruenbaum et al.,
2000; Nakayasu et al., 1991; Squarzoni et al., 1998; Furukawa et al., 1998). PARP-15 is unique
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in that it does not interact with other PARPs and shares few interaction partners with either of its
subfamily members (Figure 4 and Figure 7, top right). However, it did have three unique
interactors - protein arginine methyltransferase 5, caspase 14, and bleomycin hydrolase - that all
function in protein modification or degradation (Deng et al., 2010; Koenig et al., 2005; Lazo et
al., 1982).
Unclassified PARPs
Our analysis identified reciprocal binding interactions between PARP-4 and PARP-1,
consistent with their overlapping nuclear localizations. A functional interaction was also
suggested by cluster analysis, which grouped these structurally unrelated PARPs together (Figure
9). PARP-4 interacted with few proteins, none of which were unique in the PARP interactome
(Figure 6 and Figure 7). Highly homologous PARP-6 and PARP-8 bound proteins of similar
function, shared a large number of interaction partners (Figure 7), and clustered in our GO
analysis (Figure 9). PARP-6, like the tankyrases, bound p53, and PARP-8 bound several proteins
that were also bound by PARP-12 (IGF2, YBX1).
Interestingly, PARP-10 clustered with PARP-6 and PARP-8 in our GO analysis. Like
PARP-4, PARP-10 had no unique interactors within the PARP interactome, but did interact with
PARP-5b, consistent with the tankyrase-PARP-10 interaction we observed in our tankyrase
analysis. PARP-10 contains a ubiquitin-binding domain and demonstrates a strong association
with ubiquitin. Since the tankyrases bound a number of proteins involved in ubiquitin-mediated
protein degradation, it is possible that a complex of PARP-10, PARP-5a, and PARP-5b function
in ubiquitin-mediated protein degradation (Huang et al., 2009). PARP- 11 binds to proteins
whose functions closely match those of PARP-7 binding proteins (Figure 9). All of PARP-1 l's
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unique interactions are with cytoskeletal proteins or proteins that modify the cytoskeleton,
indicating a role in cytoskeletal dynamics.
PARP-16 bound to the DNA-dependent PARP-1 and macro PARP-14. Our GO cluster
analysis suggests that PARP-16 binds proteins of functions most similar to those of the
interaction partners of PARP-2. Consistent with its ER membrane localization pattern, PARP- 16
interacts with membrane-bound proteins such as HADHA and lamin B (Gruenbaum et al., 2000;
Jwa and Chang, 2012).
Conclusion
Together, the three techniques outlined above provide a variety of methods to address the
role of PARPs in the cell by identifying proteins which interact with the PARPs or with their
products, PAR (and possibly OAR). The data from initial purifications and mass spectrometry
analyses is largely preliminary and must be verified in the future with confirmation by both
further mass spectrometry (ideally quantitatively, for example with SILAC techniques) and
functional characterization confirmation with biochemical and immunofluorescent techniques.
Therefore, the purpose of the work in this chapter is not to provide a definitive list of all PARP
and PAR interactors, but rather to enable future research to identify the roles of each PARP in
the cell via the proteins which interact with the PARPs and their enzymatic products. We hope
that these techniques will be of use to other scientists.
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Methods
Cell culture
HeLa S3 cells were grown in DMEM (Cellgro/Mediatech, Manassas, VA) supplemented with
1% pen/strep (Cellgro/Mediatech) and 10% FBS (Tissue Culture Biologicals, Tulare, CA) at
37*C, 5% CO2, 80% humidity in an Infors Multitron rotation shaker (Appropriate Technical
Resources, Inc., Laurel, MD) set to 120 rpm.
Mitotic cell cycle arrest
We provide this protocol as one example of a cell cycle-specific enrichment. Wild type or HeLa
S3 cells engineered to express PARP fusion proteins are arrested in mitosis of the cell cycle, and
are used to purify PAR or PARP fusions containing covalently modified PAR.
Cells were incubated with 10 [tM (+)-S-trityl-L-cysteine (STLC) (Fluka/Sigma-Aldrich, Buchs,
Switzerland) for a maximum of 12 hours and mitotic index assayed by staining cells with
Hoechst 33342, trihydrochloride, trihydrate, 10 mg/ml solution in water (Invitrogen, Carlsbad,
CA) and visualizing under a fluorescent microscope.
Transfection
HeLa S3 cells were passaged at 1 x 106 cells/ ml the day prior to transfection. For GFP-PARP
expression, a typical transfection requires 50 ml of confluent cells to generate 1 pig of protein,
although this varies with transfection efficiency of various constructs. Cells were transfected
with 50 pl 293fectin transfection reagent (Invitrogen, Carlsbad, CA) in 950 pl Opti-MEM I
reduced serum media (Gibco, Grand Island, NY) and 50 pg of pure maxiprep GFP-PARP
plasmid DNA (260/280 ratio of at least 1.8) in 1 ml Opti-MEM media incubated together
according to manufacturer's protocol. Cells were transfected in media without
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penicillin/streptomycin. 6 h post transfection, cells were switched to media containing
penicillin/streptomycin.
Cytoplasmic lysate preparation
Cells were incubated with latrunculin B (Enzo Life Sciences, Plymouth Meeting, PA), an actin
depolymerizing agent, to a final concentration of 1.26 pM for 1 h under normal culturing
conditions. This reduced actin and actin binding protein contamination which is common in
HeLa S3 preparations. Cells were collected via centrifugation at 400 x g for 3 min at 4*C and
washed 3x in ice-cold PBS, then diluted in 3 x cell pellet volume of Cell Lysis Buffer, CLB (150
mM NaCl, 50 mM HEPES, pH 7.4, 1 mM MgCl 2, 0.5% Triton-X 100, 1 mM DTT, 1 mM
EGTA, made fresh on day of experiment). If the cytoplasmic lysate is for use in the cellular
PAR purification protocol, the lysate modification assay, or assembly of PAR-dependent
complexes, 1 pM adenosine 5'-diphosphate (Hydroxymethyl)pyrrolidinediol, dihydrate,
ammonium salt (ADP-HPD) (Calbiochem, La Jolla, CA) was added to the CLB. ADP-HPD is a
small molecule inhibitor of PAR glycohydrolase (PARG), an enzyme that degrades PAR and is
highly active in cytoplasmic lysates. For immunoprecipitation of PARPs for the pure PARP
modification assay, ADP-HPD addition is optional because the downstream formation of
polymer is of greater interest.
Cells were lysed for 10 min on ice and spun at 14,000 x g, 4*C, for 10 min to remove
cell membranes and nuclei from the cytoplasmic lysate. 1 pg/ml cytochalasin D (Sigma-Aldrich,
St. Louis, MO) and 25 pM nocodazole (Tocris, Ellisville, MO) were added to the lysate and the
lysate centrifuged again at 14,000 x g for 1 min to remove remaining cytoskeletal contaminants.
Cytochalasin D inhibits actin polymerization while nocodazole depolymerizes microtubules.
Both treatments minimize contamination by aggregated and precipitated cytoskeletal
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components. The remaining supernatant comprised the cytoplasmic lysate used for cellular PAR
purification or GFP-PARP immunoprecipitation.
Cellular PAR pun'fication
Cellular PAR purification is normally performed without transfection but can be combined with
cell cycle arrests to enrich for proteins that bind to PAR during specific cell cycle stages.
Cytoplasmic lysate was treated with 2 units/ml RNase cocktail (Ambion, Austin, TX) for
45 min and then resolved through a PD-10 column (GE Healthcare, Piscataway, NJ) and flow
through collected. Equal volumes of concanavalin A (ConA) lectin resin, 50% slurry
(Pierce/Thermo Fisher, Rockford, IL) and wheat germ agglutinin (WGA) lectin resin, 50% slurry
(Pierce/Thermo Fisher) were mixed, 100 pl of ConA bead slurry and 100 p1 WGA bead slurry
per 500 p1 of cytoplasmic lysate, and washed twice in CLB. The binding capacity of each matrix
is 10 mg of protein per ml of resin. Cytoplasmic lysate was added to the ConA/WGA bead
mixture and rotated for 90 min at 4'C, then spun at -100 x g to remove the ConA/WGA beads.
Supernatant was added to a boronate column and rotated for 90 min at 4'C to bind PAR
and associated proteins to the column. The boronate column, with 1/3 the volume of the
cytoplasmic lysate, was generated by rehydration of Boronate Affi-Gel (Bio-Rad Laboratories,
Hercules, CA) in CLB for at least 60 min followed by transfer to a Kontes Flex-Columns
(Kimble Chase, Vineland, NJ), and washing in 10 column volumes of CLB. The binding
capacity of Boronate Affi-Gel is 130 pmol sorbitol/ml gel.
Following incubation with the lysate, the column was washed with 20 column volumes
CLB to remove non-specifically bound components as well as remaining ADP-HPD. The
column was incubated with 1 column volume of 100 pg/ml ARH3 (Oka et al., 2006) for 30 min
on ice followed by 10 min at room temperature. ARH3 is a PAR glycohydrolase that hydrolyzes
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PAR and thus specifically elutes proteins bound to PAR. ARH3 was used instead of PARG
because it is not inhibited by ADP-HPD (in case there is residual inhibitor in the prep) and
because it is easily purified as recombinant protein. The boronate column was washed in three
column volumes CLB and beads from the column collected via resuspending in CLB,
transferring to a new tube, allowing beads to settle, and adding 1 column volume of 1x Laemmli
sample buffer in CLB containing 2% beta-mercaptoethanol to the beads. Samples were heated to
950C for 5 min and resolved on SDS-PAGE gel and amount of protein bound quantitated by
Coomassie staining. Whole samples or specific protein bands may be analyzed by mass
spectrometry.
Immunoprecipitation (lysate modification assay and pure PARP modification assay)
Cytoplasmic lysates were generated as described at 24 h post transfection. Anti-GFP, clone 3E6,
antibody (Invitrogen) was conjugated to Dynabeads protein A magnetic beads (Invitrogen,
binding capacity 250 pg IgG/ml of beads), 10 pl of magnetic bead slurry per reaction washed
once in 1 ml ice-cold PBS and antibody diluted to 1 pg/ml and rotated for 1 h at 4'C. Each
cytoplasmic lysate was added to one bead reaction and rotated for 90 min at 4'C. To perform the
lysate modification assay on the PARP being immunoprecipitated, 100 pM beta nicotinamide
adenine dinucleotide (p-NAD*, Sigma-Aldrich) was added to the cytoplasmic lysate during this
bead-binding step. After binding to lysate, beads were washed 1 x 10 min in 1 ml CLB and 2 x
10 min in 1 ml CLB containing 300 mM NaCl (for the lysate modification assay) or 450 mM
NaCl (for the pure PARP modification assay) to reduce non-specific binding, followed by one 2
min wash in 1 ml CLB + 1 pM ADP-HPD. Lysate modification assay samples are eluted in
sample buffer.
153
Pure PARP modification assay
To activate each PARP, the immunoprecipitated PARP conjugated to magnetic beads as
prepared above was incubated with 100 [tM f-NAD* in 50 pl CLB + 1 IM ADP-HPD for 30
min on ice, then washed 3 x 2 min in CLB + 0.1 ptM ADP-HPD to remove unincorporated f-
NAD'. To assemble PAR-interacting complexes, the magnetic beads containing purified PARP
and polymerized PAR were incubated with 500 pil - 1 ml of fresh cytoplasmic lysate (as
generated above) and rotated at 4'C for 1 h followed by 3 x 10 min washes in 1 ml CLB
containing 450 mM NaCl and 1 x 10 min wash in 1 ml CLB. Then, beads were incubated with
100 pg/ml ARH3 in CLB for 30 min on ice followed by 10 min at room temperature to elute
proteins bound solely through PAR interactions. Samples were eluted by addition of sample
buffer and heating to 95*C for 5 min (if the sample was to be immunoblotted for PAR, sample
was heated to only 70*C for 10 min to prevent polymer degradation). Protein was quantified by
Coomassie or silver stain and may also be followed by protein identification by mass
spectrometry or immunoblot.
Mass spectrometry
Mass spectrometry samples were prepared as described in PARP activity assays in the methods
of Chapter 2 and eluted in NuPAGE sample buffer with 20 mM DTT for 45 min at 56'C
followed by alkylation with 1% acrylamide at room temperature for 30 min. Samples were
separated via 4-12% NuPAGE gel (Invitrogen) and stained with Colloidal Blue (Invitrogen).
Stained gel lanes were cut into 5 slices with similar protein amounts. The slices were cut into
pieces and in-gel digestion was performed as described in Winter and Steen, 2011. The extracted
peptides were dried using vacuum centrifuge and resuspended in 20 gl 5% ACN, 5% FA 5 Vd of
sample was used for per analysis by LC-MS/MS. After direct injection on the analytical column,
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peptides were eluted with a linear gradient from 95% A (water with 0.2% FA), 5% B (ACN with
0.2% FA) to 65% A, 35% B in 30 min at a flow rate of 500 nl/min. Eluting peptides were ionized
in positive ion mode and analyzed using a LTQ ion trap mass spectrometer (Thermo Finnigan).
After one survey scan the 6 most abundant ions were fragmented in the MS/MS mode. Raw data
were processed to *.mgf files and searched against a concatenated database of IPI human v. 3.69
and its reversed version using MASCOT v. 2.1. Search results originating from one precipitation
were combined and peptides extracted with a false discovery rate of 1%. The cut off for the
identification of a protein was set to 2 unique peptide sequences.
Mass spectrometry visualization and analysis
Interactions identified by mass spectrometry were uploaded into GeneGo MetaCore for
visualization. Gene ontology analysis was performed with GOfact
(http://61.50.138.118/gofact/cgi/gofact2009.cgi) using standard settings. Total peptides for each
gene ontology category for each PARP were summed and divided by the total number of
peptides identified for that PARP to normalize for sample enrichment. These normalized
numbers were used as the data set for the "clustergram" command in MATLAB to generate
Figure 9.
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Chapter 5
Conclusion and Future Directions in the Characterization of PAR and PARPs
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This thesis has examined the enzymatic capability of the human PARP family proteins
through biochemical assays, explored structural reasons for different synthesis capabilities
among different PARPs, and provided a preliminary test of various techniques that could be
useful in identifying targets of each PARP in the cell or other proteins critical for the proper
function of PARPs. Together, the data and techniques presented here present a starting point for
a deeper mechanistic understanding of PARP function, but many questions about the PARP
family as a whole and each PARP individually remain unanswered.
Testing structural predictions
First, while this thesis is able to make hypotheses on the structural basis of enzymatic
activity (Chapter 3), expanding the work of Ruf and colleagues with the advantage of more
experimental data on PARP family structures and enzymatic activities, these hypotheses remain
untested (Ruf et al., 1998). A full understanding of the contributions of structural differences in
the acceptor pocket will require experimental exploration of these hypotheses.
One way to do so would be mutational analysis. Random mutation was the initial
approach taken by Rolli and colleagues to identify residues critical for the activity of PARP- 1,
although the role of many of these residues was not fully understood until initial structural work
was completed (Rolli et al., 1997; Ruf et al., 1998). Now that the PARPs are beginning to be
quite well-characterized structurally via crystallization, directed mutagenesis could be a useful
approach to study the role played by various residues. The analysis in Chapter 3 suggests that
the position of residues, more than the identity of residues, is critical for the determination of
catalytic activity. This could, however, easily be tested with directed mutagenesis, starting with
the mutation of the residue homologous to the catalytic glutamate to glutamate in PARPs other
than PARP-10 naturally capable of only oligomer synthesis (this analysis has already been
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carried out for PARP- 10; Kleine et al., 2008). If the shape of the acceptor pocket is critical for
PARP polymer synthesis, then changing the identity of a single residue will likely not affect the
catalytic capability of the PARP. Further combinations of structural work, mutational studies,
and enzymatic analysis, using many of the techniques pioneered here, could provide useful
insights into the structural reasons for PARP activity.
Examining PARP functional interaction
Second, our confirmation of the differences in enzymatic capabilities of the PARPs
(Chapter 2) and our discovery of many interactions among the PARPs (Chapter 4) provides the
basis for a hypothesis of cooperative PARP activity, in which a PARP specialized for initiation
(an OAR-synthesizing PARP) and a PARP which is more adept at elongation (a PAR-
synthesizing PARP) may work in concert to modify protein targets (Figure 1). Inactive PARPs
may even play a role in PARP synthesis by serving as a PAR modification target, a role
suggested by our work on PARP-13 in the stress granule (Leung et al., 2011).
At the same time, new structural studies have provided insights into the interactions
among individual molecules of the same PARP. For example, in their crystal structure of the
zinc fingers, WGR domain and catalytic domain of PARP-1, Langelier and colleagues
demonstrated that the automodification domain of PARP- 1 neighbors the catalytic domain,
allowing for cis modification, whereas it was previously thought that two PARP-1 molecules
must interact to achieve automodification (Langelier et al., 2012). By contrast, a structural study
of PARP-10 by Kleine and colleagues suggested that the interaction of two PARP-10 molecules
was necessary for automodification via a substrate-assisted mechanism. Therefore, more
detailed structural analyses of other PARPs could have important consequences for the
understanding of the dynamics and mechanism of the synthesis of ADP-ribose modifications.
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Protein recognition domain PARP domain
A PARP recognition site Acceptor site
Modification site0 ADP-ribose
Figure 1. A model of the functional outcome of acceptor site differences. Polymerizing
PARPs (shown in green) bind well to ADP-ribose and less well to substrate proteins, favoring
polymer synthesis (elongation). By contrast, OAR-synthesizing PARPs (shown in pink) bind
better to protein than to ADP-ribose, favoring initiation. This allows initiated substrates to be
elongated through functional interaction with polymerizing PARPs. Also suggested is a possible
model for functional domain regulation of polymer length, whereby more closely located
domains limit the flexibility of the PARP domain to continue to synthesize PAR while bound to
the target protein.
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Outlining the ADP-ribosylsome
Third, the identification of targets of PAR synthesis, such as PARP- 13, is critical to
develop a complete understanding of PARP function in the cell. The approaches of Chapter 4
provide a few ways to tackle this problem, but other methods are also in development and have
begun to yield results. The methods of Chapter 4 provide a starting point for the examination of
ADP-ribose synthesis initiation events, which likely involve close contact between the PARP
and the protein target. This implies the need to identify and study interaction surfaces between
the PARPs (particularly those that do not synthesize longer polymers) and their potential
modification targets.
By contrast, since PAR can be a very long polymer, it follows that there might not
necessarily be a protein binding interaction between polymerizing PARPs and their modification
targets once advanced stages of elongation are reached. Therefore, protein interaction studies
might not be the best method to examine PARP modification. Instead, mass spectrometry
techniques are being developed for better recognition of single ADP-ribose residues on peptides.
Since PAR is difficult to detect by mass spectrometry due to its undefined size, researchers have
devised various methods to identify residues which are modified by PAR or longer OAR. One
option, used to identify the automodification sites of PARP- 1, is to use a mutant version of the
enzyme that abolishes PAR synthesis activity while maintaining initiation capability (Tao et al.,
2009). This approach could work well if the catalytic glutamate does not play a role in the
recognition of the substrate. However, it might be the case that this might lead to ADP-
ribosylation events that the wild type enzyme would not catalyze. Another option is treatment of
the cleavage product with ARH3 or phosphodiesterase. This approach has also been used, for
example to identify the modified lysine residues of histone proteins, and should provide a
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promising way to identify ADP-ribosylated residues without changing the properties of the
polymerizing enzymes (Messner et al., 2010; Hengel and Goodlett, 2012). Together, these and
future techniques should lead to the continued elucidation of cellular targets of ADP-ribosylation
and the connection of these targets to particular PARPs. These discoveries will unlock not only
mechanistic insights into the function of each PARP, but also help to define the roles of each
PARP in the cell more clearly.
Understanding PARP inhibition
Finally, a deeper understanding of the PARP mechanisms of PAR synthesis and the roles
PARPs play in the cell will help to define and develop better or more varied uses of PARP
inhibitors as a treatment. PARP inhibitors have to date largely been used as a treatment for
various cancers because of the role of PARP- 1 in DNA damage repair. However, there is now a
dawning realization in the field that PARP inhibitors are not specific for PARP-1 and may also
impact the functions of other PARPs. Structural studies to examine the binding aff'nities of
various inhibitors by various PARPs confirm that PARP inhibitors may impact PARPs that do
not play a role in DNA repair (Wahlberg et al., 2012). However, characterization of PARP-
inhibitor binding interactions is not enough to understand the potential outcomes of PARP
inhibitors as a medical treatment. A more complete examination of the functions of each PARP
in the cell and in stress pathways will be critical both to predict and understand possible off-
target effects as well as to discover other potential treatment avenues and pathways which PARP
inhibitors might be able to impact.
Together, these four areas of future research into the PARP family have the potential not
only to deepen our understanding of the critical roles these proteins, and the variety of post-
translational modifications they synthesize on a great many targets, play in the cell, but also to
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deliver a positive impact on future medical treatments through a more thorough mechanistic
knowledge of the structure and function of the human PARP enzymes.
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Appendix I. Mass spectrometry results.
The following tables show the results of our affinity-purified liquid chromatography tandem
mass spectrometry analysis of each PARP, summarized in Figures 4-9 of Chapter 4. Shown for
each PARP are at least one "high salt" purification, performed under the purification conditions
of Chapter 2, and at least one "physiological" purification, where the salinity of the wash buffers
during purification was maintained at physiological salt (150 mM NaCl). Each number in the
table represents the number of peptides identified in that purification for that protein. Proteins
are sorted from most peptide hits to least based on the results of the physiological salt
purification. Proteins are sorted into three categories: those labeled in red are cytoskeletal
components, those labeled in yellow are heat shock or ribosomal proteins, and those in white are
potential physiological interactors. We have sorted the results in this manner to separate more
likely physiological protein interactors from likely contaminants (ribosomal components, heat
shock proteins, and cytoskeletal components are common contaminants in such purifications).
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Peptides identified per purification
PARP-1 (HS = high salt, P = physiological salt)
HS HS HS HS HS HS HS HS
IPI Gene name 1 2 HS3 4 5 6 7 8 9 P1 P2 P3 P4
PARPI Poly [ADP-ribose] polymerase
IP100449049 1 75 67 122 65 72 64 56 58 80 103 87 88 125
GNB2L1 Guanine nucleotide-binding
IP100848226 protein subunit beta-2-like 1 4 22 14 9 15
PABPC1 Isoform 1 of Polyadenylate-
IPl00008524 binding protein 1 15 10 36
HNRNPM Isoform 1 of Heterogeneous
IP100171903 nuclear ribonucleoprotein M 3 6 8 12 11
IGF2BP1 Insulin-like growth factor 2
IP100008557 mRNA-binding protein 1 7 10 5 12
IGF2BP1 insulin-like growth factor 2
IP100930694 mRNA binding protein 1 isoform 2 1 1 1 7 10
PABPC4 Isoform 1 of Polyadenylate-
IP100012726 binding protein 4 7 8 6 18
IP100783872 CAPRIN1 Isoform 1 of Caprin-1 7 8 13
HIST1H4K;HIST2H4A;HIST1H4H;HIST1
H4D;HIST1H4E;HIST1H41;HIST2H4B;HI
IP100453473 ST1H4J;HIST 1 4 8 4 8 4 4 13 5 2
ILF2 Interleukin enhancer-binding
IP100005198 factor 2 4 6
YBX1 Nuclease-sensitive element-
IP100031812 binding protein 1 3 5 9
G3BP1 Ras GTPase-activating protein-
IP100012442 binding protein 1 3 7
HIST1H2AB;HIST1H2AE;HIST1H2AD;HI
ST1H2AI;HIST1H2AM;HIST1H2AG;HIST
IP100026272 1H2AL;HIST1H 3 3 3
I PI0009057
G3BP2 Isoform A of Ras GTPase-
activating protein-binding protein 2 3
IPI00000156 LIG3 Isoform Beta of DNA ligase 3 2 2
HNRNPM Isoform 2 of Heterogeneous
IP100383296 nuclear ribonucleo protein M 13
IP100220740 NPM1 Isoform 2 of Nucleophosmin 12 3
IP100844578 DHX9 ATP-dependent RNA helicase A 11
IP100003935 HIST2H2BE Histone H2B type 2-E 3 10
IP100018534 HIST1H2BL Histone H2B type 1-L 3 10
IP100017297 MATR3 Matrin-3 10
PABPC1 Isoform 2 of Polyadenylate-
IP100410017 binding protein 1 9
HNRNPA2B1 Isoform B1 of
Heterogeneous nuclear
IP100396378 ribonucleoproteins A2/B1 8
HIST1H2AI;HIST1H2AM;HIST1H2AG;HI
ST1H2AL;HIST1H2AK;HIST1H2AJ;HIST
IP100081836 1H2AH Histon 5 5 2 7 4
HNRNPC Isoform C1 of
Heterogeneous nuclear
IP100216592 ribonucleoproteins C1/C2 7
NCL cDNA FU45706 fis, clone
FEBRA2028457, highly similar to
IP100444262 Nucleolin 6
HNRNPU Isoform Long of
Heterogeneous nuclear
IP100883857 ribonucleoprotein U 6
IP100029081 LIG3 Isoform Alpha of DNA ligase 3 5 4
SYNCRIP Isoform 1 of Heterogeneous
IP100018140 nuclear ribonucleoprotein Q 5 2
110
IP100012074
HNRNPR Isoform 1 of Heterogeneous
nuclear ribonucleoprotein R 5
DDX21 Isoform 1 of Nucleolar RNA
IP100015953 helicase 2 4 3
H2AFY Isoform 3 of Core histone
IP100059366 macro-H2A.1 4
HNRNPA1 Isoform Al-B of
Heterogeneous nuclear
IP100215965 ribonucleoprotein Al 4
CSDA Isoform 1 of DNA-binding
IP100031801 protein A 3
UBC;RPS27A;UBB ubiquitin and
IPl00179330 ribosomal protein S27a precursor 3
IP100217465 HIST1H1C Histone H1.2 3
IP100219037 H2AFX Histone H2A.x 3
DHX30 Isoform 3 of Putative ATP-
IP100477295 dependent RNA helicase DHX30 3
IP100479191 HNRNPH1 51 kDa protein 3
TOP2B Isoform Beta-2 of DNA
IP100027280 topoisomerase 2-beta 2
IP100217975 LMNB1 Lamin-B1 2
TOP2A Isoform 3 of DNA
IP100218753 topoisomerase 2-alpha 2
MDC1 Isoform 2 of Mediator of DNA
IP100470805 damage checkpoint protein 1 2
- Similar to Delta(3,5)-Delta(2,4)-
dienoyl-CoA isomerase, mitochondrial
IP100848328 prec 2
IP100879658 - 24 kDa protein 1 1 7 1 8
IP100604620 NCL Nucleolin I I 1 1 6 4
I P10093535 2
LOC653269 similar to protein
expressed in prostate, ovary, testis,
and olace 12 6
ILF3 Isoform 5 of Interleukin
IP100219330 enhancer-binding factor 3 3 3
HADHA Trifunctional enzyme subunit
IP100031522 alpha, mitochondrial 3
BASP1 Isoform 1 of Brain acid soluble
IP100299024 protein 1 3
IP100020729 IRS4 Insulin receptor substrate 4 2
PYGM Glycogen phosphorylase,
IP100218130 muscle form 6 2 9
IP100165486 - 31 kDa protein 6
DHX30 Isoform 1 of Putative ATP-
IP100411733 dependent RNA helicase DHX30 6
YBX1 Putative uncharacterized
IP100643807 protein YBX1 6
SERBP1 Isoform 1 of Plasminogen
activator inhibitor 1 RNA-binding
IP100410693 protein 4
PURA Transcriptional activator
IP100023591 protein Pur-alpha 2
PARP4 Poly [ADP-ribose] polymerase
IP100296909 4 57
DDX41 Probable ATP-dependent RNA
IP100007208 helicase DDX41 10 5
S100A9 Putative uncharacterized
IP100939362 protein S100A9 4
IP100007047 S100A8 Protein S100-A8 3
IP100007244 MPO Isoform H17 of Myeloperoxidase 3
IP100792479 PARP10 109 kDa protein 18
IGHA1 Putative uncharacterized
IP100423462 protein DKFZp686K18196 (Fragment) 4
PARP10 cDNA FU57250, highly similar
to Homo sapiens poly (ADP-ribose)
IP100064457 polym 3
ALDOA Fructose-bisphosphate
IP100465439 aldolase A 71
PYGB Glycogen phosphorylase, brain
IPI00004358 form 4 2
IP100218474 ENO3 Isoform 1 of Beta-enolase 3
POTEE Isoform 1 of POTE ankyrin
IP100479743 domain family member E 17 8
IP100003406 DBN1 Isoform 1 of Drebrin 10
IP100292953 RA114 Isoform 2 of Ankycorbin 5
H2AFV H2A histone family, member V
IP100141938 isoform 2 3
PPP1CB Serine/threonine-protein
phosphatase PP1-beta catalytic
IP100218236 subunit 3
IP100045109 HIST1H2AA Histone H2A type 1-A 4
HNRNPC Isoform C2 of
Heterogeneous nuclear
IP100477313 ribonucleoproteins C1/C2 4
GAPDH Glyceraldehyde-3-phosphate
IP100219018 dehydrogenase 2
CAI Mi 1 Caimndiuin-likPa nrntain 1
IP100152785 H IST1H2BO0 Histone H2B type 1-0 3
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SPA1B Heat shock 70 kDa
_/1B 4 12 26 6 9 5 8 11 20 26 16
-ibosomal protein S3 8 11 12 9 22
acidic ribosomal protein PO 10 8 5 16
-ibosomal protein S8 4 8 6 5 12
UPS18 40S ribosomal protein
__ _ __ _ __ 
_ - -
3 8 5 4 12
ribosomal protein S3a 7 7 13
orm 1 of 60S ribosomal
2 6 9 6 12
;ribosomal protein S13 3 6 5 5 8
ibosomal protein L3 6 4 5
)S ribosomal protein S15a- 6 3 4 6
ibosomal protein L5 6 6
ribosomal protein S5 6
osomal protein L14 variant 6 5 5 8 6 9
ribosomal protein S7 5 6 3 9
ribosomal protein L23 5 5 3
ribosomal protein L18 3 2 5 3 5
osomal protein S10 variant
t) _5
ribosomal protein L13 2 4 9 5 5
6
U'A
.......... I .  .. .. . .... . ..........
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IP100219153 RPL22 60S ribosomal protein L22 2 3 4 6 6
IP100013485 RPS2 40S ribosomal protein S2 4 4
RPL3 Putative uncharacterized protein
IP100878524 RPL3 4 2
RPS4X 40S ribosomal protein S4, X
IP100217030 isoform 4 11
IP100037070 HSPA8 54 kDa protein 4
IP100221092 RPS16 40S ribosomal protein S16 3 5 4
IP100215780 RPS19 40S ribosormal protein S19 3 4 3 6
IPt00306332 RPL24 60S ribosomal protein L24 4 3
IP100012750 RPS25 40S ribosomal protein S25 3
IP100025091 RPS11 40S ribosomal protein Sl1 3
IP100456758 RPL27A 60S ribosomal protein L27a 3
IP100478896 RPL7A Ribosomal protein L7a 3
RPL11 isoform 2 of 60S ribosomal
IP100746438 protein L11 3
IP100412579 RPL10A 60S ribosomal protein L10a 2 3
IP100299573 RPL7A 60S ribosomal protein L7a - 4 5 5 9
IP100221088 RPS9 40S ribosomal protein S9 - - ___-5 5
IP100008438 RPS10 40S ribosomal protein S10 ____ 4 5 6
IPI00012772 RPL8 60S ribosomal protein L8 4 3 6
IP100008529 RPLP2 60S acidic ribosomal protein P2 4 12
IP100025329 RPL19 60S ribosomal protein L19 - -_ -__ -- __ -____ ___4 6
RPL2 1;RPL21P19 60S ribosomal
IP100247583 protein L21 
___ 3 3 2
IP100219155 RPL27 60S ribosomal protein L27 3 3
IP100021840 RPS6 40S ribosomal protein S6 
___ 
___ ___ ___ 3 10
IP100329389 RPL6 60S ribosomal protein L6 1___3 8
W I .
IPI00003918 RPL4 60S nibosomal protein L4 6 4 17
IP100031691 RPL9 0S ribosomal Drotein 19 3P10499IRPS6 Ribosomal protein S6 1Z 31 1- [ i-
IRPL11 Isoform 1 of 60S ribosomal
2 2 4
.1 4 I 4 4 4 4 4 4 t tt1
4 2 31
:rm 1 of 40S ribosomal
1 _ _ _ _ 2 3
ribosomal protein S26 2
Heat shock protein HSP 90-
10
Isoform 2 of Heat shock
P 90-alpha 9
orm 1 of Heat shock
. kDa protein 4
IA5 protein 5 3
:ive uncharacterized
S7 3
omal protein L3 isoform b 17
Da protein 10
ribosomal protein L15 6
ribosomal protein Li0 6
Da protein 6
acidic ribosomal protein P1 5
ribosomal protein S17 5
ribosomal protein L17 _= 5
PI
IP100915363 d
5
5
IP100026302 IRPL31 60S ribosomal protein 131 131 - 1 _ I _1 1 1__1 3
1P100218606 RPS23 40S ribosomal protein S23 3 1 31-l ] i_ _ _______I__ 4
1 1 .......... .
......................................
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IP100027270 RPL26 60S ribosomal protein L26 2
IP100479058 RPS15 40S ribosomal protein S15 2
RPSAP15;RPSA Laminin receptor-like
IP100411639 protein LAMRL5 4
HSPA2 Heat shock-related 70 kDa
IP100007702 protein 2 4
HSPA7 Putative heat shock 70 kDa
IP100011134 protein 7 21
HSPA1L Putative uncharacterized
IP100940553 protein HSPA1L (Fragment) 2 1
PARP-2 Peptides Identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100026497 PARP2 Isoform 1 of Poly [ADP-ribose] polymerase 2 23 24 37
IP100029081 LIG3 Isoform Alpha of DNA ligase 3 51
IP100002564 XRCC1 DNA repair protein XRCC1 23
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 2 11 15
IP100008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 4 9
IP100783872 CAPRIN1 Isoform 1 of Caprin-1 8
IP100943304 - 31 kDa protein 4 7
IP100290684 PNKP Bifunctional polynucleotide phosphatase/kinase 7
IP100012726 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 6
IP100165486 - 31 kDa protein 6
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST
IP100453473 2H4B;HIST1H4J;HIST 5 5
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
IP100026268 beta-1 4
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H
IP100081836 2AJ;HIST1H2AH Histon 4
IP100,021266 RPL23A 60S ribosomal protein L23a 3
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 4 3
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
IP100003348 beta-2 2 3
IP100008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 3
IP100012442 G3BP1 Ras GTPase-activating protein-binding protein 1 3
IP100220740 NPM1 Isoform 2 of Nucleophosmin 3
IP100604620 NCL Nucleolin 3
LOC653269 similar to protein expressed in prostate, ovary, testis,
IP100935352 and place 3
IP100031522 HADHA Trifunctional enzyme subunit alpha, mitochondrial 2
IP100299024 BASP1 Isoform 1 of Brain acid soluble protein 1 2
IP100411460 APTX Isoform 10 of Aprataxin 2
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 2
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1
IP100930694 isoform 2 2
IP100007208 DDX41 Probable ATP-dependent RNA helicase DDX41 12
IP100218130 PYGM Glycogen phosphorylase, muscle form 11
IP100939362 S100A9 Putative uncharacterized protein S100A9 5
IP100449049 PARP1 Poly [ADP-ribose] polymerase 1 4
IP100007047 S100A8 Protein S100-A8 3
IP100216457 HIST2H2AA4;HIST2H2AA3 Histone H2A type 2-A 6
IP100942587 - Putative uncharacterized protein ENSP00000389075 5
4XRCC5 ATP-dep~endent DNA helicase 2 subunit 2IPl00220834
-1
- 17 kDa DroteinIP100398673
IF
IP100024933
0
L12
4 6I. I t 64
ial protein L4 6
mal protein L19 6
lal protein L3 6
mal protein L13 5 5
mal protein S14 4 5
m 2 of Heat shock protein HSP 90-alpha 5
mal protein L18 4 4
? 40S ribosomal protein S10-like protein 4
mal protein S13 4
60S ribosomal protein L21 4
;hock protein HSP 90-beta 4
of Heat shock cognate 71 kDa protein 4 3
nal protein S7 3 3
ribosomal protein P2 3
;omal protein L23a 3
of 40S ribosomal protein S24 3
imal protein L22 3
nal protein L5 2
imal protein L31 2
nal protein S9 2
imal protein S16 2
imal protein S17 2
40S ribosomal protein S26 2
750, highly similar to 60S ribosomal protein L8 2
AlL Heat shock 70 kDa protein 1-like 4
.. .... 
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PARP-3 Peptides identified per purification
DPI Gene name High salt 1 High salt 2 Physiological
IP100023184 PARP3 Isoform 1 of Poly [ADP-ribose] polymerase 3 37 19 30
IP100304925 HSPA1A;HSPA1B Heat shock 70 kDa protein 1A/1B 4 37
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 4 9
IP100220834 XRCC5 ATP-dependent DNA helicase 2 subunit 2 9
IP100644712 XRCC6 ATP-dependent DNA helicase 2 subunit 1 9
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 5 6
IP100008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 6
IP100008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 6
IP100020729 IRS4 Insulin receptor substrate 4 6
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 6
IP100479743 POTEE Isoform 1 of POTE ankyrin domain family member E 6
IP100003362 HSPA5 HSPA5 protein 5
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
IP100026268 beta-1 5
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
IP100003348 beta-2 4
IP100031522 HADHA Trifunctiona I enzyme subunit alpha, mitochondrial 4
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 4 3
IP100003406 DBN1 Isoform 1 of Drebrin 3
IP100012442 G3BP1 Ras GTPase-activating protein-binding protein 1 3
IP100220740 NPM1 Isoform 2 of Nucleophosmin 3
IP100299024 BASP1 Isoform 1 of Brain acid soluble protein 1 3
IP100789893 - Pseudogene candidate 3
IP100028931 DSG2 Desmoglein-2 2
wI
IP100163085r,
IP100166845 FYN Isoform 3 of Proto-oncogene tyrosine-protein kinase Fyn 2
IP100297779 CCT2 T-complex protein 1 subunit beta 2
IP100397676 - 30 kDa protein 2
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 2
IPl00449049 PARP1 Poly [ADP-ribose] polymerase 1 11
IP100007208 DDX41 Probable ATP-dependent RNA helicase DDX41 8
IP100026497 PARP2 Isoform 1 of Poly [ADP-ribose] polymerase 2 7
IP100218130 PYGM Glycogen phosphorylase, muscle form 2
IP100025753 DSG1 Desmoglein-1 7
IP100013933 DSP Isoform DPI of Desmoplakin 6
IP100398625 HRNR Hornerin 61
inIm) armt a r:An :U r Aahudrnaanac 2
2
16
5 8
HSP 90 alpha 8
10 7
cognate 71 kDa protein 7
HSP 90-beta 6
>tein PO 2 5
nal protein L12 5
3a 5
13 5
18 4 4
protein S18 4
4
31 4
19 4
4
ariant 4
3
9 3
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IP100221089 RPS13 40S ribosomal protein S13 3
P100550021 RPL3 60S ribosomal protein L3 3
IP100746438 RPL11 soform 2 of 60S ribosomal protein -11 3
IP100007765 HSPA9 Stress-70 protein, mitochondrial 2
2P100029750 RPS24 Isoform 1 of 40S ribosomal protein S24 2
IP100171903 HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 2
IP100329389 RPL6 60S ribosomal protein L6 2
IP100879238 RPS9 Ribosomal protein S9, isoform CRAc 2
HSPA1A;HSPA1B cDNA FU54408, highly similar to Heat shock 70 kDa
IP100911039 protein 1 11
IP00007702 HSPA2 Heat shock-related 70 kDa protein 2 4
IP100848331 RPL31ribosomal protein L31 isoform 2 3
PARP-4 Peptides identified per purification
IN Gene name High salt 1 High salt 2 Physiological
IP100296909 PARP4 Poly [ADP-ribose] polymerase 4 53 85 87
IP100449049 PARP1 Poly [ADP-ribose] polymerase 1 32
IP100007208 DDX41 Probable ATP-dependent RNA helicase DDX41 12
HSPA1L cDNA FU56386, highly similar to Heat shock 70 kDa protein
IP100643152 11 9
IP100879658 - 24 kDa protein 6
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 3
iPinrr)1nql R GApnH GIveraldehvde-3-nhosahate dehvdro2enase 4
.............................................. 
.
31
PARP-5a Peptides identified pe purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100021493 TNKS Isoform 1 of Tankyrase-1 14 34 56
IP100030207 GMDS GDP-mannose 4,6 dehydratase 6 5 6
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2A
IP100081836 J;HIST1H2AH Histon 4
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 4 3
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 2
IP100019270 TNKS2 Tankyrase-2 83 6
IP100792479 PARP10 109 kDa protein 43
PARP10 cDNA FU57250, highly similar to Homo sapiens poly (ADP-
IP100064457 ribose) polym 25
IP100007208 DDX41 Probable ATP-dependent RNA helicase DDX41 10
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 5
IP100299517 FAM175B BRISC complex subunit Abrol 4
IP100025087 TP53 Isoform 1 of Cellular tumor antigen p53 3
IP100164724 BRE Isoform 2 of BRCA1-A complex subunit BRE 2
IP100221159 TNKS Isoform 2 of Tankyrase-1 7
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H
....................................... 
...........
$SPAiB cDNA Fd54392, highly similar to Heat shock 70 kDa 1 J 1,8
19 1 14 11
4 4
HSP 90-alpha 3
2
PARP-5b Peptides Identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100019270 TNKS2 Tankyrase-2 74 112
IP100021493 TNKS Isoform 1 of Tankyrase-1 12 18
IP100030207 GMDS GDP-mannose 4,6 dehydratase 8 7 6
IP100025087 TP53 Isoform 1 of Cellular tumor antigen p53 3
IP100005826 HERC2 Probable E3 ubiquitin-protein ligase HERC2 2
IP00007208 DDX41 Probable ATP-dependent RNA helicase DDX41 6
IP100221159 TNKS Isoform 2 of Tankyrase-1 5
IP100028412 SSSCA1 Sjoegren syndrome/scleroderma autoantigen 1 3 3
IP100299517 FAM175B BRISC complex subunit Abrol 3
IP100654755 HBB Hemoglobin subunit beta 2
IP100025753 DSG1 Desmoglein-1 9
IP100021536 CALML5 Calmodulin-like protein 5 4
IP100789893 - Pseudogene candidate 4
IP100240503 - 48 kDa protein 3
1PI04181 21
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16 20
8IP100911039 protein 1
18 24
18
HSPA1L cDNA FLI56386, highly similar to Heat shock 70 kDa protein
IP100643152 1L 12
IP100003865 HSPA8 Isoform 1 of Heat shock cognate 71 kDa protein 4
IP100220839 PRSS3 Isoform B of Trypsin-3 3
IP100909073 - cDNA FU53752, highly similar to Heat shock 70 kDa protein 1 3
IP100339269 HSPA6 Heat shock 70 kDa protein 6 7
IPl00007702 HSPA2 Heat shock-related 70 kDa protein 2 41
IP100037070 HSPA8 54 kDa protein 41
PARP-6 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100156933 PARP6 Isoform 1 of Poly [ADP-ribose] polymerase 6 40 64 55
IP100301263 CAD CAD protein 34 41 25
IP100411733 DHX30 Isoform 1 of Putative ATP-dependent RNA helicase DHX30 11
IP100879658 - 24 kDa protein 9 5
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 5
IP100025087 TP53 Isoform 1 of Cellular tumor antigen p53 5 4 4
IP100008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 4
IPl00479509 YBX1 RcNSEP1 (Fragment) 3
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2
IP100026272 AG;HIST1H2AL;HIST1H 2 4 2
00OD
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8 2
24
22
1P00453473
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
H4B:HIST1H4J;HIST 6 21
IP100171012 PARP8 Isoform 1 of Poly [ADP-ribose] polymerase 8 19
IP100796582 PARP6 Isoform 2 of Poly [ADP-ribose] polymerase 6 44
2 MC1R:TUBB3 HCG2042771
protein 1A/1BIP100304
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IP100011
IP100215
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Isoform 2 of Heat shock protein HSP 90-alpha
IP100555744 RPL14 Ribosomal protein L14 variant 3
IP100793137 - Putative uncharacterized protein RPSAP58 3
IP100003918 RPL4 60S ribosomal protein L4 2
IP100026271 RPS14 40S ribosomal protein S14 2
IP100216587 RPS8 40S ribosomal protein S8 2
HSPA1A;HSPA1B cDNA FU54408, highly similar to Heat shock 70 kDa
IP100911039 protein 1 12
IP100413108 RPSAP15;RPSA 33 kDa protein 4
IP100007702 HSPA2 Heat shock-related 70 kDa protein 2 3
PARP-7 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100384981 TIPARP TIPARP protein (Fragment) 30 9 20
IP100152453 MC1R;TUBB3 HCG2042771 9
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 9 8 8
IP100739539 POTEF POTE ankyrin domain family member F 12 5
IP100456429 UBA52 ubiquitin and ribosomal protein L40 precursor 5
IP100789893 - Pseudogene candidate 5
IP100216457 HIST2H2AA4;HIST2H2AA3 Histone H2A type 2-A 4
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 4 3
IP100377267 PARP9 Isoform 2 of Poly [ADP-ribose] polymerase 9 3
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 14
IP100449049 PARP1 Poly [ADP-ribose] polymerase 1 14
IP100009355 PARP12 Poly [ADP-ribose] polymerase 12 11
IP100102997 WRNIP1 Isoform 2 of ATPase WRNIP1 7
IP100479743 POTEE Isoform 1 of POTE ankyrin domain family member E 5 17
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 5 5
0
IP100472171 RPL7;RPL7P32 30 kDa protein 3
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 5
IP100219018 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 4 2
IP100337415 GNA11 Guanine nucleotide-binding protein G(i) subunit alpha-1 4
IP100793330 UBC;RPS27A;UBB 12 kDa protein 4
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 4
IPl00003935 HIST2H2BE Histone H2B type 2-E 3
IP100789107 UBC;RPS27A;UBB 30 kDa protein 3
IP100290928 GNA13 Guanine nucleotide-binding protein subunit alpha-13 2
HNRNPC cDNA FU53542, highly similar to Heterogeneous nuclear
IP100909232 ribonucleoprot 2
IP00003406 DBN1 Isoform 1 of Drebrin 17
IP100163085 AMOT Isoform 1 of Angiomotin 7
LOC653269 similar to protein expressed in prostate, ovary, testis, and
IP100740545 place 7
IP100217437 TTBK2 Tau-tubulin kinase 5
LOC653781 similar to protein expressed in prostate, ovary, testis, and
olace4
BASP1 Isoform 1 of Brain acid soluble protein 1 5IP100299024
4IP100738655
AA;KSPAIB cONA FU54408, highly similar to Heat shock 70 kDa
IP100911039 protein 1 28
w.. ... ..... ..... . ...
20
IP10003865 HSPA8 Isoform 1 of Heat shock cognate 71 kDa protein 5 4
IP100939442 HSPA1L Heat shock 70 kDa protein 1-like 16
IP100007702 HSPA2 Heat shock-related 70 kDa protein 2 11 4
IP100939595 HSPA8 Isoform 2 of Heat shock cognate 71 kDa protein 8
IP100414676 HSP90AB1 Heat shock protein HSP 90-beta 7
IP100382470 HSP90AA1 Isoform 2 of Heat shock protein HSP 90-alpha 6
IP100007765 HSPA9 Stress-70 protein, mitochondrial 4
IP100011253 RPS3 40S ribosomal protein S3 2
IPl00790580 RPSAP15;RPSA 16 kDa protein 21
PARP-8 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100171012 PARP8 Isoform 1 of Poly [ADP-ribose] polymerase 8 46 126 65
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 6 13
IP100008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 4
IP100479509 YBX1 RcNSEP1 (Fragment) 4
IP100872387 - Putative uncharacterized protein RPL7P32 (Fragment) 4
IP00008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 3
SERBP1 Isoform 1 of Plasminogen activator inhibitor 1 RNA-binding
IP100410693 protein 3
IP100450235 YBX1 Nuclease sensitive element binding protein-1 3
IP100478287 - 22 kDa protein 3
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 3 2
IP100940785 LOC100132057 Putative uncharacterized protein ENSP00000402999 3
IP100217437 TTBK2 Tau-tubulin kinase 3
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PARP-9 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100377267 PARP9 Isoform 2 of Poly [ADP-ribose] polymerase 9 49 93 116
IP100449049 PARP1 Poly [ADP-ribose] polymerase 1 2 4 44
IP100026970 SUPT16H FACT complex subunit SPT16 4 26
IP100220834 XRCC5 ATP-dependent DNA helicase 2 subunit 2 25
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 16 20
IP100644712 XRCC6 ATP-dependent DNA helicase 2 subunit 1 20
IP100029081 LIG3 Isoform Alpha of DNA ligase 3 19
IP100217975 LMNB1 Lamin-B1 5 18
IP100479217 HNRNPU Isoform Short of Heterogeneous nuclear ribonucleoprotein 18
Ul
.. ........ 
UIP100003935 HIST2H2BE Histone H2B type 2-E 13 16
HNRNPA2B1 Isoform Bl of Heterogeneous nuclear
IP100396378 ribonucleoproteins A2/B1 16
IPl00017297 MATR3 Matrin-3 15
IP100032003 EMD Emerin 16 14
HIST1H2BE;HIST1H2BI;HIST1H2BF;HIST1H2BC;HIST1H2BG histone
IP100020101 cluster 1, H2bg 13 14
TMPO Isoform Beta of Lamina-associated polypeptide 2, isoforms
IP100030131 beta/gamma 11 14
IP100020127 RPA1 Replication protein A 70 kDa DNA-binding subunit 6 14
IP100296337 PRKDC Isoform 1 of DNA-dependent protein kinase catalytic subunit 14
IP100171903 HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 13 13
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2A
IP100081836 J;HIST1H2AH Histon 10 13
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 9 13
IP100005198 ILF2 Interleukin enhancer-binding factor 2 13
IP100005154 SSRP1 FACT complex subunit SSRP1 12
NCL cDNA FU45706 fis, clone FEBRA2028457, highly similar to
IP100444262 Nucleolin 12
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 12
IP100220740 NPM1 Isoform 2 of Nucleophosmin 11
IP100021405 LMNA Isoform A of Lamin-A/C 2 9
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 9
IP100217466 HIST1H1D Histone H1.3 9
IP100465084 DES Desmin 9
IP100031812 YBX1 Nuclease-sensitive element-binding protein 1 7 8
IP100479191 HNRNPH1 51 kDa protein 4 8
IP100012074 HNRNPR Isoform 1 of Heterogeneous nuclear ribonucleoprotein R 8
a\
IP100045109 HIST1H2AA Histone H2A type 1-A 5 7
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 3 7
IP00002564 XRCC1 DNA repair protein XRCC1 7
IP100844578 DHX9 ATP-dependent RNA helicase A 7
IP100008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 6
HNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins
IP100216592 C1/C2 6
IP100059366 H2AFY Isoform 3 of Core histone macro-H2A.1 6 5
IP100018278 H2AFV Histone H2A.V 4 5
IP100186338 LOC645870 similar to barrier to autointegration factor 1 3 5
IP100217465 HIST1H1C Histone H1.2 2 5
IP100008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 5
IP100031522 HADHA Trifunctional enzyme subunit alpha, mitochondrial 5
IP100165486 - 31 kDa protein 5
IP100419373 HNRNPA3 Isoform 1 of Heterogeneous nuclear ribonucleoprotein A3 5
IP100879658 - 24 kDa protein 5
IP100012451 GNB4 Guanine nucleotide-binding protein subunit beta-4 4
HNRNPU Isoform Long of Heterogeneous nuclear ribonucleoprotein
IP100883857 U 4
IP100011913 HNRNPAO Heterogeneous nuclear ribonucleoprotein AO 3
IP100013877 HNRNPH3 Isoform 1 of Heterogeneous nuclear ribonucleoprotein H3 3
IP100013939 RPA2 Isoform 1 of Replication protein A 32 kDa subunit 3
IP100020729 IRS4 Insulin receptor substrate 4 3
IP100027834 HNRNPL Heterogeneous nuclear ribonucleoprotein L 3
IP100029107 WRN Werner syndrome ATP-dependent helicase 3
IP100029744 SSBP1 Single-stranded DNA-binding protein, mitochondrial 3
IP100031801 CSDA Isoform 1 of DNA-binding protein A 3
IP100179713 IGF2BP2 Isoform 1 of Insulin-like growth factor 2 mRNA-binding 3
8IP100413108 RPSAP15;RPSA 33 kDa protein
protein 2
IPl00216402 HIST3H3 Histone H3.1t 3
SMARCA5 SWI/SNF-related matrix-associated actin-dependent
IP100297211 regulator of chrom 3
IP100398798 H2AFV H2A histone family, member V isoform 3 3
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 3
IP100783872 CAPRIN1 Isoform 1 of Caprin-1 3
IP100798401 CORO1C cDNA FU50992, highly similar to Coronin-1C 3
IP100915340 HNRNPD Putative uncharacterized protein HNRNPD 3
IP100027019 PRH1;PRH2;PRR4 Proline-rich protein 4 3 2
IP100152503 DTX3L Isoform 1 of E3 ubiquitin-protein ligase DTX3L 5 2
IP100004968 PRPF19 Pre-mRNA-processing factor 19 2
IP100017373 RPA3 Replication protein A 14 kDa subunit 2
IP100025039 FBL rRNA 2'-O-methyltransferase fibrillarin 2
IP100168336 LEMD2 LEM domain-containing protein 2 2
IP100219018 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 2
IP100375358 RFC1 Isoform 1 of Replication factor C subunit 1 2
IP100942312 - Putative uncharacterized protein ENSP00000404946 2
IGHA1 Putative uncharacterized protein DKFZp686G21220
IP100423460 (Fragment) 5
IP100027803 PARP9 Isoform 1 of Poly [ADP-ribose] polymerase 9 47
HNRNPC Isoform C2 of Heterogeneous nuclear ribonucleoproteins
IP100477313 C1/C2 7
IP100514204 LMNA Lamin A/C 3
RALY RNA binding protein, autoantigenic (HnRNP-associated with
IPl00011268 lethal yellow 2
IP100216044 RALY Isoform 1 of RNA-binding protein Raly 2
IP100465363 HIST1H2BA Histone H2B type 1-A 2
IP100789107 UBC;RPS27A;UBB 30 kDa protein 2
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IlPl00003865 H SPA8 Isoform 1 of Heat shock cognate 71 kDa protein 41
PARP-10 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100792479 PARP10 109 kDa protein 137 146 179
PARP10 cDNA FU57250, highly similar to Homo sapiens poly (ADP-
IPl00064457 ribose) polym 120 118 149
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 6 20 20
IP100240503 -48 kDa protein 15
IP100456429 UBA52 ubiquitin and ribosomal protein L40 precursor 5
IP100794925 UBC;RPS27A;UBB 21 kDa protein 4
IP100789893 - Pseudogene candidate 5 2
IPl00007208 DDX41 Probable ATP-dependent RNA helicase DDX41 5
IP100219221 LGALS7B;LGALS7 Galectin-7 5
IP100019270 TNKS2 Tankyrase-2 4
IP100793330 UBC;RPS27A;UBB 12 kDa protein 3
IP100784990 UBC;RPS27A;UBB Ubiquitin C splice variant 8.
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IPIAA27777 r.-HIeT1H7AI -HIST1H 2
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PARP-11 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100006899 PARP11 Isoform 1 of Poly [ADP-ribose] polymerase 11 10 21 15
IP100020729 IRS4 Insulin receptor substrate 4 10
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 8 5 8
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 3 7
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 7 6
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 10 6
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2A
IP100081836 J;HIST1H2AH Histon 6 5 5
GTPBP3 cDNA FU51910, highly similar to Homo sapiens GTP binding
IP100464994 protein 3 ( 3 5 5
IP100021536 CALML5 Calmodulin-like protein 5 5
IP100217269 GNAT2 Guanine nucleotide-binding protein G(t) subunit alpha-2 5
IP100219221 LGALS7B;LGALS7 Galectin-7 5
IP100031522 HADHA Trifunctional enzyme subunit alpha, mitochondrial 4
GNB1 Guanine nucleotide binding protein (G protein), beta
IP100639998 polypeptide 1 4
IP100852685 DIAPH1 Isoform 1 of Protein diaphanous homolog 1 4
IP100010303 SERPINB4 Serpin B4 11 3
IP100479743 POTEE Isoform 1 of POTE ankyrin domain family member E 3 2 3
IP100018534 HIST1H2BL Histone H2B type 1-L 3
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 3
GSN cDNA FU35478 fis, clone SMINT2007796, highly similar to
IP100513782 Gelsolin 3
0
IP100798401 CORO1C cDNA FU50992, highly similar to Coronin-1C 3
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 3
IP100171903 HNRNPM Isoform l of Heterogeneous nuclear ribonucleoprotein M 2
HNRNPU Isoform Short of Heterogeneous nuclear ribonucleoprotein
IP100479217 U 2
IP100022204 SERPINB3 Isoform 1 of Serpin B3 11
IP100465248 ENOl Isoform alpha-enolase of Alpha-enolase 7
IP100027462 S100A9 Protein S100-A9 6
IP100008918 LIMA1 Isoform Beta of LIM domain and actin-binding protein 1 4
LOC653269 similar to protein expressed in prostate, ovary, testis, and
IP100935352 place 4
IP100025447 EEF1A1 Elongation factor 1-alpha 3
IP100607708 LDHA Isoform 2 of L-lactate dehydrogenase A chain 3
HSPA1A;HSPA1B cDNA FU53071, highly similar to Heat shock 70 kDa
IP100910047 protein 1 2_
IP100798387 - Putative uncharacterized protein ENSP00000319235 4
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PARP-12 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100009355 PARP12 Poly [ADP-ribose] polymerase 12 66 69 62
IP100008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 9 2 17
IP100383296 HNRNPM Isoform 2 of Heterogeneous nuclear ribonucleoprotein M 16
IP100240503 - 48 kDa protein 14
IPI00008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 10 18 10
IP100031812 YBX1 Nuclease-sensitive element-binding protein 1 8 6 10
IP100879658 - 24 kDa protein 10
IP100003881 HNRNPF Heterogeneous nuclear ribonucleoprotein F 7 4 8
IP100013881 HNRNPH1 Heterogeneous nuclear ribonucleoprotein H 8
IP100012726 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 5 10 6
IP100027834 HNRNPL Heterogeneous nuclear ribonucleoprotein L 6
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2A
IP100081836 J;HIST1H2AH Histon 3 5
IP100789893 - Pseudogene candidate 4 4
IP100005198 ILF2 Interleukin enhancer-binding factor 2 4
IP100031801 CSDA Isoform 1 of DNA-binding protein A 4
IP100300990 Clorf77 Isoform 1 of Uncharacterized protein Clorf77 4
IGF2BP3 Isoform 1 of Insulin-like growth factor 2 mRNA-binding
IP100658000 protein 3 4 3
IP100018140 SYNCRIP Isoform 1 of Heterogeneous nuclear ribonucleoprotein Q 3
IP100219221 LGALS7B;LGALS7 Galectin-7 6 2
IP100012074 HNRNPR Isoform 1 of Heterogeneous nuclear ribonucleoprotein R 2
IP100219330 ILF3 Isoform 5 of Interleukin enhancer-binding factor 3 2
HNRNPA2B11 Isoform Bl of Heterogeneous nuclear
IP100396378 ribonucleoproteins A2/B1 2
IP100418313 ILF3 interleukin enhancer binding factor 3 isoform d 2
IP100514561 HNRNPK Heterogeneous nuclear ribonucleoprotein K 2
C
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.HNRNPM Isoform 1 of Heteroeneous nuclear ribonucleoroteinHNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins
IP100216592 C1/C2 9 2
IP100410067 ZC3HAV1 Isoform 1 of Zinc finger CCCH-type antiviral protein 1 9
IGF2BPi insulin-like growth factor 2 mRNA binding protein 1 isoform
IP100930694 2 9
IP100479509 YBX1 RcNSEP1 (Fragment) 7
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 6 11
IP100479191 HNRNPH1 51 kDa protein 5 7
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 5
IP100009328 EIF4A3 Eukaryotic initiation factor 4A-Ill 3 6
IP100337415 GNA11 Guanine nucleotide-binding protein G(i) subunit alpha-1 3
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 3
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 2 8
IP100444454 MOV10 Isoform 2 of Putative helicase MOV-10 2
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 6
IP100472171 RPL7;RPL7P32 30 kDa protein 5
IP100450235 YBX1 Nuclease sensitive element binding protein-i 4
IP100006899 PARP11 Isoform 1 of Poly [ADP-ribose] polymerase 11 3
IP100219018 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 3
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 2
IP100217437 TTBK2 Tau-tubulin kinase 2
0
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bosomal protein S8 4 6
PSA 33 kDa protein 4
ribosomal protein S10 3 3
bosomal protein S9 3
Heat shock protein HSP 90-beta 3
4A F1J56386, highly similar to Heat shock 70 kDa protein
12
>S18 40S ribosomal protein S18 9
bosomal protein S7 8
ribosomal protein S4, X isoform 7
ribosomal protein S3a 7
rm 1 of 60S ribosomal protein L12 6
ribosomal protein L7a 6
ribosomal protein L13 6
,somaI protein L14 variant 6
ribosomal protein L19 5
bosomal protein S6 4
3rm 1 of 40S ribosomal protein S24 4
ribosomal protein S17 4
acidic ribosomal protein P2 3
bosomal protein S2 3
ribosomal protein S14 3
>rm 1 of 60S ribosomal protein L11 3
,a protein 3
ribosomal protein L31 2
bosomal protein L9 2
5 ribosomal protein S15a 2
ribosomal protein L15 21
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PARP-13.1 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100410067 ZC3HAV1 Isoform 1 of Zinc finger CCCH-type antiviral protein 1 144 59 63
IP100479743 POTEE Isoform 1 of POTE ankyrin domain family member E 8 21
IP100739539 POTEF POTE ankyrin domain family member F 14
IP100240503 - 48 kDa protein 12
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 6 10
LOC653269 similar to protein expressed in prostate, ovary, testis, and
IP100935352 place 10
IP100018534 HIST1H2BL Histone H2B type 1-L 9
IP00008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 10 5 7
IP100171903 HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 5 4 7
IP100031812 YBX1 Nuclease-sensitive element-binding protein 1 7
IP00008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 6
IP00012726 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 5 5
IP100163085 AMOT Isoform 1 of Angiomotin 5
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 5
LOC653781 similar to protein expressed in prostate, ovary, testis, and
IP100738655 place 5
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 5
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2A
IP100081836 J;HIST1H2AH Histon 3 3
IP100798387 - Putative uncharacterized protein ENSP00000319235 3
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
IP100003348 beta-2 3 2
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
IP100026268 beta-1 3 2
IP100925530 GNB2 32 kDa protein 2
0
I100296337I PRKDfC isofn 1n NAdonetroinkasctltcsuunit 16
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 15 7
IP100009355 PARP12 Poly [ADP-ribose] polymerase 12 10
IP100939753 - 64 kDa protein 8
IP100410070 ZC3HAV1 Isoform 4 of Zinc finger CCCH-type antiviral protein 1 7
IP100219682 STOM Erythrocyte band 7 integral membrane protein 6
IP100479509 YBX1 RcNSEP1 (Fragment) 4 2
IP100789107 UBC;RPS27A;UBB 30 kDa protein 4
HNRNPC cDNA FU53542, highly similar to Heterogeneous nuclear
IP100909232 ribonucleoprot 3
IP100444452 MOV10 Isoform 1 of Putative helicase MOV-10 2
IP100332936 ZC3HAV1 Isoform 2 of Zinc finger CCCH-type antiviral protein 1 8
IP100020729 IRS4 Insulin receptor substrate 4 6
IP100297779 CCT2 T-complex protein 1 subunit beta 3
IP100299024 BASP1 Isoform 1 of Brain acid soluble protein 1 3
owlil
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14 40S ribosomal protein S14 2 3
.13 60S ribosomal protein L13 5 2
90AA1 Isoform 2 of Heat shock protein HSP 90-alpha 2 2
;8 40S ribosomal protein S8 7
P3 28S ribosomal protein S29, mitochondrial 6
4X 40S ribosomal protein S4, X isoform 6
L14 Ribosomal protein L14 variant 5 3
L7;RPL7P32 60S ribosomal protein L7 5
L22 60S ribosomal protein L22 5
313 40S ribosomal protein S13 5
LA Ribosomal protein L7a 5
PA2 Heat shock-related 70 kDa protein 2 4 5
L8 60S ribosomal protein L8 4
515A40S ribosomal protein S15a 4
L24 60S ribosomal protein L24 4
L11 Isoform 1 of 60S ribosomal protein L11 4
L23 60S ribosomal protein L23 3
tPS22 28S ribosomal protein S22, mitochondrial 3
L12 Isoform 1 of 60S ribosomal protein L12 3
L31 60S ribosomal protein L31 3
519 40S ribosomal protein S19 3
L27 60S ribosomal protein L27 3
516 40S ribosomal protein S16 3
526 40S ribosomal protein S26 3
L26 13 kDa protein 3
59 RPS9 protein (Fragment) 3
510 40S ribosomal protein S10 2
L15 60S ribosomal protein L15 21
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IP100911039
HSPA1A;HSPA1B cDNA FU54408, highly similar to Heat shock 70 kDa
protein 1 37
IP100003865 HSPA8 Isoform 1 of Heat shock cognate 71 kDa protein 6
IP100939595 HSPA8 Isoform 2 of Heatshock cognate 71 kDa protein 6
IP100003362 HSPA5 HSPA5 protein 3
IP100008530 RPLPO 60S acidic ribosomal protein PO 3
IPl00414676 HSP90AB1 Heat shock protein HSP 90-beta_ 31
PARP-13.2 Peptides identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100332936 ZC3HAV1 Isoform 2 of Zinc finger CCCH-type antiviral protein 1 18 48 70
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 12 5
IP100165486 - 31 kDa protein 8 2
IP100410067 ZC3HAV1 Isoform 1 of Zinc finger CCCH-type antiviral protein 1 110 6
IP00008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 16 7
IP100171903 HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 11
IP100012726 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 9 6
IP100397676 - 30 kDa protein 6
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2A
IP100081836 J;HIST1H2AH Histon 4
IP100444452 MOV10 Isoform 1 of Putative helicase MOV-10 4
IP100031812 YBX1 Nuclease-sensitive element-binding protein 1 3
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 3
IP100479509 YBX1 RcNSEP1 (Fragment) 3
IP100792870 PHF1 PHD finger protein 1 3
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 2
IP100240503 - 48 kDa protein 2
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IP100012726 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 6
IP100216457 HIST2H2AA4;HIST2H2AA3 Histone H2A type 2-A 5
IP100479743 POTEE Isoform 1 of POTE ankvrin domain family member E
'plc 33 kDa
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PARP-14 Peptides identified per purification
IPI Gene name High salt Physiological
IP100291215 PARP14 poly (ADP-ribose) polymerase family, member 14 186 198
IP100029081 LIG3 Isoform Alpha of DNA ligase 3 4 34
IP100449049 PARP1 Poly [ADP-ribose] polymerase 1 2 17
IP100008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 18 16
IP100296337 PRKDC Isoform 1 of DNA-dependent protein kinase catalytic subunit 13
IP100644712 XRCC6 ATP-dependent DNA helicase 2 subunit 1 13
IP100002564 XRCC1 DNA repair protein XRCC1 11
IP100026970 SUPT16H FACT complex subunit SPT16 11
IP100220834 XRCC5 ATP-dependent DNA helicase 2 subunit 2 11
IP100005154 SSRP1 FACT complex subunit SSRP1 9
IPIOO008557 IGF2BP1 Insulin-like growth factor 2 mRNA-binding protein 1 9
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 8
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2H4
IP100453473 B;HIST1H4J;HIST 7
IP100012726 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 9 6
IP100171903 HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 4 6
IP100003935 HIST2H2BE Histone H2B type 2-E 6
IP100012442 G3BP1 Ras GTPase-activating protein-binding protein 1 6
IP100794461 HIST1H2BN Histone H2B type 1-N 6
IP100867509 CORO1C Coronin-1Ci3 protein 6
IP100398673 - 17 kDa protein 5
IP100783872 CAPRIN1 Isoform 1 of Caprin-1 5
IP100020729 IRS4 Insulin receptor substrate 4 4
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2AJ;
IP100081836 HIST1H2AH Histon 4
IP100297151 PARP16 Isoform 3 of Poly [ADP-ribose] polymerase 16 4
IP100410067 ZC3HAV1 Isoform 1 of Zinc finger CCCH-type antiviral protein 1 4
IP100450235 YBX1 Nuclease sensitive element binding protein-1 4
IP100942012 - Putative uncharacterized protein ENSP00000414664 4
IP100020127 RPA1 Replication protein A 70 kDa DNA-binding subunit 3
IP100220740 NPM1 Isoform 2 of Nucleophosmin 3
IP100290684 PNKP Bifunctional polynucleotide phosphatase/kinase 3
SERBP1 Isoform 1 of Plasminogen activator inhibitor 1 RNA-binding
IP100410693 protein 3
IP100479509 YBX1 RcNSEP1 (Fragment) 3
IP100479743 POTEE Isoform 1 of POTE ankyrin domain family member E 3
IGF2BP3 Isoform 1 of Insulin-like growth factor 2 mRNA-binding protein
IP100658000 3 3
IP100789893 - Pseudogene candidate 3
IP100910763 CAPRIN1 cDNA FU57278 3
PTPN13 Isoform 3 of Tyrosine-protein phosphatase non-receptor type
IP00006714 13 2
IP100031522 HADHA Trifunctional enzyme subunit alpha, mitochondrial 2
IP100941488 - 29 kDa protein 2
IP100783216 PARP14 Isoform 1 of Poly [ADP-ribose] polymerase 14 39
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 4
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 4
IP100031812 YBX1 Nuclease-sensitive element-binding protein 1 3
HNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins
IP100216592 C1/C2 2
XRCC6 X-ray repair complementing defective repair in Chinese hamster
cells 62
RPL23A Putative uncharacterized protein RPL23AIP100794894 4
IP100893179 2
Pz
!in S7
m1
DS
37
......... ............. .......
hi
.. ... .....
I I IIP100554723
IP100008530 RPLPO 60S acidic ribosomal protein PO 12
IP100003362 HSPA5 HSPA5 protein 3
PARP-15 Peptides identified per purification
IPI Gene name High salt 1 High saft 2 Physiological
IP100166182 PARP15 poly (ADP-ribose) polymerase family, member 15 isoform 1 3 18 13
IP100152453 MC1R;TUBB3 HCG2042771 9
IP100479743 POTEE Isoform 1 of POTE ankyrin domain family member E 8 8
IP100013885 CASP14 Caspase-14 6
IP100021536 CALML5 Calmodulin-like protein 5 5
HIST1H2AB;HIST1H2AE;HIST1H2AD;HIST1H2AI;HIST1H2AM;HIST1H2A
IP100026272 G;HIST1H2AL;HIST1H 4 2
IP100942474 - Putative uncharacterized protein ENSP00000388436 4
IP100219575 BLMH Bleomycin hydrolase 3
IP100793191 - 14 kDa protein 31
IP00008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 2 3
IP100217437 TTBK2 Tau-tubulin kinase 2
IP100218130 PYGM Glycogen phosphorylase, muscle form 14
IP100004358 PYGB Glycogen phosphorylase, brain form 10
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 ~_8
LOC653269 similar to protein expressed in prostate, ovary, testis, and
IP100935352 place 6
IP100783313 PYGL Glycogen phosphorylase, liver form 4
IP100942587 - Putative uncharacterized protein ENSP00000389075 3
IP100945048 PARP15 Isoform 1 of Poly [ADP-ribose] polymerase 15 17
IP100064328 PRMT5 protein arginine methyltransferase 5 isoform b 7
IP100879658 - 24 kDa protein 5
IP100798155 UBC;RPS27A;UBB Ubiquitin 2
I P 100418471 W.V IMne ntin 101 51131
RPL10 60S ribosomal protein L10 2
IP100911039 protei 1
IP100304925 HSPA1A;HSPA1B Heat shock 70 kDa protein 1A/lB 4 17 14
IP100007702 HSPA2 Heat shock-related 70 kDa protein 2 3 4
IP100003865 HSPA8 Isoform l of Heat shock cognate 71 kDa protein 3
IP100003918 RPL4 60S ribosomal protein L4 3
tP100339269 HSPA6 Heat shock 70 kDa protein 6 8
IP100414676 HSP90AB1 Heat shock protein HSP 90-beta 8
IP100465361 RPL13 60S ribosomal protein L13 6
IP100413108 RPSAP15;RPSA 33 kDa protein 3 4
IP100011253 RPS3 40S ribosomal protein S3 4
IP100026271 RPS14 40S ribosomal protein S14 4
5 19 15
IP100008530 RPLPO 60S acidic ribosomal protein PO 3
IP100215719 RPL18 60S ribosomal protein L18 3
IP100215780 RPS19 40S ribosomal protein S19_ 3
IP100555744 RPL14 Ribosomal protein L14 variant 3
IP100012772 RPL8 60S ribosomal protein L8 2
IP100029750 RPS24 Isoform 1 of 40S ribosomal protein S24 2
IP100419880 RPS3A 40S ribosomal protein S3a 2
IP100909073 - cDNA FU53752, highly similar to Heat shock 70 kDa protein 1 2 1
PARP-16 Peptides Identified per purification
IPI Gene name High salt 1 High salt 2 Physiological
IP100794653 PARP16 Isoform 1 of Poly [ADP-ribose] polymerase 16 19 24
IPl00291215 PARP14 poly (ADP-ribose) polymerase family, member 14 18
HIST1H4K;HIST2H4A;HIST1H4H;HIST1H4D;HIST1H4E;HIST1H41;HIST2
IP100453473 H4B;HIST1H4J;HIST 3 12 11
IP100171903 HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 9
IP100018534 HIST1H2BL Histone H2B type 1-L 8
IP100003935 HIST2H2BE Histone H2B type 2-E 9 7
IP100220578 GNA13 Guanine nucleotide-binding protein G(k) subunit alpha 3 6
IP100020729 IRS4 Insulin receptor substrate 4 6
IP100179330 UBC;RPS27A;UBB ubiquitin and ribosomal protein S27a precursor 6
HNRNPA2B1 Isoform Bl of Heterogeneous nuclear
IP100396378 ribonucleoproteins A2/B1 5
IP100409590 LMO7 Isoform 1 of LIM domain only protein 7 5
GNA12 Isoform 1 of Guanine nucleotide-binding protein G(i) subunit
IP100748145 alpha-2 5
HIST1H2AI;HIST1H2AM;HIST1H2AG;HIST1H2AL;HIST1H2AK;HIST1H2A
IP100081836 J;HIST1H2AH Histon 5 8 4
IP100008524 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 4
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HISTlH2AB;HISTlH2AE;HISTlH2AD;HISTlH2AI;HISTlH2AM;HISTlH2A
IP100026272 G;HISTlH2AL;HISTlH 4
IP100867509 CORO1C Coronin-1C_i3 protein 4
IP100012726 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 3
IP100031522 HADHA Trifunctional enzyme subunit alpha, mitochondrial 3
HNRNPA1 Isoform Al-B of Heterogeneous nuclear ribonucleoprotein
IP100215965 Al 3
IP100217975 LMNB1 Lamin-B1 3
HNRNPU Isoform Short of Heterogeneous nuclear ribonucleoprotein
IP100479217 U 3
IP100604620 NCL Nucleolin 3
IP100848226 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 3
IP100005198 ILF2 Interleukin enhancer-binding factor 2 2
IP100012074 HNRNPR Isoform 1 of Heterogeneous nuclear ribonucleoprotein R 2
IP100018140 SYNCRIP Isoform 1 of Heterogeneous nuclear ribonucleoprotein Q 2
IP100163085 AMOT Isoform 1 of Angiomotin 2
IP100217519 RALA Ras-related protein Ral-A 2
IP100449049 PARP1 Poly [ADP-ribose] polymerase 1 2
IP100783872 CAPRIN1 Isoform 1 of Caprin-1 2
IP100789740 GEMIN4 Gem (Nuclear organelle) associated protein 4 2
IP100218130 PYGM Glycogen phosphorylase, muscle form 6
IP100794653 PARP16 Isoform 1 of Poly [ADP-ribose] polymerase 16 5
IP100004358 PYGB Glycogen phosphorylase, brain form 4
IP100783313 PYGL Glycogen phosphorylase, liver form 4
IP100789893 - Pseudogene candidate 8
IP100796843 - 20 kDa protein 8
IP100217437 TTBK2 Tau-tubulin kinase 3
IP100376215 PRKDC Isoform 2 of DNA-dependent protein kinase catalytic subunit _ _ 3
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IP100414676
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IP100555744
IP100003362
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ISPA1B cDNA FJ54408, highly similar to Heat shock 70 kDa
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IP100008530 RPLPO 60S acidic ribosomal protein PO 5
IP100216587 RPS8 40S ribosomal protein S8 5
IP100478896 RPL7A Ribosomal protein L7a 5
IP100550021 RPL3 60S ribosomal protein L3 5
IP100219153 RPL22 60S ribosomal protein L22 2 4
IP100026271 RPS14 40S ribosomal protein S14 4
IP100215780 RPS19 40S ribosomal protein S19 4
IP100413108 RPSAP15;RPSA 33 kDa protein 4
IP100455599 HSP90AB2P Similar to Heat shock protein HSP 90-beta 4
IP100472171 RPL7;RPL7P32 30 kDa protein 4
IP100011253 RPS3 40S ribosomal protein S3 3
IP100029750 RPS24 Isoform 1 of 40S ribosomal protein S24 3
IP100221089 RPS13 40S ribosomal protein S13 3
IP100376798 RPL11Isoform 1 of 60S ribosomal protein L11 3
IPl00003918 RPL4 60S ribosomal protein L4 2
IP100012772 RPL8 60S ribosomal protein L8 2
IPIOO13415 RPS7 40S ribosomal protein S7 2
IP100013485 RPS2 40S ribosomal protein S2 2
IPI00024933 RPL12 Isoform 1 of 60S ribosomal protein L12 2
IP100456758 RPL27A 60S ribosomaI protein L27a 2
IP100470528 RPL15 60S ribosomal protein L15 2
IP100940553 HSPA1L Putative uncharacterized protein HSPAlL (Fragment) 6
IP100007702 HSPA2 Heat shock-related 70 kDa protein 2 41
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IPI00008438 RPS10 40S ribosomal protein S10 5
